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LIST OF ABBREVIATIONS 
 
2-TT, 2-thiazoline-2-thiol.  
B. fragilis, Bacteroides fragilis.  
Boc, t-butyloxycarbonyl.  
CAP, community-acquired pneumonia.  
CC50,
 
concentration that reduces cell 
viability by 50%.  
CIP, ciprofloxacin.  
CLI, clinafloxacin.  
DCC, N,N‘-dicyclohexylcarbodiimide.  
DIPEA, diisopropylethylamine.  
DMSO, dimethylsulfoxide.  
E. coli, Escherichia coli.  
EARSS, european antimicrobial resistance 
surveillance system.  
EC50, half maximal effective concentration.  
FLE, fleroxacin.  
FQ, fluoroquinolone.  
GAT, gatifloxacin.  
GEM, gemifloxacin.  
GRE, grepafloxacin.  
HOBt, 1-hydroxybenzotriazole.  
HPLC, high-performance liquid 
chromatography.  
IC50, concentration of compound required 
for 50% inhibition effect.  
ITQ, isothiazoloquinolones.  
K. pneumoniae, Klebsiella pneumoniae.  
LEV, levofloxacin.  
M. smegmatis, Mycobacterium smegmatis.  
M. tuberculosis, Mycobacterium 
tuberculosis.  
MBC, minimum bactericidal concentration.  
MDR, multi-drug resistant.  
MDRSA, multidrug resistant 
Staphylococcus aureus.  
MIC, minimum inhibitory concentration.  
MOX, moxifloxacin.  
MPC, mutant prevention concentration.  
MRSA, methicillin-resistant Staphylococcus 
aureus.  
MTD, maximum tolerated dose.  
MTT, 3-[4,5-dimethylthiazol-2yl]-diphenyl 
tetrazolium bromide.  
NAD, nadifloxacin.  
NAL, nalidixic acid.  
NHS, N-hydroxysuccinimide.  
NMR, nuclear magnetic resonance.  
NOR, norfloxacin.  
OFL, ofloxacin.  
P. aeruginosa, Pseudomonas aeruginosa.  
PAZ, pazufloxacin.  
PBS, phosphate buffer saline.  
PEF, pefloxacin.  
QRDR, quinolone-resistance determining 
region.  
S. aureus, Staphylococcus aureus.  
S. pneumoniae, Streptococcus pneumoniae.  
S. pyogenes, Streptococcus pyogenes.  
SAR, structure-activity relationship.  
SPA, sparfloxacin.  
TB, tuberculosis.  
TBAI, tetrabutylammonium iodide.  
TCA, trichloroacetonitrile.  
TMP, 2,4,6-trimethylpyridine.  
TPP, triphenylphosphine.  
TRO, trovafloxacin.  
ULI, ulifloxacin.  
UTI, urinary tract infections.  
UV, ultraviolet.  
VRSA, vancomycin-resistant 
Staphylococcus aureus.  
WHO, world health organization.  
XDR, extensively drug-resistant.  
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 INTRODUCTION GÉNÉRALE 
Le ciprofloxacine (CIP) et la lévofloxacine (LEV) sont des antibiotiques de la famille des 
fluoroquinolones (FQs). Ce sont des agents à large spectre qui ciblent les topoisomérases 
bactériennes de type II. Certaines FQs ont également été approuvées comme médicaments de 
seconde ligne pour le traitement des tuberculoses multirésistantes. Même si la recherche de 
nouvelles FQs antibactériennes a déjà été largement développée, ces molécules sont encore un 
sujet d'étude en particulier à cause de la demande continue de nouveaux composés actifs contre 
les agents pathogènes résistants. Des récentes études structure-activité ont montré les avantages 
de la modification en position C-7 des FQs conduisant à une activité accrue contre des bactéries 
à Gram-positif, en particulier Staphylococcus aureus (S. aureus) résistant à la méticilline. 
Etant donné les similitudes structurelles existant entre les topoisomérases de type II chez 
les procaryotes et les eucaryotes, les quinolones ont, plus récemment, été étudiées pour leur 
capacité à inhiber la topoisomérase II mammifère. Des études ont montré que des modifications 
des quinolones en positions C-7 et C-3 peuvent conduire à une nouvelle classe d'agents anti-
tumoraux. Compte tenu de ce qui précède, nous nous sommes intéressés à développer de 
nouveaux dérivés des FQs. Deux voies ont été envisagées : la modification en position C-7 de la 
CIP et la modification sur l‘acide carboxylique en C-6 de la LEV. 
Le premier chapitre de cette thèse sera consacré à une revue bibliographique relative à 
l'état actuel des recherches dans le domaine des FQs en tant qu‘agents antibiotiques, 
antimycobactériens et antitumoraux. Un accent particulier sera mis sur les composés modifiés en 
C-7 et en C-3 (ou C-6) du pharmacophore. Cela permettra une meilleure compréhension du 
mécanisme d'action et de résistance ainsi que la possibilité de justifier nos choix de 
modifications structurales, et d'expliquer les résultats des tests biologiques. 
Le deuxième chapitre décrit la synthèse des nouveaux dérivés de la CIP et la LEV. Nous 
passerons en revue les voies de synthèse déjà essayées  et des défis rencontrés. Des études 
d'optimisation et la comparaison des différentes méthodes mises au point seront mentionnés ainsi 
que les conditions optimales dans chacune des séries de composés. 
Dans le troisième chapitre nous discuterons les diverses activités biologiques obtenues 
pour les dérivés synthétisés.  L'influence du type de substitution, de la structure dimère (ou 
monomère), du noyau quinolone sur l'activité antibactérienne, antimycobactérienne et 
antiproliférative des composés sera présentée. Finalement, nous essayerons de généraliser les 
facteurs régissant l'activité et la spécificité contre les différentes cibles biologiques. 
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1. Les quinolones antibactériennes 
1.1 Généralités 
Pour des raisons de compréhension, avant de détailler les propriétés antibactériennes des 
quinolones, certains concepts fondamentaux de microbiologie seront présentés. La plupart des 
bactéries peuvent être classées dans deux groupes selon la coloration de Gram. Cette technique  
permet de mettre en évidence les propriétés de la paroi bactérienne, et d'utiliser ces propriétés 
pour les distinguer et les classifier (à Gram-positif et à gram-négatif). Des exemples 
représentatifs des bactéries à Gram-négatif sont: Escherichia coli (E. coli) et Pseudomonas 
aeruginosa (P. aeruginosa). Des bactéries à Gram-positif d'importance médicale incluent: S. 
aureus et Streptococcus pneumoniae (S. pneumoniae). Une autre classification est basée sur la 
nécessité (ou pas) de la présence de dioxygène dans le milieu de culture des microorganismes: on 
parle alors de bactéries aérobies ou anaérobies. 
1.2 Histoire 
Le motif quinolone est apparu il y a 50 ans
1
 et c‘est toujours l'une des structures les plus 
courantes dans le domaine des molécules biologiquement actives. Les quinolones sont des agents 
anti-infectieux totalement synthétiques dont la structure moléculaire se compose de plusieurs 
systèmes cycliques (hétérocycliques). Les plus importants, ainsi que leurs systèmes de 
numérotation sont illustrés sur la Figure 1. 
 
Figure 1 Structures et systèmes de numérotation des quinolones les plus 
importantes 
Les quinolones de première génération ont été reconnues comme des antibiotiques dont le 
spectre d‘activité était limité aux bactéries à Gram négatif aérobies. Au fil des années, de 
nouvelles quinolones ont vu le jour avec l'introduction en 1980 de l'atome de fluor en position C-
6. Les fluoroquinolones (FQs) ne sont pas seulement plus actives que les agents précédents 
contre les bactéries à Gram-négatif, mais leur spectre a été étendu successivement aux bactéries à 
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Gram positif et aux anaérobies cliniquement importantes. Les FQs sont devenues l'un des 
groupes les plus utilisés des antibiotiques à large spectre2. 
La famille des quinolones antibactériennes est généralement divisée en générations, dans 
le paragraphe suivant nous allons utiliser la classification basée sur le spectre antimicrobien3. 
1.2.1 Première génération 
Les quinolones sont issues des premiers travaux de George Lesher et ses collaborateurs 
en 1962
1
. L'activité antimicrobienne de l'acide nalidixique (NAL, Tableau 1) a été étudiée sur un 
panel de micro-organismes, elle a révélé son activité contre les agents pathogènes à Gram négatif 
comme E. coli et Klebsiella pneumoniae (K. pneumoniae). Cependant, plusieurs inconvénients 
tels qu‘une pharmacocinétique défavorable, des effets indésirables, et une faible activité contre 
les bactéries à Gram-positif et anaérobies, ont limité les indications de NAL aux infections des 
voies urinaires non compliquées (IVU)4. Néanmoins, ce composé a stimulé un intérêt croissant 
pour cette classe et a donné lieu à des développements ultérieurs. 
1.2.2 Deuxième génération 
Les quinolones de deuxième génération sont marqués par l'introduction d'un atome de 
fluor en position C-6, ce qui a grandement amélioré leur spectre d‘action et augmenté l 
'absorption des médicaments par les cellules bactériennes5. Ce groupe est généralement 
représenté par deux sous-classes. 
La classe I est représentée par la norfloxacine (NOR, Tableau 1) et la péfloxacine (PEF, 
Tableau 1) qui possèdent une activité remarquablement augmentée contre les bactéries à Gram-
négatif et une activité importante contre certains agents pathogènes à Gram-positifs, comme S. 
aureus  sensible à la méticilline. Pourtant, cette classe présente encore des inconvénients majeurs 
par exemple, une distribution tissulaire faible
6
. 
La classe II est marqué par l'émergence de la ciprofloxacine7 (CIP, Tableau 1), dérivant 
de NOR par le remplacement du substituant N-1 éthyl par cyclopropyl. CIP possède l'une des 
activités les plus puissantes contre une large gamme d'organismes à Gram-négatif, une 
augmentation d'activité contre les bactéries à Gram-positif et les bactéries atypiques8. Un autre 
représentant  de cette classe est l'ofloxacine  (OFL, Tableau 1) qui introduit un pont entre les 
positions N-1 et C-8 du noyau quinolone, conduisant au squelette 1,4-benzoxazine. En raison de 
la pharmacocinétique améliorée9 (biodisponibilité et distribution tissulaire) et du large spectre 
d'activité, la LEV et la CIP sont devenues des antibiotiques par voie orale largement utilisés et 
ont élargi les indications des FQs pour inclure : les infections gastro-intestinales, génitales, 
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osseuses et ostéo-articulaires. Cependant, les molécules de cette classe II n'ont pas d'activité anti-
streptocoques à Gram-positif telles que S. pneumoniae. Par ailleurs, l'utilisation importante (et 
parfois abusive) du CIP a provoqué l'émergence de souches résistantes dans les hôpitaux et les 
communautés10. 
1.2.3 Troisième génération 
La séparation des énantiomères de OFL a montré que l'isomère R est presque inactif alors 
que l'isomère S est responsable de l'activité du racémate11. L'isomère S a été nommé 
lévofloxacine  (LEV, Tableau 1) et a présenté un niveau élevé d'activité contre les 
staphylocoques et les anaérobies, y compris les souches résistantes à la méticilline. Toutefois, la 
LEV a présenté une activité légèrement inférieure à CIP contre les agents pathogènes à Gram-
négatif, y compris P. aeruginosa12. Les autres représentants de cette classe, la gatifloxacine 
(GAT, Tableau 1) et la moxifloxacine  (MOX, Tableau 1) ont également une bonne activité 
contre les souches à Gram-positif 13, y compris les souches résistantes à la CIP14. Les 8-OMe 
FQs ont été introduites avec l‘intention de diminuer la fréquence de sélection des mutants15. Les 
concentrations sériques élevées et les demi-vie plus longues ont permis le dosage une seule fois 
par jour pour les représentants de la troisième génération16. Ces caractéristiques ont élargi la 
gamme de leurs indications à la pneumonie acquise en communauté (PAC)  en comparaison avec 
les générations précédentes. 
1.2.4 Quatrième génération 
Les quinolones de quatrième génération sont les composés les plus puissants avec un 
spectre large et un haut degré d'activité. Avec l'augmentation de l'activité anti-Gram-positif ces 
dérivés possèdent une activité considérablement augmentée contre les anaérobies17 et les 
bactéries à Gram-négatif, y compris P. aeruginosa18. L‘élargissement du spectre et 
l‘augmentation du degré d'activité antibactérienne a permis de nouvelles indications aux FQs de 
4ème génération dans le traitement des infections intra-abdominales. Du point de vue de la 
structure chimique, en plus des changements de substituants en position C-7, ces agents comme 
la trovafloxacine (TRO) et la gémifloxacine  (GEM,) sont des dérivés de type 1,8-naphtyridine, 
similaires à NAL, tandis que ulifloxacin19 (ULI, Tableau 1) qui est utilisé sous la forme de 
prodrogue (prulifloxacin
20
, PRU, Tableau 1) comporte une annélation originale entre le N-1 et le 
C-2 de la quinolone. 
Pour conclure, au cours des différentes modifications structurales les quinolones ont 
considérablement augmenté leur spectre antibactérien et leur degré d‘activité. Ces 
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caractéristiques, combinées à l'amélioration de leur pharmacocinétique ont permis un 
élargissement de leur indication pour le traitement des infections urinaires, des voies 
respiratoires et intra-abdominales. Toutefois, les problèmes de toxicités ont entraîné le retrait de 
plusieurs quinolones commercialisées. Par ailleurs, l‘apparition de phénomènes de résistance aux 
anciennes quinolones a également perturbé le développement de cette classe d'antibactériens. 
Dans le prochain paragraphe, nous donnerons un aperçu du mécanisme d'action et de résistance 
des FQs, ce qui nous aidera à rationaliser nos synthèses et à expliquer nos résultats biologiques. 
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Tableau 1 Structures représentatives des différentes générations de quinolone 
 
Génération Nom R8 R1 R2 R5 R6 R7 
1 NAL N Et H H H CH3 
2 
Class I 
NOR C-H Et H H F 
 
PEF C-H Et H H F 
 
ENO N Et H H F 
 
FLE C-F CH2CH2F H H F 
 
 LOM C-F Et H H F 
 
2 
Class II 
CIP C-H 
 
H H F 
 
PAZ 
 
H H F 
 
OFL 
 
H H F 
 
3 
LEV 
 
H H F 
 
NAD 
 
H H F 
 
GRE C-H 
 
H CH3 F 
 
MOX C-OMe 
 
H H F 
 
GAT C-OMe 
 
H H F 
 
SPA C-F 
 
H NH2 F 
 
4 
TRO N 
 
H H F 
 
GEM N 
 
H H F 
 
CLI C-Cl 
 
H H F 
 
ULI C-H 
 
H F 
 
PRU C-H 
 
H F 
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1.3 Mechanism of action and resistance 
1.3.1  Targets for antibacterial quinolones 
DNA gyrase was first found in Gram-negative organisms. For many years it was thought 
to be the only quinolone target
21
. However, in 1990 DNA topoisomerase IV, a homolog of 
gyrase, was discovered
22
 and it was demonstrated that this enzyme is a primary target of FQ in 
Gram-positive S. aureus
23
. Both gyrase and topoisomerase IV are composed of two subunits 
(GyrA and GyrB in gyrase, ParC and ParE
*
 in topo IV) assembled into a functional 
heterotetramer i.e. A2B2 and C2E2 respectively. Both enzymes are type II topoisomerases as they 
cleave both strands of DNA double-helix. After the passage of unmodified strand (T-segment) 
through the temporary gap (G-segment) they promote religation of broken strands
24
 (Figure 2). 
 
Figure 2 Two-gate mechanism of type II topoisomerase action (From ref 
24
 with 
permission of Nature Publishing Group) 
 
In this way topoisomerases manage DNA topology: they could resolve knots and release 
superhelical tensions which are produced during DNA transcription and replication. In the cell 
DNA gyrase facilitates DNA unwinding in front of the moving replication fork and 
topoisomerase IV has a specialized function in mediating the decatenation of interlocked 
daughter chromosomes behind the replication fork (Figure 2). In this way these enzymes are 
vital for the normal cell‘s functioning. 
                                                 
*
Historically in S. aureus these two subunits of topoisomerase IV: were named GrlA and 
GrlB 
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Quinolones bind the DNA-enzyme complex where DNA is kept in the intermediate stage 
of double helix passing in which both DNA strands are cut. Ternary complex forms a barrier to 
the moving replication fork and arrests it 10 base-pairs upstream the DNA cleavage sites
25
. 
However due to reversibility of the quinolone-enzyme-DNA complex formation, DNA inhibition 
cannot be the cause of immediate cell death and fails to correlate with rapid cell death in terms of 
kinetics, quinolone concentration. The most straightforward model is that drug-enzyme-DNA 
complexes block bacterial growth (determined by Minimum inhibitory concentration, MIC - is 
the lowest concentration of drug that inhibits more than 99% of the bacterial population) while 
the release of double-stranded DNA breaks was proposed to be the cause of lethal 
consequences
26
. 
1.3.2 Structure of ternary complex 
For a long time the structure of the ternary complex remained unresolved and only 
tentative models based on structure-activity relationship (SAR) and mutations studies were 
proposed for the quinolone-DNA-topoisomerase interaction. Recently Lapogonov et al. finally 
resolved the crystal structure of the quinolone-DNA cleavage complex of the topoisomerase IV 
from S. pneumoniae
27
. Two molecules of MOX are intercalated in the gap between -1 and +1 
nucleotides at the two ends of DNA double-strand cut (Figure 3). 
 
Figure 3 Two molecules of MOX bound to the S. pneumoniae topoisomerase IV-
DNA cleavage complex. (From ref 
27
 with permission of Nature Publishing 
Group) 
 
The bulky substituent at C-7 position is positioned next to the DNA bases at +4 and +5 
positions on the opposite DNA strand and projects into large solvent-accessible volume above 
the DNA cut (Figure 3). This result is consistent with SAR studies showing that large variations 
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at C-7 position are accepted (see section 2.3.2). The N-1 cyclopropane ring is located close to 
ParC -helix residue Ser79 and Asp83, whose mutation is responsible for quinolone resistance 
28
(Figure 4).  
 
Figure 4  MOX bound to S. pneumoniae topoisomerase IV-DNA cleavage 
complex. Quinolone-enzyme interactions (From ref 
27
 with permission of Nature 
Publishing Group) 
 
The fluorine atom at C-6 position is situated far from the protein chain and DNA strand 
so its influence on the quinolone potency might be explained by altering the electron density of 
the heterocyclic core. Studies have shown that by fine tuning of other substituents one could 
achieve high level of potency without fluorine atom at C-6
29
. The 3-carboxy and 4-keto groups 
of the quinolone are located closest to the ParC -helix Gly77, Asp78 residues which are 
possible partners for hydrogen bonding; but far away from the magnesium binding side of the 
ParC TOPRIM (topoisomerase-primase) domain, though direct metal chelation is questioned. 
1.3.3 Resistance to quinolones 
Over the 30 years that have elapsed since the introduction of FQs, resistance to these 
agents has become common and widespread. A number of reports of the European Antimicrobial 
Resistance Surveillance System (EARSS) showed gradual increase of the part of FQ-resistant 
pathogens in Europe: for example from 9% (2001) to 20% (2009) for E. coli
30
. These facts show 
the growing threat of emerging non-susceptibility to older quinolones and the constant need for 
the development of new agents. 
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1.3.3.1 Modifications at the target site and target preference 
The most important mechanism of FQ resistance is mediated by amino acid substitutions 
in the target enzymes. This type of resistance arises stepwise. In several species, the first-step 
mutations occur in the gyrA and occasionally in gyrB (genes encoding GyrA and GyrB subunits 
of DNA gyrase) while in others they occur in parC and less often in parE (genes encoding ParC 
and ParE subunits of topoisomerase IV). Genetic evidences of this type are often used to prove 
the target preference of the FQ. 
In Gram-negative species, GyrA is the primary target of 4-quinolones, as the first 
mutations conferring resistance occur in GyrA and single ParC mutations do not change the MIC  
of quinolones for E. coli
31
. The whole set of the most frequently occurred mutation was named 
―quinolone-resistance determining region‖ (QRDR) which is located between amino acids 
positions 67 and 106 in GyrA subunit of E. coli gyrase
32
. These residues are situated in the 
proximity to the putative quinolone binding pocket in the enzyme-DNA cleavage complex and 
thus reduce the drug affinity to the complex of modified enzyme and DNA. Amino acid 
positions 447 and 426 in GyrB subunit were found to be responsible for the low-level 
resistance
33
. 
In Gram-positive species, the situation with target preference is not so evident; both 
topoisomerase IV and gyrase may be the targets with different degree of preference.  
Research with a large number of S. aureus isolates showed that the Ser80Phe alteration in 
GrlA and Ser84Leu change in GyrA are the principal ones and both mutations in DNA gyrase 
and topoisomerase IV are needed for high-level resistance
34
. 
The target preference in S. aureus varies between quinolones and according to studies of 
Takei et al.
35
 these agents can be divided into three categories. The first type includes NOR, 
ENO, fleroxacin (FLE), CIP, OFL and LEV (Tableau 1); which have greater MICs for grlA 
mutant strains (grlA is the gene encoding GrlA subunit of topo IV) than for gyrA mutant strains 
(gyrA is the gene encoding GyrA subunit of gyrase). These quinolones displayed lower half 
maximal inhibitory concentration (IC50) values (the concentration of drug required for 50% 
inhibition of enzyme activity in vitro) for purified topoisomerase IV from wild-type strain than 
IC50 values for DNA gyrase. These results suggest the preferential topoisomerase IV inhibition 
by this group of quinolones. 
The second type includes sparfloxacin (SPA) and nadifloxacin (NAD) (Tableau 1). 
These quinolones showed reversed order of activity: greater MICs for gyrA than for grlA mutants 
and lower IC50 values for DNA gyrase. These results suggest the preferential DNA gyrase 
inhibition by these analogs. 
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The third type comprises GAT, pazufloxacin (PAZ), MOX and clinafloxacin (CLI) 
(Tableau 1). In this group, similar values of MICs and IC50 for both targets were observed. It has 
been suggested that antibacterial activity of these compounds are mediated by dual-inhibition of 
both DNA gyrase and topoisomerase IV. 
The most frequent resistance mutations in S. pneumoniae comprise alterations in ParC 
(Ser79Tyr/Phe, Ala84Thr) and in GyrA (Ser81Tyr)
36
, which are analogous to the previously 
mentioned in other species. Also single mutations in ParC conferred only low-level resistance 
while for the high-level resistance both DNA gyrase and topoisomerase IV have to be altered
37
. 
The target preference at S. pneumoniae is also dependent on type of quinolone. Comparing IC50 
of purified enzymes and single-step mutations it was proposed that for CIP, LEV, NOR, TRO
38
 
topo IV is a primary target, while for SPA, GAT
38
, grepafloxacin
39
 (GRE, Tableau 1) it is the 
DNA gyrase; CLI seems to be equipotent against both enzymes
40
. 
1.3.3.2 Efflux mediated resistance 
The second mechanism of resistance in bacteria is an active drug efflux by 
overexpression of certain efflux pumps. These are transmembrane proteins which are responsible 
for the active transport of different molecules. Efflux pump mechanisms probably have a 
preexisting physiological role, protecting the bacillus against high intracellular levels of toxic 
molecules. In addition, efflux pumps maintain cellular homeostasis and physiological balance 
through transport of the toxins or metabolites to the extracellular environment
41
. Specific gene 
norA was found to confer quinolones resistance in S. aureus
42
. The study of relative contribution 
of efflux mediated resistance by selective inhibition of multidrug efflux pumps showed that 
hydrophilic quinolones are more susceptible to the active transport while more hydrophobic 
MOX, SPA and TRO are less affected by this type of resistance
43
. Bulky substituents and large 
molecular weight of compounds should also reduce their transport by efflux pumps. 
1.3.3.3 Plasmid mediated resistance 
The third and recently discovered mechanism of resistance is associated with intracellular 
plasmids. A multiresistance plasmid was recently discovered that encodes transferable resistance 
to quinolone
44
. The plasmid-quinolone resistance gene was termed qnr and the corresponding 
protein Qnr was shown to protect E. coli DNA gyrase from the inhibition by CIP. It was 
hypothesised that protective action of Qnr results from the formation of Qnr–gyrase complex 
which occurs before the formation of the cleavage complex with DNA. It is noteworthy that 
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plasmids are extrachromosomal genetic elements, thereby granting plasmid mediated resistance a 
high degree of mobility which poses risks of the resistance spreading among different organisms. 
In this paragraph, we have shown that bacterial type II topoisomerases are intracellular 
targets of FQs that turn these enzymes into cellular poisons. Between different resistance 
mechanisms, mutations at the target site are the most important. However, the relative activity of 
FQs is influenced by their intracellular concentration in the cell. The latter is determined by the 
ability of drug molecules to penetrate the cellular wall and will be discussed in detail in the next 
paragraph. 
1.3.4 Penetration into bacterial cell 
Penetration of quinolones into bacterial cell is tightly related with cellular efflux/influx 
balance. In the case of extracellular flow, there are evidences for the presence of active multidrug 
efflux in resistant strains, as we have described in the section 1.3.3.2. By contrast, quinolone 
influx seems to be energy-independent, governed by the passive diffusion
45
.  
 
Figure 5 Protonation equilibria of FQ 
 
To date, there are numerous studies that reveal correlations between lipophilicity, 
molecular weight, acidity/basicity and FQ uptake in different organisms. Because quinolones 
present both acidic and basic functionality, these molecules could exist in four different 
microspecies in aqueous solution: cationic H2Q
+
, neutral HQ
0
, zwitterionic HQ
+–
 and anionic Q
–
 
(Figure 5). Several experimental evidences testify that in Gram-positive organisms with a single 
cell membrane FQ transferred in the neutral HQ
0
 form by passive diffusion through phospholipid 
bilayer membrane; more lipophilic analogs should have higher transport rates
46
. In Gram-
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negative species penetration is complicated by the presence of the additional lipopolysacharide 
outer membrane, which is 2 orders of magnitude less permeable than ordinary phospholipid 
bilayer towards lipophilic compounds (Figure 6). 
 
Figure 6 Simplified cell wall structures in Gram-positive and Gram-negative 
bacteria and their penetration by FQ. 
 
In this case the main part of the FQ influx assisted through the porin channels. Porins are 
beta-barrel proteins that cross an outer membrane and act as a pore with size-limited 
permeability (with slight cation selectivity). So only relatively small and hydrophilic molecules 
can freely penetrate them
47
. Chelation of FQ with magnesium ions would provide hydrophilic 
positively-charged species which are thought to be responsible for the FQ influx in Gram-
negative species
45
. 
In this paragraph, we have described the modern understanding of quinolone action and 
resistance which will help us to understand some of structure-activity dependencies in the next 
paragraph. 
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1.4 Structure-activity relationships 
The history, development and SARs of the quinolones have been extensively reviewed
48
. 
Quinolone SARs are usually examined position by position so in this section we will introduce 
general findings; then we will focus on the C-3 and C-7 positions which are relevant to our work. 
1.4.1 General trends 
As synthetic antibacterial agents, FQ consist of the main 3-carboxy-4-pyridone 
pharmacophore and, as auxopharmacophore, a fused aromatic ring with attached substituents 
which serves to modulate the potency and antibacterial spectrum (Figure 7). 
 
Figure 7 General trends in FQ SAR 
 
SAR studies in the early era suggested that optimal groups to be attached to the N-1 
position should be relatively small and hydrophobic
5
. Apart from the N-1 ethyl substituent in 
NOR or cyclopropyl group in CIP, some aryl groups at N-1 could improve Gram-negative 
spectrum of activity in comparison to NOR
49
 (Table 2). 
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Table 2 Antibacterial activity of some N-1 substituted quinolones: alkyl and aryl 
substituents 
 
R1 
MIC, M 
Gram (–) Gram (+) 
E. coli
a
 S. aureus
b
 
CH3 1.26 20.2 
CH2CH3 (NOR) 0.16 1.22 
CH2CH2CH3 0.60 4.68 
CH2CH2F 0.30 4.64 
CH2CH2OH 1.16 4.65 
 E. coli
c
 S. aureus
d
 
CH2CH3 (NOR) 
0.31 2.44 
C6H5 
0.56 1.06 
4'-FC6H4 
0.13 0.54 
Data from ref 
5, 49
 
a
E. coli NIHJ JC-2 strain 
b
S. aureus 209P strain 
c
E. coli Juhl strain 
d
S. 
aureus ATCC 6538P strain 
 
Further research for possible N-1 substituents has led to preparation of tricyclic quinolone 
ring systems in which a new saturated ring is formed to give 1,8-bridged quinolones – LEV and 
OFL.  Studies have shown that there is a  stereochemical preference for the methyl at the 
bridging 3-position
50
. Stereochemistry of LEV gives approximately 12 fold increase in DNA 
gyrase inhibitory activity in comparison to its enantiomer, while ratio for the in vitro MICs 
varies in 31-125 fold increase and is much greater than expected from gyrase inhibition
50b
 
(Table 3) 
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Table 3 Antibacterial activity of 1,8-bridged quinolones: Stereoselectivity 
 
Name R1 R2 
MIC( M) IC50 ( M), 
DNA 
gyrase
 a
 
Gram (+) Gram (–) 
E. coli
b
 P. aeruginosa
c
 S. aureus
d
 
OFL 
(racemate) 
H/CH3 H/CH3 0.14 0.55 1.1 2.10 
LEV H CH3 0.07 0.28 0.55 1.05 
- CH3 H 2.16 17.3 69 13.0 
Data from ref 
50
 
a
Corresponds to 50% inhibition of DNA gyrase supercoiling activity 
isolated from E. coli KL 16 
b 
E. coli KL 16 strain 
c
P. aeruginosa 32122 strain 
d
S. aureus 209P 
strain 
The C-2 position is also close to the fixation site, so for a long period of time hydrogen 
atom was the only successful substituent. However, an example of C-2 modified potent 
compound is ULI (Table 4) with a broad-spectrum activity comparable to that of CIP
19
. 
 
Table 4 Ulifloxacin antimicrobial activity 
 
Compound 
MIC50, M
a
 
Gram (–) Gram (+) 
E. coli(43
b
) P. aeruginosa(42
b
) S. aureus(37
b
) 
ULI 0.29 1.13 2.26 
CIP 0.15 0.60 1.18 
Data from ref 
19
 
a
Compounds were tested against collection of clinical isolates; MIC50 is 
MIC for 50% of isolates tested. 
b
Total number of isolates in a collection 
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Initial findings showed that modifications in the 4-pyridone ring render significantly less 
active compounds. There are no analogs with alterations at C-3 and C-4 positions that reached 
noticeable degree of activity. From the structural data of the quinolone-DNA-enzyme complex, it 
was proposed that these positions take part in the quinolone fixation at the active site of enzyme. 
The C-5 position is left unsubstituted in the large part of commercial quinolones. It is 
thought to influence potency and provide additional Gram-positive activity. This position 
demonstrates important phenomena of the different substituent interaction within quinolone 
heterocyclic core. While C-5 substitution itself induces chromosomal injury the use of finely 
tuned combination of 5-NH2 and C-8 substituents results in a significant decrease of toxicity
51
. 
Thus far, there are few examples of successful 5-position modification and 5-NH2 (SPA), 5-CH3 
(GRE) are the most beneficial for in vitro activity
52
 (Table 5). 
 
Table 5 Comparative in vitro antimicrobial activity of GRE and SPA 
 
Compound 
MIC90, M
a
 
Gram (–) Gram (+) 
E. coli P. aeruginosa S. aureus 
GRE 0.17 22.3 0.33 
SPA 0.15 10.2 0.31 
Data from ref 
52
 
a
Compounds were tested against collection of clinical isolates; MIC90 is 
MIC for 90% of strains tested. 
 
Original quinolones were often unsubstituted at C-6 position. The main finding of the 
pioneering work of Koga et al.
5
 illustrated a very clear superiority of NOR, a derivative bearing 
a fluorine atom at the 6 position over its non-fluorinated analog (Table 6). 
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Table 6 In vitro antimicrobial activity of C-6 fluorinated vs non-fluorinated NOR 
 
R6 
MIC ( M) 
Gram (–) Gram (+) 
E. coli
a
 P. aeruginosa
b
 S. aureus
c
 
F (NOR) 0.16 1.22 1.22 
H 2.59 10.4 41.5 
Data from ref 
5
 
a
E. coli NIHJ JC-2 strain 
b
P. aeruginosa V-1 strain 
c
S. aureus 209P strain 
 
Strong increase of activity due to fluorine atom at C-9 has also been demonstrated among 
LEV derivatives
53
 (Table 7). 
 
Table 7 In vitro antimicrobial activity of C-9 fluorinated vs non-fluorinated LEV 
 
R9 
MIC ( M) 
Gram (–) Gram (+) 
E. coli
a
 P. aeruginosa
b
 S. aureus
c
 
F (LEV) 0.044 1. 0.33 
H 23 >93 12 
Data from ref
 53
 
a
E. coli ES142 strain 
b 
P. aeruginosa PS 96 strain 
c
S. aureus MI246 strain 
 
It has become almost a dogma that a fluorine atom at C-6 position (or C-9 position on 
benzoxazine skeleton) is essential for antibacterial activity. However, several studies have shown 
that positive effect of a C-6 fluorine atom is diminished when the molecule contains other 
helpful substituents. The development of the first marketed drug without fluorine atom at C-6 
position – Garenoxacin54 (GAR, R6 = H, Table 8) resulted from a number of analogs by fine 
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tuning of other substituents in order to minimize toxicity while maintaining high levels of 
potency. 
 
Table 8 Antimicrobial activity and IC50 of GAR and its fluorinated analog 
 
R6 
IC50( M) MIC ( M) 
E. coli 
Gyrase
a
 
S. aureus 
topo IV
b
 
Gram (–) 
E. coli
c 
Gram (+) 
S. aureus
d
 
H
 
(GAR) 0.40 5.14 0.14 0.016 
F 0.36 10.4 0.28 0.016 
Data from ref 
54
 
a
Corresponds to 50% inhibition of gyrase supercoiling activity 
b
Corresponds to 50% inhibition of topoisomerase IV decatenation activity 
c
E. coli A29179 
strain: genotype GyrA Ser83Leu 
d
S. aureus 
 
MR A27223 strain: genotype homogeneous MR 
 
It has long been known that the substituent at C-8 position controls in vivo efficacy and 
affects the antibacterial spectrum. The 8-position substituent can improve anaerobic activity, 
modulate physicochemical properties and adverse effects. The most commonly studied groups at 
C-8 position were X= C-H, C-F, C-Cl and N, with the following order of in vitro antibacterial 
potency: C-Cl ≈ C-F > C-H > N55 (Table 9). While 8-F and 8-Cl substituents showed improved 
activity, these groups were associated with a serious adverse effect of phototoxicity
56
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Table 9 In vitro activities of C-8 modified quinolones 
 
X 
Gyrase-drug induced 
cleavage
a 
E. coli H560 
IC50( M) 
MIC ( M) 
Gram (–) 
E. coli
b
 
Gram(+) 
S. aureus
c
 
N 3.0 0.15 4.8 
C-H (CIP) 1.5 0.15 9.4 
C-F 1.44 0.29 1.1 
C-Cl 1.4 0.068 0.27 
Data from ref 
55
 
a
Minimum concentration of drug needed to produce linear DNA at an 
intensity relative to oxolinic acid at 10 g/mL 
b
E. coli Vogel strain 
c
S. aureus H228 strain 
 
The 8-OMe group was found to improve the potency against S. pneumoniae resistant 
strains with alterations in target enzymes
57
 and to slower the development of quinolone 
resistance
58
. In contrast to 8-F derivatives, 8-methoxy quinolones are photostable and do not 
cause phototoxicity
58
. The 8-OMe quinolone MOX (Tableau 1) is characterized by a safety 
profile comparable to that of older monofluorinated quinolones
59
. 
1.4.2 Position C-7 
The C-7 position is one of the most widely explored among all other positions. From 
numerous studies it was deduced that this position determines the antibacterial spectrum, may 
influence target preference and is tightly related to pharmacokinetics. In the foregoing section we 
will discuss separately ―dimeric‖ and ―monomeric‖ C-7 modified compounds.  
1.4.2.1 Monomers 
Many thousands of analogs have been prepared employing various substituents at this 
promising position, leading to conclusion that a cyclic system containing a secondary or tertiary 
amine moiety is preferred
2
. 
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After the discovery of NOR and PEF the piperazinyl moiety or its N-methyl analogue 
became a standard feature among the quinolones. Unsubstituted piperazine ring (as in NOR, 
ENO and CIP) confer potency against Gram-negative bacteria, while addition of methyl groups 
can improve both oral absorption
6b
 and anti-Gram-positive activity. However, the improved 
activity against Gram-positive bacteria can sometimes be at the expense of activity against P. 
aeruginosa
60
 (Table 10). 
 
Table 10 Influence of C-7 piperazine methylation on antibacterial spectrum 
 
R 
MIC ( M) 
Gram (–) Gram (+) 
E. coli
a
 P. aeruginosa
b
 S. aureus
c
 
H (CIP) <0.05 0.18 1.51 
CH3 <0.05 1.45 0.36 
Data from ref 
60
 
a
E. coli ATCC25922 strain 
b
P. aeruginosa
 
ATC1C 9027 strain 
c
S. aureus 
ATCC29213 strain 
 
These changes in antimicrobial spectrum may be related to the alteration of 
physicochemical properties of target compounds. As shown in section 1.3.4, more lipophilic 
compounds exhibit increased penetration into Gram-positive organisms while lowering the 
porin-mediated influx into Gram-negative bacteria. Indeed, it was observed that lipophilic N-
methyl and N-ethyl CIP derivatives are equipotent to CIP against S. aureus, while only N-
methylated analog displays MIC values toward E. coli comparable to that of CIP
61
 (Table 11). In 
addition, authors demonstrated that increased lipophilicity had direct positive impact on 
intestinal absorption rates of compounds
62
. 
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Table 11 Comparative antimicrobial activity of N-alkyl CIP analogs 
 
R LogP
a
 
MIC ( M) 
Gram (–) 
E. coli
b
 
Gram (+) 
S. aureus
c
 
H (CIP) -1.12 0.076 0.76 
Me 0.27 0.073 0.73 
Et 0.37 0.14 0.70 
n-Pr 1.05 0.27 1.34 
n-Bu 1.48 0.51 1.29 
Data from ref 
62a
 
a
P is the bulk phase partition coefficient determined between n-octanol 
and 0.066 M Sörensen phosphate buffer, pH 7.00 bE.coli ATCC25922 strain cS. aureus 
ATCC29213 strain 
 
Recently, Abuo-Rahma et al.
63
 reported the synthesis, physicochemical parameters and 
antibacterial activity for a series of N-4-piperazinyl modified NOR (Table 12). The authors 
showed that the succinimide Mannich base and the N-formyl analogue revealed a better activity 
than NOR in all the tested strains. Interestingly, strong correlation was established between 
logMIC and LogP values for P. aeruginosa (r
2
 = 0.97), while less evident dependence was found 
for microorganisms such as S. aureus and E. coli (r
2 
= 0.67, 0.62 respectively). These results 
were explained by the fact that the penetration into bacterial cell is not the only determining 
factor which can affect activity. Target affinity is another factor which can influence in vitro 
MIC. The difference in the steric bulk at the C-7 substitution may play an important role in the 
accomodation of these molecules in the active site of enzyme. Another set of correlations 
between molecular weight and activity were obtained, which are consistent with assumption of 
porin-mediated quinolone penetration into Gram-negative organisms and passive diffusion 
through membrane at Gram-positives. 
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Table 12 MICs of NOR derivatives: Mannich bases 
 
R LogP
a 
Mw 
MIC ( M) 
S. aureus
b 
E. coli
b 
P. aeruginosa
b 
H (NOR) 1.49 319 200 44 28 
 
0.55 347 <2.9 32 17 
 
1.16 429 23 <2.4 21 
 
0.43 430 9.3 <2.3 12 
Data from ref 
63
 
a
Calculated by ACD/labs (TM) software 
b
Bacterial strains were supplied 
from department of Microbiology, Faculty of Pharmacy, El-Minia University. 
 
Studies have shown that substitution at C-7 position could also alter the distribution 
between charged and uncharged quinolones species in solution. Alovero et al.
64
 reported the 
synthesis and in vitro antibacterial activity of N-piperazinyl sulfanilyl substituted FQs. These 
derivatives exhibited more favorable kinetics of access to S. aureus cells than do unmodified 
quinolones. It was postulated that this modification at piperazine ring greatly reduces basicity of 
distal nitrogen, therefore leaving only one ionizable carboxyl group in the biological pH range. 
In comparison with zwitterionic parent quinolones (R = H), N-sulfanilyl derivatives (R = H2N-
SO2-C6H4-) have higher fraction of non-ionizated species (HQ
0
) which are the one responsible 
for uptake in Gram-positive organisms (Table 13). This factor appears to be of primary 
importance in determining their high in vitro activity against S. aureus. 
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Table 13 In vitro antimicrobial activity of N-sulfanilyl CIP derivatives 
 
R 
MIC ( M) 
Gram (–) 
E. coli
a
 
Gram (+) 
S. aureus
b
 
H (CIP) 0.75 0.09 
 
0.26 4.1 
Data from ref 
64b
 
a
E. coli
 
ATCC 25922 strain 
b
S. aureus
 
ATCC29213 strain 
 
Another important result is that modifications at C-7 position determine not only the 
potency but also the target enzyme preference. The authors established that unlike unsubstituted 
CIP which targets topoisomerase IV in S. pneumoniae, N-sufanilyl CIP derivatives demonstrated 
a target preference for DNA gyrase. Moreover, N-sulfanilyl CIP selected first-step mutant with 
alterations at QRDR of DNA gyrase. These genetic studies revealed that 4-
aminobenzenesulfonamide group attached to the distal nitrogen at piperazine moiety provokes 
target shift in S. pneumoniae from topoisomerase IV to DNA gyrase and increases activity in 
vitro
65
. However, it is not clear whether the target shift is related with improved potency or not. 
It is worth to mention N-piperazinyl modified CIP derivatives synthesized by Foroumadi 
et al. (Table 14). The development started from derivatives containing a N-[2-(furan-3-
yl)ethyl]
66
 and N-[2-(thiophen-3-yl)ethyl
67
 residues. These compounds exhibited improved 
activity against Gram-positive S. aureus, including methicillin-resistant strains (MRSA) with 
respect to CIP. Generally, these agents were significantly less active than parent quinolone 
towards Gram-negative P. aeruginosa and E. coli (entry 2, 3 Table 14). Further exploration 
yielded a series of compounds with attached phenyl moiety
68
. Tuning the substitution pattern at 
phenyl ring allowed to greatly increase their potency against Gram-negatives, while maintaining 
activity generally comparable to that of parent quinolone against Gram-positives S. aureus and 
MRSA (entry 4, Table 14). More recently, the authors created conformationally-constrained 
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analogs
69
 (entry 5, Table 14). This approach lead to coumarine based compound
70
 that exhibited 
improved potency against Gram-positive S. aureus and MRSA. It is noteworthy to mention that 
this derivative was more active against E. coli and P. aeruginosa in comparison with CIP which 
exhibits one of the lowest MIC towards Gram-negatives (entry 6, Table 14). 
 
Table 14 Antibacterial activity of various N-substituted piperazinylquinolones 
synthetized by Foroumadi et al. 
 
N R 
MIC ( M) 
Ref 
Gram (–) Gram (+) 
E. 
coli
a
 
P. 
aeruginosa
b
 
S. 
aureus
c
 
MRSA I
d
 MRSA II
d
 
1 H (CIP) 0.04 1.2 0.57 1.2 1.2 
66
 
2 
 
0.42 28 0.22 0.42 0.42 
66
 
3 
 
0.83 >212 0.21 0.40 0.40 
67
 
4 
 
0.046 2.9 0.71 0.71 0.71 
68
 
5 
 
1.6 102 0.1 0.2 - 
69
 
6 
 
0.025 0.75 0.37 0.75 0.75 
70
 
a
E. coli ATCC 8739 strain 
b
P. aeruginosa ATCC 9027 strain 
c
S .aureus
 
ATCC 6538p 
strain 
d
MRSA I and II: methicillin-resistant S. aureus (clinical isolates I and II) 
 
All these reports showed that C-7 position possesses unique features, like great tolerance 
for modifications coupled with high influence on antibacterial potency, spectrum, target 
preference and physiochemical properties. Cyclic amines are preferred substituents at this 
position, with piperazine and aminopyrrolidine being the most popular. Attachment of different 
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groups to the distant 4-nitrogen atom at piperazine moiety, generally increases the potency 
against Gram-positives bacteria, including MRSA and lowers activity towards Gram-negatives. 
These results could be related to the fact that increased steric bulk and lipophilicity are better 
tolerated in Gram-positive organisms with a single cellular membrane. In contrast, substitutions 
at piperazine moiety that increase lipophilicity and steric bulk, generally decrease the potency 
towards Gram-negatives. However, no single property of C-7 modification determines activity. 
The combination of different factors, like structural features, LogP, molecular weight governs 
the degree and the spectrum of activity. 
1.4.2.2 “Dimers” 
Since the first insights into mechanism of inhibition by quinolones it was proposed that 
there is more than one molecule present in the quinolone-enzyme complex. In 1989, Shen et al.
71
 
reported for the first time, the coupling of two quinolone pharmacophores in a single molecule. 
He showed that among the synthesized N-1 linked NOR ―dimers‖, the derivative containing 4 
methylene units, was the most potent against E. coli gyrase (with IC50 value roughly equal to that 
of NOR). Further study of Kerns et al.
72
 identified piperazinyl-linked CIP ―dimers‖ that 
displayed equivalent or lowered MIC values compared with those of parent FQ against S. 
pneumoniae and E. coli. However, raised MIC values were observed for ―dimers‖ in comparison 
with CIP against P. aeruginosa (Table 15). The most potent linkers were trans-butenyl and 
para-xylenyl and corresponding ―dimers‖ were tested against wild-type isolate and drug-
resistant strains of S. aureus. 
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Table 15 Piperazinyl-linked CIP ―dimers‖: spectrum of antibacterial activity 
 
Linker 
MIC ( M) 
Gram (–) Gram (+) 
E. coli
a
 P. aeruginosa
b
 S. pneumoniae
c 
 
0.17 >22 0.17 
 
0.33 >21 1.3 
— 
(CIP) 
<0.9 1.5 0.75 
Data from ref 
72-73
 
a
E. coli R973 strain 
b
P. aeruginosa
 
27853 strain 
c
S. pneumoniae
 
49616 
strain 
These CIP-based ―dimers‖ displayed up to 10-fold increased activity against wild-type S. 
aureus and methicillin-resistant strains of S. aureus
73
 (Table 16). More interestingly, a 50-fold 
increased potency was observed against resistant mutant possessing both NorA efflux-mediated 
resistance and a topoisomerase IV mutation. The authors also demonstrated that dimerization 
affected the target preference in S. aureus. In fact, the target of ―dimer‖ in S. aureus is primarily 
DNA gyrase, whereas topoisomerase IV is the primary target of CIP
74
. This could explain 
increased potency against topoisomerase IV mutant strain. The authors also reported similar 
switch in target preference in S. pneumoniae
75
 (Table 16). 
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Table 16 CIP “dimers‖: antibacterial activity against wild-type and resistant 
strains of S. aureus 
Linker 
MIC ( M) 
Strains of S. aureus 
S. aureus 
 1199
a
 
S. aureus 
1199-3
b
 
S. aureus 
 1199B
c
 
MRSA 494
d
 
 
0.04 0.08 0.04 0.17 
 
0.16 0.16 0.16 0.16 
— 
(CIP) 
0.38 3.0 24 1.5 
Data from ref 
73
 
a
SA 1199, wild-type isolate; 
b
SA 1199-3, mutant with norA gene 
overexpression (efflux-mediated resistance) and no gyrase or topo IV mutations; 
c
SA-1199B, 
constitutively overexpresses norA and harbors topo IV mutation (A116E), known to correlate 
with raised FQ MICs; 
d
MRSA 494, methicillin resistant S. aureus isolate. 
 
These reports demonstrated that some piperazinyl linked ―dimeric‖ compounds 
displayed: 
 Increased activity against Gram-positive S. aureus and S. pneumoniae 
 Switch in target preference from topo IV to DNA gyrase  (S.aureus and S. 
pneumoniae) 
 Increased potency against various S. aureus resistant strains, including MRSA 
All these features make ―dimeric‖ quinolones interesting subject of further research. 
1.4.3 Position C-3 
The C-3 position is one of the less explored in the quinolone core, probably due to initial 
modifications which were usually unsatisfactory
48b
. Positions 3 and 4 must be a carboxyl group 
and oxygen atom respectively, because quinolone binding at ternary complex drug-DNA-enzyme 
occurs primarily at these positions. Chu et al.
76
 have shown that bioisosteric substitution of the 
carboxylic acid at C-3 is generally detrimental to the antibacterial activity of quinolones. 
However, isothiazoloquinolones (ITQs) represent one of the few examples of successful 
replacement of the 3-carboxylic acid of FQs (with a ring-fused isothiazolone) without 
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compromising antibacterial activity. The subsequent work of Chu et al
77
 initially investigated 
compound A-62824 (Table 17), in which the 3-carboxylic acid group of CIP is replaced by a 
fused isothiazolo ring and demonstrated that A-62824 was more potent (4 to 10 times) in vitro 
than CIP and possessed enhanced activity against DNA gyrase. The isothiazolo ring system in A-
62824 possesses an aromatic character and the nitrogen proton which is very acidic, can be 
considered to mimic carboxylic acid. The authors also suggested that the planarity between the 
4-oxo group and the enolized isothiazolo group must be important for the DNA gyrase binding.
 
Unfortunately, these molecules also inhibited mammalian topoisomerase II
78
 and caused 
mammalian cytotoxicity. Consequently, ITQs were underexplored until 2006 when Wiles et al.
 
reported that several ITQs bearing functionalized with phenyl
79
 or heteroaromatic groups
80
 at the 
C-7 position, displayed reduced cytotoxicity in Hep2 human laryngeal carcinoma cell line and 
increased activity against a multi-drug-resistant S. aureus strain when compared with A-62824, 
CIP and MOX (Table 17). 
 
Table 17 Antibacterial and cytotoxic activities of ITQs 
 
R7 R8 
MIC ( M) 
CC50 ( M)
d
 Gram (–) Gram (+) 
E. coli
a
 S. aureus
b
 MRSA
c
 
e
 
H 0.01 0.14 11 7 
 
H 0.08 0.01 0.34 8 
 
H 
0.16 0.01 1.36 36 
 
OMe 
– 0.005 0.30 >100 
CIP 0.06 0.76 96.68 >100 
Data from ref 
79-81
 
a
E. coli ATCC 25922 strain 
b
S. aureus
 
ATCC 29213 strain 
c
methicillin-resistant, quinolone-resistant, vancomycin intermediate-resistant S. aureus ATCC 
700699 strain 
d
Cytotoxic concentration: Concentration that reduces the proliferation of Hep2 
human laryngeal carcinoma cells by 50% after 72h 
e
A-62824 
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Further modification of the ITQ nucleus at C-8 position
81
 provided the 8-methoxy 
derivative with the most attractive in vitro biological profile (Table 17). ITQs displayed broad-
spectrum activities especially against Gram-positive pathogens, including several antibiotic-
resistant organisms, such as MRSA, vancomycin-resistant S. aureus (VRSA) and quinolone-
resistant strains
82
. Moreover, ITQs were proved to interact with both DNA gyrase and 
topoisomerase IV – so called dual-targeting mode of inhibition, with the preference for DNA 
gyrase
83
. Genetic studies suggested the potential utility of heteroaryl isothiazolones in combating 
infections caused by S. aureus, including multidrug-resistant MRSA. 
Another interesting approach is represented by the introduction of amide moiety as a 
mimic of carboxyl group. Patel et al.
84
 described the synthesis and antimicrobial activity of CIP 
carboxamides, whereas LEV carboxamides were evaluated by Sultana et al.
85
. Significant 
enhancements of potency towards Gram-positive organisms were achieved in comparison with 
unmodified precursor (Table 18) 
 
Table 18 Zone of inhibition of LEV and its C-6 carboxamide derivative 
 
R 
Zone of inhibition, mm
a
 
Gram (–) Gram (+) 
E. coli P. aeruginosa S. aureus S. pneumoniae 
OH (LEV) 16 14 12 16 
NH-C6H5 15 14 16 19 
Data from ref 
85
 
a
Diameter of inhibited zone proportional to the bacterial susceptibility to 
the antimicrobial present in the disk; measured at 10 ppm concentration. The bacterial strains are 
not indicated. 
 
In this section, we have shown studies demonstrated that in spite of the low tolerance for 
a structural modification an efficient mimic of carboxylate group with acidic moiety could be 
introduced at C-3 position. This would increase in vitro potency and broader the spectrum of 
activity. Varying substituents at this position could also control the target preference.  
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2. Quinolones as antimycobacterial agents 
2.1 Introduction 
Tuberculosis (TB) is one of the most common infectious diseases known to humans. 
About 32% of the world‘s population (1.9 billion people) is infected with TB. Every year, 
approximately 9.4 million of the infected people develop active TB and almost 1.8 million of 
these infected people die from the disease, a life lost due to TB every 15 s. The first-line drugs 
currently used for the treatment of TB, an infection caused by M. tuberculosis, are isoniazid, 
ethambutol, pyrazinamide and rifampicin (Figure 8)
86
. However, TB is still a challenging 
worldwide health problem, especially due to the emergence of multi-drug resistant (MDR) strain 
of M. tuberculosis that is resistant to, at least, the two first-line medications, isoniazid and 
rifampin. It is estimated that, 5% of the more than 9 million persons who develop TB every year 
are infected with a MDR strain of TB
87
. 
 
Figure 8 WHO recommended first-line drugs in TB treatment 
 
The anti-TB activity of FQs has been under investigation since the 1980s. Many are 
active in vitro but only a few, including OFL, CIP, SPA, LEV, MOX have been clinically 
tested
88
.
 
On the basis of these studies CIP, OFL and LEV have been suggested as alternative 
treatments in TB (second-line therapy). FQs and injectable agents (aminoglycosides such as 
amikacin, kanamycin and peptide capreomycin, Figure 9) are the most effective second-line 
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anti-TB drugs and the only ones that have bactericidal effect. They are therefore recommended 
in the initial phase of any MDR-TB treatment regimen. 
 
Figure 9 Examples of second-line antiTB drugs 
 
In 2006, extensively drug-resistant (XDR) tuberculosis emerged, which is basically 
MDR-TB that is additionally resistant to at least one of the FQs and one of the three injectable 
second-line drugs
89
. Combining data from 46 countries that have reported continuous 
surveillance of drug resistance showed that 5.4% of MDR-TB cases were found to have XDR-
TB. Furthermore, the association of TB and HIV infections has caused an urgent need in search 
of alternative chemotherapeutics for M. tuberculosis infection. 
The 13
th
 annual report on global control of TB published by World Health Organization 
(WHO) in 2009 recommended LEV, OFL and MOX as a second-line drug in treating MDR-TB 
and drug-susceptible TB
90
. 
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2.2 Mechanism of action and resistance 
2.2.1 Quinolone target in M. tuberculosis 
As previously described in section 1, the bacterial targets of quinolones are type II 
topoisomerases (DNA gyrase and topoisomerase IV) which grant quinolone antibiotics with 
dual-inhibition mode, lower rates of resistance emerging and high potency. In 1998 the full 
genome sequence of M. tuberculosis was revealed and two genes gyrA and gyrB were identified 
to encode A and B subunits of DNA gyrase
91. However, contrary to ―common‖ bacteria there is 
no evidence of the parC and parE genes for topoisomerase IV in the genome of M. tuberculosis. 
DNA gyrase is the only type II topoisomerase present in this organism and hence is the only 
target for FQ action. Because topoisomerase IV is necessary for the decatenation of daughter 
chromosomes during DNA replication; functions of the single M. tuberculosis type II 
topoisomerase were explored by Aubry et al.
92
 The intermolecular passage activities of purified 
DNA gyrase from M. tuberculosis was demonstrated: decatenation activity of this enzyme was 
30-fold higher than that of E. coli DNA gyrase, but was lower than that of topoisomerase IV 
from S. pneumoniae. Overall, the type II topoisomerase from M. tuberculosis exhibits classical 
supercoiling activity of DNA gyrase while having additional decatenation topo IV like activity. 
The absence of dual inhibition together with unique topoisomerase protein sequence marks out 
M. tuberculosis among ―common‖ Gram-positive/negative bacteria. 
2.2.2 Penetration into Mycobacterium cell 
Bacterial topoisomerases are intracellular targets and quinolones have to pass through the 
cell wall to get into the intracellular space. Mycobacterium species share a characteristic cell 
wall, thicker than in many other Gram-positive and Gram-negative bacteria, which is 
hydrophobic, waxy and rich in mycolic acids/mycolates
93
. Mycobacteria possess, in addition to 
phospholipid bilayer and peptidoglycan, the hydrophobic layer of long chain (C70-C80) fatty acids 
known as mycolic acids. They are held together with peptidoglycan layer by the polysaccharide, 
arabinogalactan (Figure 10). 
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Figure 10 Structure of Mycobacterium cell wall in comparison with Gram-
positive and Gram-negative bacteria. 
 
The low permeability of the mycobacterial cell wall, with its unusual structure, is now 
known to be a major factor in intrinsic antibiotic resistance of M. tuberculosis
94
. In addition to 
the cell wall, there are evidences for the outer capsule existence that creates a barrier for 
diffusion of foreign molecules into the inner parts of the envelope
95
. It is supposed that more 
hydrophilic agents cross the cell wall slowly because the mycobacterial porin is expressed in low 
quantities and is inefficient in allowing the permeation of solutes. More lipophilic agents are 
presumably slowed down by the lipid bilayer which is of unusually low fluidity and abnormal 
thickness. 
2.2.3 Resistance to quinolones 
In 1970s a dramatic decline in the prevalence of TB infections was observed and TB 
ceased to be a problem in industrialised countries. Unfortunately, TB yet remains one of the most 
deadly infections primarily due to the emergence of resistance development. As the rate of 
mutations conferring resistance to multiple drugs is very low, the WHO-recommended standard 
chemotherapy consists of a combination of four first-line drugs (isoniazid, ethambutol, 
pyrazinamide and rifampicin), while second-line drugs (FQs, aminoglycosides) are mostly used 
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in the treatment of MDR-TB. Another approach has been proposed to prevent resistance; the FQ 
must be administred at doses that produce serum concentrations that exceed the ―mutant 
prevention concentration‖ (MPC). This drug concentration is capable of inhibiting all 
spontaneous first-step mutants
96
. However, to date there is no quinolone which possesses such a 
good pharmacodynamic safety profile and high degree of activity. 
Emerging resistance poses a serious problem on the way of the world-wide eradication of 
TB and there is a constant need for new antimycobacterial agents. 
2.2.3.1 Mutations at the target site 
The primary source of quinolone resistance in M. tuberculosis is mutations at the DNA 
gyrase. Various studies demonstrated that laboratory-selected FQ resistant mutants of M. 
tuberculosis showed exactly the same changes described in clinical isolates. Significant 
resistance to FQs can be achieved with a single gyrase mutation, whereas at least two mutations 
(two mutations in gyrA, or mutations in gyrA plus gyrB) found to be necessary for the highest 
level of resistance. Mutations encoutered in FQ-resistant M. tuberculosis were located in codons 
equivalent to those in GyrA genes of other FQ-resistant bacteria. The most frequently mutated 
codons were: codon 90 (with a Ala/Val change), codon 91 (Ser/Pro) and codon 94 (with five 
different amino acid change: Asp/Ala-Gly-His-Tyr or Asn)
97
.  
2.2.3.2 Efflux mediated resistance 
Previously mentioned cell wall barrier alone cannot produce significant level of drug 
resistance, which requires synergistic contribution from a second factor, such as the efflux 
pumps. Recent evidence suggests that Mycobacteria extrude many drugs via active efflux 
systems
98
 and efflux-mediated FQ resistance has been described in the Mycobacterium 
smegmatis (M. smegmatis)
99
. The LfrA protein gene has been identified in M. smegmatis; it was 
shown to have greater affinity for hydrophilic FQ‘s (CIP, LEV) than for lipophilic ones (SPA, 
NAL)
100
. 
2.2.3.3 DNA mimicking 
In 2001 genetic selection for FQ resistance in M. smegmatis identified a new type of 
resistance mechanism mediated by the MfpA protein
101
. The sequence of MfpA revealed it to be 
a member of the ―pentapeptide repeat‖ family of bacterial proteins, in which every fifth amino 
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acid is either a leucine or phenylalanine. This protein forms an adduct with gyrase from M. 
tuberculosis and inhibits its activity
102
.  
 50 
 
2.3 Structure-activity relationships 
2.3.1 General trends 
In comparison with thousands of quinolones tested against ―common‖ bacteria, there are 
less data on structure activity studies for Mycobacteria. Because M. tuberculosis divides very 
slowly (about 15-20 hours for division), 20-30 days are necessary for testing. In addition, 
analysis requires special protective conditions. For all these reasons, several authors utilized less 
hazardous and rapidly growing M. fortuitum to estimate the quinolone potency against M. 
tuberculosis. Testing results against M. smegmatis were often included for comparative 
purposes. Generally, M. fortuitum was more sensitive to the compounds than M. smegmatis. 
Renau et al.
103 
carried out systematic studies focused on the influence of lipohilicity at N-1 and 
C-7 positions on quinolone antimycobacterial activity. The evident rationale for these studies 
was the fact that, unlike ―common‖ bacteria, M. tuberculosis possesses a thick and lipophilic cell 
wall that forms a transport barrier for antibiotics. However, the authors showed that ―intrinsic‖ 
activity against Gram-positive and/or Gram-negative bacteria is the important factor for 
antimycobacterial activity, more determining than lipophilicity of N-1 substituent. The results 
summarized (Table 19), demonstrated that compounds with close CLogP values exhibit 
dramatic differences in activities toward Mycobacteria. 
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Table 19 Comparative effect of N-1 substituents on antibacterial / 
antimycobacterial activity 
 
R1 CLogP
e
 
MIC ( M) 
Bacteria G(–)/G(+) Mycobacteria 
E. coli
a
 S. aureus
b
 M. fortuitum
c
 M. smegmatis
d
 
Et (NOR) 2.21 0.31 9.7 1.6 6.3 
 (CIP) 2.04 0.15 2.4 0.18 0.75 
i-Pr 2.52 2.4 >9.3 3.0 12 
 
2.60 1.2 9.0 1.5 5.8 
t-Bu 2.92 0.6 2.3 <0.09 0.37 
 
4.85 0.25 1.0 0.62 1.2 
 
5.20 0.5 2.0 2.5 10 
 
5.53 2.0 >7.8 41 81 
Data from ref 
103
 
a
E. coli Vogel strain 
b
S. aureus H-228 strain 
c
M. fortuitum ATCC6841 
strain 
d
M. smegmatis ATCC19420 
e
A computational model (MedChem Version 3.54, Pomona 
College, Pomona, CA) was used to determine the theoretical distribution coefficients (clog P) for 
each compound 
 
In this study, the most active agents against mycobacteria were compounds substituted at 
N-1 with a tert-butyl and cyclopropyl group. CIP was further modified at C-7 piperazine moiety 
with side chains bearing various alkyl substituents in order to modify the lipophilic character of 
the heterocycle
103
. Detailed results on the influence of the C-7 substituent on the 
antimycobacterial activity will be discussed in the corresponding section. 
C-8 substituent has influence on the potency against Mycobacteria. In the case of M. 
smegmatis the following order was demonstrated for activity against both wild-type strains and 
resistant mutants: OMe ≈ Cl > Br > F > H104 (Table 20). Moreover, the C-8 methoxy group, 
when compared to unsubstituted C-8 analog greatly reduced the selection of resistant mutants of 
M. tuberculosis
105
.  
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Table 20 Influence of C-8 position on the activity against M. smegmatis 
 
R8 
M. smegmatis, MIC99 ( M)
a
 
gyrA
+b 
gyrA
c
 
H 0.290 8.10 
F 0.099 3.30 
Br 0.075 2.26 
Cl 0.076 1.73 
OMe 0.080 1.30 
Data from ref 
104
 
a
The MIC at which 99% of the isolates tested were inhibited 
b
M. 
smegmatis wild-type mc
2
155 strain 
c
M. smegmatis gyrA (Asp95Gly) quinolone-resistant mutant 
KD2003 
2.3.2 SAR at C-7 position 
C-7 position tolerates large structural changes, but an important difference between 
mycobacteria and other Gram-positive or Gram-negative bacteria was demonstrated. Haemers et 
al.
106
 studied the influence of N-substitution of C-7 piperazine on antimycobacterial activity of 
CIP. Derivatives with longer alkyl chain (and higher lipophilicity) showed higher 
antimycobacterial activity. However, introduction of bulky phenyl or benzyl substituents 
lowered the potency in spite of high lipophilicity (Table 21). 
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Table 21 Influence of the C-7 piperazine alkylation on the antimycobacterial 
activity of CIP 
 
R 
M. tuberculosis, MIC ( M) 
MIC50
a
 MIC90
a
 
H (CIP) 1.5 3.0 
Me 0.36 1.5 
Et 0.35 0.70 
n-Pr 0.33 0.67 
Ph 4.9 9.8 
CH2Ph 2.4 4.8 
Data from ref 
106
 
a
Compounds were tested against collection of M. tuberculosis strains; 
MIC50 and MIC90 are MIC for 50% and 90% of isolates tested, respectively. 
 
As it was demonstrated that C-8 methoxy FQs are more active against M. tuberculosis, 
Aldeida et al.
107
 described the anti-TB evaluation of various 8-methoxy-FQ derivatives bearing 
some mono N-alkylated 1,3-propane diamine substituents at C-7 position. It was observed that, 
similarly with earlier discussed N-alkyl CIP analogs, in the series of GAT analogs 10 carbon 
atoms chain length confer maximum potency. In the same time, compounds with shorter or 
longer chains are less active (Table 22). 
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Table 22 Activity of C-7 modified GAT analogs against M. tuberculosis H37Rv 
(virulent strain) 
 
n m MIC ( M) 
3 5 115 
3 7 2.71 
3 9 0.63 
3 11 1.20 
GAT 0.27 
Data from ref 
107
  
 
The group of Renau et al. conducted systematic studies on the influence of C-7 
substituent on the activity against Mycobacteria. The authors have demonstrated that N-1 
cyclopropyl (and t-butyl) quinolones were more active than N-1 2,4-difluorophenyl analogs 
(Table 19)
103
. This report also included over 15 different residues based on piperazine and 
pyrrolidine side chains at C-7 position. The biological evaluation of this series of compounds 
revealed that an increase in lipophilicity (via alkyl substitution of piperazine moiety) led to a 
decrease in antimycobacterial activity. Results from Table 23 show that in each series the most 
lipophilic compounds were the less active towards M. fortuitum. Comparison between the two 
series of compounds demonstrated that piperazine-substituted analogs were almost equipotent to 
pyrrolidine-substituted derivatives. 
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Table 23 Piperazine vs pyrrolidine side chain at C-7 position: influence on the 
antimycobacterial activity 
 
R7 CLogP
a
 
MIC ( M) 
M. fortuitum M. smegmatis 
 
(CIP) 
2.04 0.18 0.75 
 
2.89 0.17 0.72 
 
3.42 0.17 0.36 
 
3.73 0.67 0.67 
 
4.48 2.6 1.3 
 
1.94 <0.09 0.75 
 
2.13 0.69 1.4 
 
2.62 0.35 1.3 
 
2.66 1.3 1.3 
 
2.97 0.65 1.3 
Data from ref 
103
 
a
A computational model (MedChem Version 3.54, Pomona College, 
Pomona, CA) was used to determine the theoretical distribution coefficients (clog P) for each 
compound 
 
The group of Sriram et al.
108
 synthesized and evaluated some OFL and CIP derivatives 
modified at C-7 position. The authors first explored the in vitro antimycobacterial activity of 
some Mannich bases of CIP (Table 24) and demonstrated that simply increasing the lipophilic 
character of the C-7 substituent (as seen for clogP values) increased the activity. 
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Table 24 Mannich bases of CIP and their antimycobacterial activity 
 
R R' CLogP
a
 
% Inhibition at 
6.25 g/mL
b
 
MIC ( M)
b
 
NHCONH2 Br 2.04 99 1.98 
NHCSNH2 Br 1.66 100 1.88 
 
F 5.29 100 1.00 
CIP 0.01 95 6.04 
Ethambutol – 98 9.22 
Data from ref 
108
 
a
Calculated using online service www.logp.com 
b
M. tuberculosis H37Rv 
strain 
 
To investigate this observation in more depth, the authors prepared and evaluated a series 
of C-7 substituted CIP analogs (Table 25)
109
. Biological evaluation showed that compounds with 
high bulky substituent at C-7 position could display high potency towards M. tuberculosis. In 
addition, the most active derivatives were evaluated against MDR strains of M. tuberculosis 
showing low values of MICs. A comparison of substitution pattern at C-7 position demonstrated 
the following order of activity: piperidine > piperazine > morpholine. 
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Table 25 Influence of bulk and liphophilicity at C-7 position on in vitro 
antimycobacterial activity 
 
R7 
MIC ( M) 
M. tuberculosis
a
 MDR-TB
b
 
 (CIP) 6.04 – 
 
0.17 0.17 
 
0.94 0.94 
 
1.08 2.16 
Data from ref 
109
 
a
M. tuberculosis H37Rv strain 
b
MDR-TB clinical isolate from 
Tuberculosis Research Center, Chennai, India 
 
The authors recently described a series of OFL analogs bearing various substituents at C-
8 and C-10 positions on the benzoxazine moiety (Table 26)
110
. The results demonstrated the 
positive impact of C-8 nitro group on antimycobacterial activity with the following order of 
activity NO2 > H > NH2. Concerning the substitution pattern at C-10 position the authors have 
found the following trend in antimycobacterial activity: piperidine > morpholine > piperazine; 
this is quite similar to that obtained for CIP derivatives. 
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Table 26 Influence of C-8 and C-10 substitution on antimycobacterial activity of 
OFL derivatives 
 
R8 R10 
MIC99 ( M) 
M. tuberculosis
a
 MDR-TB 
NO2 
 
2.63 2.63 
H 
 
0.91 0.44 
NO2 
 
0.19 0.09 
H  (OFL) 2.16 34.6 
Data from ref 
110
 
a
M. tuberculosis H37Rv strain  
2.3.3 SAR at C-3 position 
Similar to antibacterial potency C-3 position have low tolerance for modification and 
carboxyl group is generally kept to render high levels of antimycobacterial activity. However, 
some ITQs that have been already mentioned as potent antibacterials showed noticeable activity 
against Mycobacteria. The most potent compound among them is ACH-702
111
 (Table 27), 
which exhibited MICs towards the clinical isolates of M. tuberculosis superior or equal to that of 
marketed quinolones. 
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Table 27 Chemical structure of ACH-702 and its antimycobacterial activity 
 
Compouund 
M. tuberculosis (31)
a
 ( M) 
MIC50 MIC90 
ACH-702 0.14 0.28 
MOX 0.30 0.62 
Data from ref 
111
 
a
M. tuberculosis H37Rv strain (number of clinical isolates) 
 
In summary, we can conclude that Mycobacteria species represent a specific target for 
FQs with different SAR trends established for other bacteria. Lipophilicity of the antibacterial 
agent was shown to play an important role but it is not the only governing factor in determining 
the potency towards Mycobacteria. Intrinsic antibacterial activity was also necessary to achieve 
high levels of antimycobacterial activity. Recent studies have shown that FQs have a full 
potential of becoming a safe and reliable tool for the treatment of classic and resistant TB. 
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3. Quinolones as antiproliferative agents 
3.1 Introduction 
We have described (section 1.3) the quinolone‘s mechanism of antibacterial action, which 
comprises inhibition of bacterial type II DNA topoisomerase enzymes (gyrase and topoisomerase 
IV)
112
. In order to manage DNA, eukaryotic cells have also evolved a topoisomerase II. 
Eukaryotic type II topoisomerase cannot introduce supercoils; it can only relax them. As a result 
of its catalytic function, topoisomerase II is necessary for the viability of all organisms from 
unicellular bacteria to humans and is the target for some of the most active anticancer agents 
used for the treatment of human malignancies
113
. 
One of the first reports of possible anticancer effect of quinolones came in the middle of 
80‘s. It was found that antibacterial quinolones such as CIP, NOR and OFL display only slight 
inhibitory activity against calf thymus topoisomerase II
114
. Meanwhile, to improve the quinolone 
activity toward Gram-positive bacteria, a series of C-7 aryl derivatives were explored and some 
of them, bearing 4-pyridinyl substituent, enhanced topoisomerase II-mediated DNA damage and 
turned out to be too toxic for the use as antibiotic
115
. These early findings provided lead 
compounds for further exploration of potential antitumor quinolones with different biological 
targets
78, 116
. As a result of numerous efforts SNS-595 (Voreloxin®)117 and CX-3543 
(Quarfloxin®)118 were discovered and entered phase II clinical trials on patients. However, 
currently there is no quinolone-based anticancer drug on the market. 
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3.2 Eukaryotic quinolone targets 
3.2.1  Topoisomerase II 
First exploited target in eukaryotic species was topoisomerase II, an enzyme responsible 
for relaxing superhelical tension in DNA strands during transcription, replication and 
recombination. Eukaryotic topoisomerase II have been first isolated from lower eukaryotes such 
as yeast and Drosophila; these species have only a single isoform of the enzyme. On the other 
hand, studies have confirmed the existence of two closely related topoisomerase II isoforms in 
higher eucaryotes (vertebrate species), termed topoisomerase II  and 
119
. Multiple sequence 
alignments between species revealed a striking degree of similarity between the type II DNA 
topoisomerases of different species, including rat, mouse, hamster, drosophila, yeast, bacteria 
and viruses
120
. In addition, Wasserman et al. have demonstrated that yeast can be used in the 
study of anticancer drugs targeting human DNA topoisomerase II . 
The two mammalian topoisomerase II isoforms, α and β possess a high degree of amino 
sequence identity (~70%) while being encoded by different genes. However, they are expressed 
differently during growth cycle. Whereas topoisomerase II appears to be present in most cell 
types, topoisomerase II  concentrates in rapidly proliferating cells, while being almost 
nonexistent in resting tissues. Prokaryotic type II topoisomerases are heterodimers (A2B2), 
whereas eukaryotic analogs are homodimeric (A2) in nature. Over the course of evolution the 
ParC and ParE parts of bacterial enzyme fused into single protein, encoded by single gene in 
mammalians
122
. 
 62 
 
 
Figure 11 Representative examples of anticancer drugs acting through 
topoisomerase II inhibition 
 
Mammalian topoisomerase II is a target for a number of anticancer drugs, such as 
etoposide, doxorubicin, mitoxantrone and amsacrine (Figure 11)
123
. These drugs can be divided 
into inhibitors and poisons. While topo II poisons stabilize specifically covalent DNA-
topoisomerase complex (cleavage complex), topo II inhibitors act at any other step of catalytic 
cycle. Topo II inhibitors bind the enzyme, thus excluding it from catalytic cycle. This blocks 
DNA related processes, like replication, translation and transcription and causes some cytostatic 
effects
124
. Topo II poisons can act in two possible ways: they could block enzyme in the ternary 
complex with torn DNA and inhibit religation of DNA breaks or increase the forward rate of 
topoisomerase II-DNA cleavage complex formation, in each case producing double-stranded 
breaks in DNA. The presence of numerous double-stranded breaks starts up a repair mechanism, 
which tends to provoke single-nucleotide exchanges or single-base deletions. In such way topo II 
poisons turn topoisomerase into endogenous toxin which causes damage to genetic material. This 
triggers a sequence of biochemical events leading to a programmed cell death, apoptosis
125
. 
Quinolone derivatives with postulated action as topo II poisons are CP-115,953
116a, 126
 , 
WIN-58,161
127
 and SNS-595
128
, while A-62,176 is likely to be a catalytic topo II inhibitor
129
 
(Figure 12). 
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Figure 12 Representative examples of quinolone topo II inhibitors and poisons 
3.2.2 Topoisomerase I 
A number of currently used antitumor drugs such as camptothecin derivatives, topotecan 
and irinotecan target topoisomerase I
130
. This enzyme has functions similar to those of 
topoisomerase II; it relieves tension in duplex DNA by introducing a temporary, enzyme-bond, 
single-strand break in the DNA double-helix. The resulting nick permits rotation of the 
downstream helix about one or more bonds in the intact strand that is driven by the free energy 
associated with DNA supercoiling. Topo I targeted drugs act by trapping enzyme-DNA covalent 
complex and by reducing the rate of religation they prolong the lifetime of nicked intermediated. 
It is generally believed that lethal action of these drugs is mediated through stabilization of 
topoisomerase-DNA complex that could produce lethal double-stranded breaks when 
encountered by DNA replication enzymes
131
. You et al.
132
 designed, synthesized and evaluated a 
series of 32 quinolone derivatives as potential topoisomerase I inhibitors. The 2 most potent 
compounds (Figure 13) presented a significant inhibitory effect on topo I, was proved to induce 
cell death via apoptosis and accelerated DNA strand breaks without significant alteration in cell 
cycle populations. 
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Figure 13 Quinolone-based topo I inhibitors synthesized by You et al.
132 
3.2.3 G-quadruplex structures 
During the course of extensive search for potent anticancer drugs new targets recently 
started to emerge. G-quadruplex structures are known to inhibit telomerase activity by 
sequestration of the substrate required for enzyme activity
133
. Therefore small organic molecules 
with planar structure that stabilize or induce G-quadruplex structures have been suggested as 
potential anticancer therapeutic agents. Indeed, research in this direction led to discovery of the 
fluoroquinonaphtoxazine CX-3543 which is the first G-quadruplex interactive agent to enter 
human clinical trials. This molecule is currently under evaluation against 
carcinoid/neuroendocrine tumors in a phase II clinical trial
118
. Various FQs with attached 
naphtoxazine or anthroxazine rings and planar structure are able to interact with duplex DNA 
and to intercalate with the more expansive planarity of G-quadruplex structures
116b, 134
 (Figure 
14). CX-3543 binds to G-quadruplex DNA and was shown to selectively disrupt interaction of 
rDNA G-quadruplexes with the nucleolin protein thereby inhibiting RNA Polymerase I complex 
transcription and inducing apoptotic death in cancer cells
135
. 
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Figure 14 Representative quinolone-based G-quadruplex inhibitors 
3.2.4 Microtubules 
Microtubules are intracellular targets for anticancer chemotherapy. These fibrillar 
structures play important role in a variety of cellular processes, in particular the cell mitosis. 
Microtubules are formed as a result of polymerization of - and -tubulin with microtubule 
associated proteins. Wide range of drugs could interfere with normal formation of microtubule 
and mitotic spindle thereby provoking the cell cycle arrest in the metaphase
136
. Compounds that 
target microtubules are usually divided into stabilizers and destabilizers. Microtubule stabilizers 
are represented by drugs from taxane family, paclitaxel and docetaxel, along with the natural 
epothilones and their analogs (Figure 15).  
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Figure 15 Microtubule stabilizing anticancer agents 
 
Theses drugs bind to microtubule and prevent it from disassembly which causes cell 
death by apoptosis
137
. Microtubule destabilizers predominantly bind at central -tubulin subunit 
and thus prevent it from polymerization
138
. Quinolone agents who showed significant antimitotic 
activity are generally represented by 2-aryl derivatives (NSC 664171
139
, CHM-1
140
, YJC-1
141
, 
Figure 16). These microtubule destabilizers inhibit the tubulin polymerization, leading to mitotic 
arrest in G2/M phase and induce apoptosis by Cdk-1 involved signaling pathways
142
. In this 
series the most potent representatives demonstrated in vitro nanomolar IC50 and reached 
preclinical trials in humans. 
 
 
Figure 16 Representative examples of antimitotic quinolones 
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3.3 Structure-activity relationships 
In contrast to the quinolone antibacterials with thousands of tested compounds and 
detailed SAR studies, quinolone-based anticancer agents only started to emerge with a few most 
potent representatives. There are numerous obstacles to define SAR for cytotoxic quinolones, 
like the variety of intracellular targets and a large diversity of tested cancer cell line types. 
Moreover, similar to the previously described antibacterial SARs, no single position has a 
controlling effect on the observed antitumor activity but, more likely, a combination of various 
substituents contributes to the cytotoxic potency. So, in order to maintain clarity and reliability, 
one should account for the type of cancer cell line used, biological target and the nature of other 
substituents presented in the molecule. In the following sections quinolone structures will be 
discussed separately for each target (if known) and a last paragraph will be devoted to ―cytotoxic 
quinolones‖ with unidentified target. 
3.3.1  Topoisomerase II poisons and inhibitors 
In vitro binding studies have revealed a common domain of interaction between 
eukaryotic topoisomerase II with both antineoplastic inhibitors such as etoposide and FQs
143
. 
However, the FQ concentrations required in vitro to form a cleavage complex with native 
eukaryotic type II topoisomerase were 100- to 1000-fold higher than those required for gyrase
114-
115, 144
. Initial studies were directed by attempts to shift inhibitory activity from bacterial to 
eukaryotic topoisomerase II. As a result of these reports several compounds with high potency 
were identified and SARs were established. A schematic historical development of anti-
topoisomerase II quinolones is reported in Figure 17. 
New structures with C-7 aryl substituents were first identified and the antibacterial lead 
compound Rosoxacin was transformed into cytotoxic CP-67,015 by addition of two fluorine 
atoms at C-6 and C-8 positions
115
. Further optimization led to CP-67,804 and CP-115,953 with 
4-hydroxyphenyl substituent at C-7 position. These compounds were both cytotoxic in vitro and 
number of experimental evidences indicated that they target topoisomerase II
116a
. 
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Figure 17 Schematic development of anti-topoisomerase II quinolones (IC50, 
concentration that inhibits human HeLa topoisomerase II-DNA complex 
formation by half). 
 
The discovery of C-7 aryl cytotoxic quinolones lead to SAR concerning the role of C-7 
substituent
144
. Examples shown in Table 28 illustrate some general trends:  
1) C-7 position is of high importance, in comparison to C-8 and N-1 positions  
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2) 4-Hydroxyphenyl substituent at C-7 position increase anti-topoisomerase II activity 
but also increase the cytotoxicity of compounds 
It is worth to note that a clear correlation exists between in vitro topoisomerase II 
inhibitory activity, DNA cleavage and cytotoxicity. This supposes that the common biological 
target of these derivatives is topoisomerase II, in spite of structural differences at C-7 position. 
 
Table 28 Anti-topoisomerase II activity and cytotoxicity of various C-7 modified 
CP-115,953 analogs 
 
Compound R7 
DNA cleavage, 
EC2 ( M)
a
 
DNA relaxation, 
IC50 ( M)
b
 
Cytotoxicity, 
CC50( M)
c
 
CP-115,953  0.3 3.2 9 
CP-162,600 
 
105 198 >500 
CP-171,472 
 
53 140 104 
Difluorociprofloxacin 
 
63 132 235 
Data from ref 
144
 
a
EC2, Effective concentration of agent required to enhance calf thymus 
topoisomerase II-mediated DNA cleavage twofold 
b
The agent concentration required to inhibit 
DNA relaxation by calf thymus topoisomerase II by 50% 
c
Concentration of compound required 
to kill 50% of Chinese hamster ovary (CHO) cells. 
 
At the same time Wentland et al. studied a series of pyridine based C-7 substituents and 
their influence on topoisomerase II inhibition
145
. The authors demonstrated that 4-pyridinyl 
moiety at C-7 position could also give rise to cytotoxic compounds; however, their levels of 
potency were lower than that of 4-hydroxyphenyl analog (CP-115,953) and tuning with 
additional methyl groups is needed to increase the topoisomerase II inhibitory activity (Table 
29). 
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Table 29 Pyridinyl vs phenyl substituent at C-7 position with regard to anti-
topoisomerase II activity 
 
R7 IC50
 
( M)
a
 
 
(
 
CP-115,953) 
1.2 
 
17 
 
(WIN-57,294) 
7.6 
Data from ref 
145
 
a
Concentration that inhibits human HeLa topoisomerase II-DNA 
complex formation by half 
 
During the initial studies SNS-595 didn‘t induce topoisomerase II-mediated DNA 
cleavage, thereby it wasn‘t supposed to act as a topoisomerase poison146. However, detailed 
studies established that voreloxin intercalates DNA and poisons topoisomerase II, inducing site-
selective double-strand DNA breaks and G2 arrest
128
. During the development of SNS-595 large 
number of derivatives bearing different groups at C-7 position were prepared and evaluated. 
Some SARs were established and, particularly, aminopyrrolidine moieties at C-7 provided 
promising cytotoxic activity against murine P388 leukemia cells. Analysis of different 
substitution patterns revealed that additional substitution at 4‘-position of pyrrolidine cycle 
further increases the cytotoxicity. Among all, 3'-methoxy-4'-methylaminopyrrolidinyl analog 
showed the highest cytotoxic activity in both in vitro and in vivo assays
146b
. 
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Table 30 In vitro antiproliferative activity of SNS-595 and its C-7 analogs against 
murine P388 leukemia cells 
 
R7 IC50 ( M)
a
 
 
18 
 
19 
 
0.16 
 
0.028 
 
SNS-595 (®Voreloxin) 
0.019 
Data from ref 
146b
 
a
Concentration of agent that reduces murine P388 leukemia cell 
viability by 50%  
 
In the previously discussed work, Wentland et al.
145
 also studied the influence of N-1 and 
C-3 positions on overall potency. Although all compounds were less active than CP-115,953 the 
authors demonstrated that (Table 31):  
1) Ethyl and unsubstituted N-1 position are not tolerated, with cyclopropyl being 
the optimal for topoisomerase II inhibition;  
2) The presence of 3-CO2H group is not necessary for high levels of anti-
topoisomerase II activity and 3-H analog was also significantly active; 
3) In the absence of C-3 carboxylic group, C-2 position could be substituted with 
small groups (CH3) without loss of activity, while larger phenyl derivative is 
inactive 
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Table 31 Influence of R-1, R-2, R-3 substituents on human topoisomerase II 
inhibition 
 
R1 R2 R3 IC50,( M)
a
 
c-Pr 
(WIN-57,294) 
H CO2H 7.6 
Et H CO2H 110 
H H CO2H >300 
c-Pr H H 17 
c-Pr CH3 H 16 
c-Pr Ph H >240 
Data from ref 
145
 
a
Concentration that inhibits human HeLa topoisomerase II-DNA 
complex formation by half 
 
This unexpected result contrasts the SAR determined in quinolone antibacterials, where 
the 3-CO2H (or isosteric replacement) is required for prokaryotic topoisomerase inhibition. 
Interestingly, these results induced further structural exploration at C-3 position, leading 
to the discovery of WIN-64,593. This 2,6-dihydroxybenzyl derivative is a topoisomerase II 
inhibitor
147
 (Figure 17, Figure 18) with IC50 of 0.096 M (80-fold more active than parent 
WIN-57,294) and in vivo antitumor properties in mice.  
In addition, a series of compounds with annulated cycles at C-3 position showed 
enhanced cytotoxicity against mammalian cells. Studies have shown that the requirement for 
inhibition of eucaryotic enzyme seems to be the coplanarity of the C-3 substituent with the 
quinolone. Isothiazoloquinolones A-65,281 and A-65,282, (Figure 18) inhibited DNA 
unknotting with 50% inhibitory concentrations of 21 M and were found to induce significant 
DNA breakage mediated by calf thymus topoisomerase II
78
. Another interesting example of 
successful C-3 modification is represented by derivatives bearing a pyrazolo-ring fusion at the 3- 
and 4-positions of the quinoline moiety (Figure 18). The most potent pyrazoloquinoline 
displayed human HeLa topoisomerase II IC50 = 0.5 M, Figure 18), and demonstrated antitumor 
activity both in vitro (P388 mouse leukemia cells) and in vivo (mice)
148
. 
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Figure 18 Representative examples of anti-topoisomerase II quinolones with 
modified C-3 position 
 
Robinson et al.
149
 conducted a detailed study concerning the role of C-8 fluorine and N-1 
cyclopropyl substituents. The authors showed that, in comparison with CP-115,953, 
defluorinated analog CP-115,955 (Table 32) had lower levels of DNA cleavage and 
topoisomerase II inhibition which is thought to be related with lower in vitro cytotoxicity 
towards mammalian cells. Moreover, CP-115,953 with N-1 cyclopropyl substituent turned out to 
be more potent than N-1 ethyl analog CP-67,804 (Table 32). Some levels of cross resistance to 
quinolones in etoposide-resistant cell line (etoposide also targets topoisomerase II) suggested 
that topoisomerase II is a target for these quinolones). 
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Table 32 Influence of C-8 fluorine and N-1 substituents on topoisomerase II 
activity and cytotoxicity 
 
Compound R1 R8 
Topoisomerase II activity
a
 Cytotoxicity CC50 ( M)
d
 
DNA cleavage
b
 IC50 ( M)
c
 Wild type Vpm
R
-5
e
 
CP-115,953 c-Pr F 1,00 60 9 12 
CP-115,955 c-Pr H 0.38 130 20 40 
CP-67,804 Et F 0.39 325 70 265 
Data from ref 
116a, 149
 
a
Drosophila melanogaster topoisomerase II 
b
Relative scale of 
potency with 1,00 value set for CP-115,953 
c
Concentration that inhibits topoisomerase II DNA 
relaxation ability by half 
d
Concentration that reduces the proliferation of Chinese hamster ovary 
(CHO) cells by 50% 
e
Selected cell line with resistance to etoposide  
 
At the same time Suto et al.
150
 investigated a large number of FQs for their cytotoxicity 
towards mammalian cells, which is thought to be related with topoisomerase II inhibition. In this 
report, halogens at C-8 and cyclopropyl at N-1 gave the most cytotoxic derivatives, which is 
consistent with previous results of Robinson et al.
149
 (Table 32) 
Numerous SARs were established during the development of SNS-595
146
 from 
antibacterial lead compound AT-3639
151
 (Figure 19). 
 
Figure 19 Development of SNS-595, promising antitumor quinolone 
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Interesting results were obtained by Tsuzuki et al.
151
 when different C-3 substituents 
where introduced into SNS-595 molecule. The authors provided another prove for tolerating 
modifications at C-3 position with regard to cytotoxic activity. The analog bearing formyl group 
was almost equipotent to parent SNS-595 compound both in vitro and in vivo (mice implanted 
with P388 leukemia cells) (Table 33). However, low solubility of the formyl analog hampers its 
practical usage as a therapeutic agent. Notwithstanding these studies gave basis to the further 
exploration of more usefull antitumor drug candidates. 
 
Table 33 In vitro cytotoxicity and in vivo antitumor activity of C-3 modified 
SNS-595 analogs 
 
R3 
In vitro In vivo 
IC50
a
 ( M) Dose, mg/kg T/C
b
, % 
CO2H 
(SNS-595) 
0.01 3.13 200 
CHO 0.03 3.13 188 
CH2OH 0.06 – – 
Data from ref 
151
 
a
Concentration of agent that reduces murine P388 leukemia cell 
viability by 50% 
b(Median survival time of treated mice)/(median survival time of controls)×100. 
 
While exploring C-6 substituent Tomita et al
146a
 reported that non-fluorinated analog was 
twofold more cytotoxic against murine P388 leukemia cells than fluorinated AT-3639 (Table 
34). In comparison with the 6-F counterpart, 6-NO2, 6-NH2 and 6-OH derivatives were 
significantly less active (IC50 values were 5.1; 2.4; 10 M respectively). In addition, the authors 
demonstrated that further modifications at C-5 position of the 6-unsubstituted 1,8 naphthyridone 
lead to less cytotoxic activity, with exception of 5-NH2 derivative which was almost equipotent 
to the unsubstituted compound with IC50 = 0.019 M. 
 76 
 
Table 34 Cytotoxic activity of C-6 fluorinated vs unsubstituted 1,8 
naphthyridones against murine P388 leukemia cells 
 
R6 IC50
a
 ( M) 
H 0.028 
F 
(AT-3639) 
0.056 
Data from ref 
146a
 
a
Concentration of agent that reduces murine P388 leukemia cell 
viability by 50% 
 
The shift from bacterial to mammalian topoisomerase inhibition activity was also noted 
for LEV analogs. Wentland et al.
127, 152
showed that the benzothiazene-6-carboxylic acid WIN-
58,161 (Figure 20) displayed significant inhibitory potency for mammalian HeLa topoisomerase 
II. Interestingly enough, the anti-topo II activity was strongly dependent on the stereochemistry 
of C-3 atom, with the preference for the S-enantiomer (Figure 20). The same preference was 
previously observed for E. coli gyrase inhibition by LEV (S enantiomer of OFL)
50
. The authors 
also showed that replacing the sulfur atom of WIN-58,161 with oxygen decreased the potency 3-
fold (Figure 20). 
 
Figure 20 Influence of stereochemistry on human HeLa topoisomerase II 
inhibition
152 
 
Another path of LEV modification is represented by quinobenzoxazines, a family of 
cytotoxic quinolones (Table 35). The attachment of benzene ring to oxazine moiety provokes 
shift from bacterial to mammalian topoisomerase inhibition. Moreover, the mode of action is 
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different. Quinobenzoxazines don‘t mediate topoisomerase II dependent DNA double-strand 
breaks. Instead, the in vitro cytotoxicity of compounds correlates well with both topoisomerase II 
inhibition and DNA binding
153
 (Table 35). Thus, the authors supposed that quinobenzoxazines 
are catalytic topoisomerase II inhibitors
129
 which act before DNA cleavage stage in contrast to 
previously mentioned topo II poisons
154
. 
 
Table 35 Quinobenzoxazines: relationship between in vitro cytotoxicity, DNA 
binding and topoisomerase II inhibition 
 
Compound 
Cytotoxicity 
CC50, M
a
 
DNA binding
b
 
Topoisomerase II 
inhibition 
IC50, M
c
 
(R)-A-62,176 0.89 ++ 3.1 
(S)-A-62,176 0.53 +++ 0.9 
Data from ref 
153b a
Concentration of compound that reduces A-549 cell viability by 50% 
b
 
(+++) – compound fully protects DNA sequence from DNase I at 1 M; (++) – compound fully 
protects DNA sequence from DNase I at 10 M 
c
Concentration of compound that inhibits 
kinetoplast DNA decatenation by human topoisomerase II by 50% 
3.3.2 G-quadruplex inhibitors 
G-quadruplex inhibitors, in order to effectively interact with nucleotide bases, should 
possess extensive degree of planarity. Historically, these molecules evolved from antibacterial 
lead LEV by step-wise annelation of flat aromatic cycles (Figure 21). 
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Figure 21 Development of G-quadruplex inhibitors 
 
The quinobenzoxazine (S)-A-62,176 termed AT-62,176, a mammalian cytotoxic agent, 
was shown to be both a topoisomerase II catalytic inhibitor
129
 and poison
154
. The 
pyridobenzophenoxazine analogs, with an expanded ring system, also showed strong cytotoxic 
effects on several tumor cell lines and potent inhibitory effects against human topoisomerase 
II
153a
.
 
CX-3543
135
 and the fluoroquinophenoxazine QQ58
116b 
both demonstrated enhanced 
stacking interactions with G-quadruplex, but had lost the topoisomerase II poisoning activity. On 
the other hand, the fluoroquinoanthroxazines, containing a naphthyl ring in the cis orientation, 
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were able to recognize and bind quite specifically to G-quadruplex structures and topoisomerase 
II-DNA complexes. Within this group, FQA-CR showed a higher G-quadruplex interaction, 
while FQA-CS displayed more potent topoisomerase II poisoning activity (Table 36)
134
. 
 
Table 36 Biological activities of fluoroquinoanthroxazines 
 
 FQA-CS FQA-CR 
G-quadruplex interaction: 
polymerase stop assay (IC50, M) 
0.67 0.06 
Topoisomerase II inhibition: 
cytotoxic ratio topoisomerase II-R/-S 
cells
a
 
4.02 1.55 
Cytotoxicity: 
MCF7 breast cells (IC50, M) 
1.1 0.46 
Major mechanism of action topoisomerase II poison G-quadruplex interaction 
Data from ref 
134
 
 a
The ratio of cytotoxicity of FQA-CS and FQA-CR against 
8226/DOX1V (topoisomerase II-resistant) and 8226/S (topoisomerase II-sensitive) cells. 
3.3.3 Antimitotic agents 
The key structural features which shifted quinolone‘s biological action from 
topoisomerase II poisoning to inhibition of tubulin polymerization are C-2-aryl substituent and 
unsubstituted N-1 atom
155
. A large tolerance for aromatic groups at C-2 position was 
demonstrated and carboxylic group at C-3 position serves to improve activity and 
pharmacokinetics
141
. The C-6 substituent plays very important role for antimitotic activity and 
generally, the groups attached at C-6 should be lipophilic and electrondonating, such as methyl, 
hydroxymethyl, fluor and some cyclic amines. Other positions like C-5, C-7 and C-8 are 
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preferred to be unsubstituted (Figure 22). The most potent representatives of antimitotic 
quinolones were previously shown on the Figure 16 (page 66) 
 
Figure 22 Summary of SAR for antimitotic quinolones 
3.3.4 Cytotoxic quinolones 
In this section we decided to present cytotoxic agents with ―unidentified mechanism of 
action‖. This paragraph discusses the influence of modifications at C-3 and C-7 positions on 
cytotoxicity. 
Detailed investigation of C-7 piperazinyl and pyrrolidinyl substituents was held by 
Yamashita et al.
156
 and Suto et al.
150
. A large number of derivatives were evaluated for antitumor 
activity both in vitro and in vivo and the authors showed that:  
1) pyrrolidinyl based derivatives are generally more cytotoxic in vitro (an 
example is presented Table 37) 
2) piperazinyl and pyrrolidinyl based derivatives have comparable activities in 
vivo 
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Table 37 Evaluation of C-7-piperazinyl vs pyrrolidinyl cytotoxic quinolones 
 
R7 
In vitro 
cytotoxicity IC50 ( M)
a
 
In vivo antitumor activity 
ILS %
b
 
 
134 30 
 
30 34 
Data from ref 
150, 156
 
a
Concentration of compound that reduces Chinese hamster V79 cells 
viability by 50% 
b
Increased life span (ILS) in murine P388 leukemia model 
 
Recently novel substitutions were introduced at C-7 position, which can provide good 
models for further design of potent antitumor quinolones. Substitution of distal nitrogen atom at 
piperazine moiety provides significant improvement in cytotoxicity. Initial findings of Fang et 
al. 
157
 demonstrated that 7-[4-(2-hydroxyiminoethyl)piperazin-1-yl] quinolones displayed 
significant activities against renal cancer cell lines, among them, 7-4-[2-(4-chlorophenyl)-2-
hydroxyiminoethyl]-1-piperazinyl-derivative was the most potent. Foroumadi et al. identified 
new aromatic moieties (furan-2-yl and thiophen-2-yl) that provide highly cytotoxic 
compounds
158
. In addition, the cytotoxicity was further enhanced by converting the oxime group 
to the respective O-benzyl or O-4-chlorobenzyl oxime
159
 (Table 38).  
To analyse the data authors have utilized the similar approach as in the screening 
program of National Cancer Institute with the panel of 60 human tumor cell lines used to screen 
for the antiproliferative activity. During these tests a new method of getting an idea on the 
substance‘s mechanism of action was discovered. In fact, the pattern of growth inhibition in 
these cell lines was similar for compounds of similar mechanism of action
160
. In the current 
article the Foroumadi et al. have compared log IC50 values of synthesized compounds with those 
of etoposide against less numerous panel of cancer cell lines. Finally they suggested that these 
quinolone derivatives share a similar mechanism of action with etoposide, already mentioned 
topoisomerase II inhibitor
 
(Table 38).  
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Table 38 Cytotoxic oxyiminoethyl CIP derivatives 
 
Ar R 
Cytotoxicity IC50, M
a
 
MCF-7
b
 A-549
c
 SKMEL-3
d
 KB
e
 
 
H 117 108 125 108 
 
Me 116 111 127 102 
 
4-Cl-Bn 3.6 2.1 3.1 2.3 
 
Bn 1.8 1.6 3.3 1.9 
 
Me 2.9 – 7.7 17 
CIP 199 – 181 160 
Etoposide 11.6 1.5 0.34 4.8 
Data from ref 
158-159
 
a
Concentration of compound that reduces cell viability by 50% 
b
Breast carcinoma cell line 
c
Lung cancer cell line 
d
Melanoma cell line 
e
Cervical carcinoma cell 
line 
 
Concerning C-3 position 3-oxadiazole-aryl derivatives showed moderate cytotoxic 
activity against human tumor lung cancer cells (A-549)
161
. It is worth to note, that CIP 
derivatives were more potent than corresponding NOR analogs. The most active compounds bear 
para-nitrophenyl and -naphtyloxymethyl substituents attached to the oxadiazole moiety (Table 
39). 
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Table 39 Cytotoxic 3-oxadiazoyl quinolone derivatives 
 
Ar IC50 ( M)
a
 
 
1.7 
 
3.1 
Data from ref
 161 a
Concentration of compound that reduces human lung tumor cell (A 
549) viability by 50% 
 
 Analogously to antibacterials, cytotoxic quinolones were obtained by combining 
two pharmacophores through appropriate linker. By using fused heterocyclic triazolo[2,1-
b][1,3,4]thiadiazole linker a series of ―dimeric‖ FQ derivatives were prepared and showed in 
vitro cytotoxicity against CHO Chinese hamster ovary and L-1210 murine leukemia cell lines. 
The most potent compounds are CIP ―heterodimers‖ presented in Table 40162. 
 
Table 40 C-3 linked cytotoxic FQ ―dimers‖ 
 
FQ1 FQ2 IC50 ( M)
a
 
CIP CIP 0.2 
CIP N-Me-CIP 1.2 
CIP N-Et-CIP 2.5 
Data from ref 
162
 
a
Concentration of compound that reduces L210 (murine leukemia) cell 
viability by 50%  
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In summary, initial cytotoxic FQs developed from antibiotic agents exhibitied target shift 
from bacterial to mammalian topoisomerase inhibition. Studies revealed new potent stuctures 
which contrasted with previously established antibacterial SARs. The most active compounds 
possessed C-7 aryl substituents and, what is more interesting, some analogs exhibited structural 
modifications at C-3 position which was not tolerated in regard to antibacterial activity. Further 
research prompted the emergence of new structures for different targets, like G-quadruplex and 
tubulin polymerization inhibitors, therefore broadening the FQs spectrum of biological activity. 
4. Conclusion 
In this chapter we have described the different aspects concerning FQs, their emergence, 
development, mechanism of action and discussed their SARs for different biological targets. FQs 
represent an important group of molecules with crucial applications in medicine. However, old 
FQs displayed several drawbacks, such as emerging resistance, so the development of new 
agents is needed. For all these reasons, the synthesis of new FQ derivatives will be described in 
the next chapter along with the detailed rationalization for chosen compounds. 
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CHAPITRE II SYNTHÈSE DES DÉRIVÉS DE LA CIPROFLOXACINE ET 
DE LA LÉVOFLOXACINE 
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1. Introduction 
Dans ce chapitre, nous décrivons le développement et la synthèse de nouveaux dérivés de 
la LEV et de la CIP. 
Tout d'abord, le choix des composés synthétisés sera examiné. Nous discuterons les 
modifications structurales envisagées et la rationalisation pour l'introduction de différents 
substituants au niveau de l'acide carboxylique en position C-6 de la LEV et de la fonction amine 
N-4-pipérazine en position C-7 de la CIP. 
Dans la deuxième partie, nous décrirons la synthèse des dérivés sélectionnés. Nous 
discuterons des travaux antérieurs effectués au laboratoire et nous détaillerons les différentes 
voies de synthèse choisies après optimisation. 
La troisième partie de ce chapitre sera consacrée à l'étude de la stabilité des composés 
synthétisés dans un tampon phosphate aqueux, pH 7.4 à 37 °C, effectuée par HPLC. 
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2. Dérivés “monomères” de la ciprofloxacine 
2.1 Introduction 
Dans le premier chapitre, nous avons résumé quelques-uns des résultats de la littérature 
qui indiquent que la modification de la position C-7 des FQs ouvre des perspectives intéressantes 
pour le développement de nouveaux composés possédant des activités antibactériennes, 
antimycobactériennes ou antitumorales. En effet, l'inhibition de l'ADN topoisomérase par les 
quinolones est fortement influencée par la nature du substituant en position C-7. De plus, des 
modifications structurales en cette position auraient des effets sur la sélectivité enzymatique 
procaryotes versus eucaryotes. Certains auteurs ont montré que l'introduction de substituants 
volumineux au niveau du motif pipérazine des quinolones entraîne un déplacement de l'activité 
biologique antibactérienne de ces composés vers des agents cytotoxiques contre les cellules 
cancéreuses humaines157-158. Toutes ces caractéristiques ont suscité l'intérêt de notre laboratoire.  
Trois séries homologues de dérivés lipophiles de la CIP ont été conçues et synthétisées lors de 
travaux antérieurs dans notre groupe. Ces dérivés constituent une famille de dérivés 7-((4-
substitué)pipérazin-1-yl)-CIP considérés comme des dérivés ―monomères‖. La CIP a été choisie 
pour sa disponibilité commerciale et la possibilité de fonctionnalisation de l‘amine secondaire N-
4-pipérazine. En outre, l‘introduction de groupements de longueurs de chaîne variables pourrait 
permettre de moduler les propriétés physico-chimiques des composés et ainsi modifier le profil 
de l'activité biologique. Les trois séries de composés synthétisés diffèrent les unes des autres par 
la nature de la fonction reliant la chaîne alkyle à l'atome d'azote N-4 du groupement pipérazine 
(Figure 23). 
 
Figure 23 Représentation schématique des dérivés ―monomères‖  7-((4-
substitué)pipérazin-1-yl)-CIP 
 
Il est important de mentionner que la fonction acide carboxylique en C-3 de la CIP a une 
valeur de pKa élevé (6.08)61 comparée aux autres aryl-acides. Cette fonction est en outre 
désactivée en raison de la formation d‘une liaison hydrogène intramoléculaire avec la fonction 
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carbonyle adjacente en position 4 (Figure 24). Ainsi, aucune protection de l‘acide carboxylique 
n‘est nécessaire lors des synthèses pour la fonctionnalisation de la pipérazine de la CIP décrites 
dans la section suivante. 
 
Figure 24 Liaison hydrogène intramoléculaire dans la molécule de CIP 
 
2.2 Synthèse des dérivés 7-(4-(alcanoyle)pipérazin-1-yl) de la CIP 
La première série de dérivés 7-(4-(alcanoyle)pipérazin-1-yl) de la CIP (dite ―mono-
amides‖) a été aisément préparée en une seule étape d‘acylation de la CIP par les chlorures 
d‘alcanoyle disponibles commercialement pour conduire aux composés correspondants 1a-l avec 
de bons rendements variant de 45% à 90% (Schéma 1, Tableau 41). Certains dérivés de cette 
même série ont été difficiles à purifier, ce qui explique les différences entre les rendements. 
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Schéma 1 Préparation des dérivés 7-(4-(alcanoyle)pipérazin-1-yl) de la CIP 1a-l 
 
Tableau 41 Rendements de synthèse des dérivés 7-(4-(alcanoyle)pipérazin-1-yl) 
de la CIP 1a-l ―mono-amides‖a 
Composé R Rdt, % 
1a -CH3 88 
1b -CH2CH3 75 
1c -(CH2)2CH3 76 
1d -C(CH3)3 90 
1e -(CH2)3CH3 64 
1f -(CH2)5CH3 50 
1g -(CH2)7CH3 61 
1h -(CH2)8CH3 45 
1i -(CH2)10CH3 66 
1j -(CH2)12CH3 65 
1k -(CH2)14CH3 58 
1l -CH2C6H5 50 
a
Nicolas Dellus, Master 1 – Juillet 2006 ; Nichola Murphy, Projet d’Erasmus, Octobre – 
Décembre 2006 ; Julie Vaysse, Master 1 – Juin – Juillet 2007 
 
2.3 Synthèse des dérivés 7-(4-(2-oxoéthylalcanoate)pipérazin-1-yl) de la CIP 
Pour préparer la deuxième série des dérivés ―monomères‖, une acylation de la CIP par le 
chlorure du 2-chloroéthanoyle en présence de triéthylamine dans CH2Cl2 conduit à la N-
chloroacétylciprofloxacine 2 avec un rendement de 73% après purification.   
La substitution nucléophile de 2 par des acides alcanoïques commerciaux a été réalisée en 
présence de K2CO3 dans le diméthylformamide (DMF) pour conduire aux dérivés 7-(4-
(oxoéthylalcanoate)pipérazin-1-yl) 3a-j (appelés ―mono-oxoéthylesters‖) avec des rendements 
isolés variant de 27 à 75% (Schéma 2, Tableau 42). 
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Schéma 2 Préparation des dérivés 7-(4-(oxoéthylalcanoate)pipérazin-1-yl) de la 
CIP 3a-j 
 
Tableau 42 Rendements de synthèse des dérivés 7-(4-
(oxoéthylalcanoate)pipérazin-1-yl) de la CIP 3a-j ―mono-oxoéthylesters‖a 
Comoposé n Rdt, % 
3a 0 60 
3b 2 63 
3c 4 75 
3d 6 45 
3e 7 27 
3f 8 47 
3g 9 43 
3h 10 46 
3i 12 41 
3j 14 46 
a
 Florence Argeliès, Master 2, Février – Juin 2006. 
 
L‘hydrolyse enzymatique ou chimique de ces dérivés 3a-j conduirait à la formation de la 
CIP native ou du dérivé 7-(4-(2-hydroxyéthanoyle)pipérazin-1-yl) 4 (Figure 25). 
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Figure 25 Hydrolyse possible des dérivés ―mono-oxoéthylesters‖ de la CIP 
 
Afin d‘évaluer la stabilité des composés synthétisés 3a-j et de pouvoir comparer leurs 
activités biologiques à celles du produit d‘hydrolyse, le composé 4 a été synthétisé. L‘acylation 
de la CIP par le chlorure de benzyloxyéthanoyle dans CH2Cl2 conduit au dérivé 7-(4-(2-
benzyloxyéthanoyle)pipérazin-1-yl) 5 (rdt: 43%) qui, soumis à une hydrogénation catalytique 
(Pd/C) dans le DMF, permet d‘obtenir le composé 4 avec un rendement de 60% (Schéma 3). 
 
Schéma 3 Synthèse du dérivé 7-(4-(2-hydroxyéthanoyl)pipérazin-1-yl) de la CIP 
4 (Florence Argeliès, Master 2, Février – Juin 2006) 
 
2.4 Synthèse des dérivés 7-(4-(alkyloxycarbonyl)pipérazin-1-yl) de la CIP 
La troisième série des dérivés 7-(4-(alkyloxycarbonyl)pipérazin-1-yl) de la CIP (nommés 
"mono-carbamates") a été préparée par condensation de la CIP avec divers alkylchlorofomates 
commerciaux. La réaction a été réalisée dans le CH2Cl2 et les composés 6a-f ont été isolés avec 
des rendements allant de 33% à 66% (Schéma 4, Tableau 43) Seul le composé 6g portant un 
groupement t-butyloxycarbonyle (Boc) a été préparée en utilisant Boc2O dans un mélange 
hydroxyde de sodium aqueux 2M / dioxane (Schéma 4, Tableau 43). 
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Schéma 4 Synthèse des dérivés 7-(4-(alkyloxycarbonyl)pipérazin-1-yl) de la CIP 
6a-g 
 
Tableau 43 Rendements de synthèse des dérivés 7-(4-
(alkyloxycarbonyl)pipérazin-1-yl) de la CIP 6a-g: ―mono-carbamates‖a 
Composé n Rdt, % 
6a 1 66 
6b 3 42 
6c 7 37 
6d 8 33 
6e 9 41 
6f 11 38 
6g - 74 
a
 Nichola Murphy, Projet d’Erasmus, Octobre – Décembre 2006 ; Julie Vaysse, Master 1 
– Juin – Juillet 2007. 
 
Les dérivés ―monomères‖ de la CIP appartenant à ces trois séries homologues ont été 
évalués pour leurs activités antibactériennes, antiprolifératives et antimycobactériennes. Les 
résultats biologiques obtenus, qui seront discutés dans le chapitre suivant, nous ont conduit à 
explorer la synthèse de dérivés ―dimères‖ bis-C-7-((4-substitué)pipérazin-1-yl) de la CIP. Les 
travaux préliminaires de synthèse avaient déjà été réalisés au début de cette thèse, qui a été 
concentrée sur l'optimisation de la synthèse de ces dérivés dimères de CIP.  
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3. “Dimeric” ciprofloxacin derivatives 
3.1 Choice of compounds to develop 
We were motivated to develop a series of C-7-((4-substituted)piperazin-1-yl)-linked CIP 
―dimers‖ because of several practical and theoretical considerations. 
The influence of lipophilicity on antibacterial activity was extensively studied and it was 
proven to have a positive effect on activity against Gram-positive microorganisms. This feature 
is thought to be related with increased penetration of more lipophilic compounds through the 
single cellular wall. Inspired by biological results obtained for previously synthesized 
―monomeric‖ CIP derivatives, that had an enhanced activity against standard and resistant S. 
aureus strains (which will be discussed in the corresponding 0), we extended our field to 
―dimeric‖ compounds as more lipophilic agents. 
Increased steric bulk was proven to enhance the activity towards strains of S. aureus with 
efflux-mediated resistance. In fact, multidrug-efflux proteins are less susceptible to bulkier and 
lipophilic agents. This could be responsible for the enhanced activity of ―monomeric‖ CIP 
derivatives. Thus bulkier and more lipophilic ―dimers‖ should be interesting candidates for their 
evaluation against resistant strains of S. aureus. 
It has been long proposed that more than one molecule of quinolone binds to the target 
enzyme; however until recently there was no clear evidence about the structure of binding 
complex. Nowadays, it is thought that the target bacterial enzyme forms a ternary complex with 
DNA and two molecules of quinolone which are oriented in a ―tail-to-tail‖ manner (Figure 26). 
 
Figure 26 Schematic view of quinolone-enzyme complex and representation of 
multibinding concept (7 – piperazinyl ―tails‖ of quinolone) 
 
This finding prompted the detailed study of quinolone ―dimers‖ with most representative 
works of Kerns et al (Figure 27). The authors demonstrated increased activity of ―dimeric‖ 
compounds towards S. aureus strains in comparison to parent FQs. However linkers used by 
Kerns were relatively rigid and short. Taking into account recent structural data on the ternary 
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quinolone-enzyme-DNA complex, these ―dimers‖ were unlikely to have a favorable structure to 
allow multiple binding. 
 
Figure 27 C-7-((4-substituted)piperazin-1-yl)-linked CIP ―dimers‖ developed by 
Kerns et al 
 
The situation with anticancer activity is more complicated because of multiple 
mechanisms of action and multiple targets for quinolones. There are less data in the literature on 
SAR studies for antiproliferative quinolones, in comparison with antibacterial ones. Expanding 
this relatively unexplored area could reveal important dependencies and trends. 
For all these reasons, we decided to synthesize two series of CIP ―dimers‖. We chose a 
flexible linker based on alkyl chain of varying length. The linking groups were chosen as the 
ones from the most active ―monomeric‖ derivatives, that were ―ester‖ and ―amide‖ functions 
(Figure 28).  
 96 
 
 
Figure 28 The choice of C-7-((4-substituted)piperazin-1-yl)-linked CIP ―dimers‖ 
 
In summary, the rationale for the introduction of a carbon-chain spacer between two CIP 
moieties is based on the binding of two quinolone molecules per target bacterial enzyme
27
 and 
successful ―dimers‖ examples in the literature. Varying the bridge length should also result in 
compounds with different hydrophobicity and steric hindrance, thus providing a useful model for 
antibacterial and antiproliferative SAR studies. In the next section, we will discuss the synthetic 
pathway for C-7-((4-substituted)piperazin-1-yl)-linked CIP ―dimers‖ and some challenges faced. 
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3.2 Synthesis of 7-(4-(alkanoyl)piperazin-1-yl))-linked CIP “dimers” 
3.2.1 Previous attempts 
There are a lot of classical methods described in the literature for the synthesis of 
carboxamides. First of all we searched through the most suitable and effective procedure to 
access to 7-(4-(alkanoyl)piperazin)-linked CIP ―dimer‖ 7a-f, termed ―di-amides‖ (Figure 29). 
 
Figure 29 Target molecules of 7-(4-(alkanoyl)piperazin)-linked CIP ―dimers‖ 
 
Preliminary assays were done to access to the 7-(4-(octanoyl)piperazin)-linked CIP 
―dimer‖ 7a (n=8). Acylation of aliphatic amines with acyl chlorides in the presence of 
triethylamine is a general and reliable method for the carboxamides synthesis. This method 
applied to the acylation of CIP by commercially acyl chlorides led to the ―mono-amide‖ series 
1a-l in good yields (Tableau 41). Nevertheless, if decanedioyl chloride and dodecanedioyl 
chloride were commercially available, the other diacyl chlorides (n = 12, 13, 14 and 16) were not 
available. So, we decided to generate in situ the diacyl chloride by a classic reaction of oxalyl 
chloride with commercially available alkanedioïc acids. 
After the stepwise procedure involving initial reaction of oxalyl chloride with 
decanedioïc acid in CH2Cl2 and the subsequent addition to a solution of CIP and triethylamine, 
the isolated yield of the target ―di-amide‖ 7a was less than 7% (Scheme 5). The possible 
explanation for the observed yield is that FQ heterocyclic system doesn‘t tolerate strong acidic 
environment generated by commonly used thionyl and oxalyl chlorides. 
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Scheme 5 Synthesis of 7-(4-(octanoyl)piperazin)-linked CIP ―dimer‖ 7a through 
an acyl chloride pathway 
 
During further attempts the main idea was to utilize a ―powerful‖ activating agent for 
alkanoïc diacid which is mild enough to preserve the heterocyclic system of CIP. It was decided 
to avoid acidic agents by using carbodiimide reagents which are a widely used class of agents for 
peptide synthesis. Dicyclohexyl carbodiimide
163
 (DCC) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride salt
164
 (EDCI) are frequently used as a carboxyl activating 
agent for amide bond formation. Additives, such as N-hydroxybenzotriazole (HOBt), N-
hydroxysuccinimide (NHS)  or 2-thiazoline-2-thiol (2-TT) are often added to increase yields 
and/or decrease side reactions (Figure 30). 
 
Figure 30 Examples of carbodiimide reagents and additives 
 
No additional amine is theoretically required during this one-pot procedure. Concerning 
the mode of reaction (Figure 31), the carbodiimide reacts with the carboxylic acid to form the O-
acylisourea I. The nucleophilic substitution of amine on I yields the desired amide and the urea 
by-product II. The isolation of the symmetric carboxylic anhydride from the reaction mixture 
suggested, however, that a more complex mechanism might co-exist
165
. The driving force of this 
reaction is the formation of the urea II. However, the racemisation and acetyl transfer which 
form the unreactive N-acylurea III are often observed This side reaction can be considerably 
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diminished by carrying out the procedure in a two-step manner : the initial reaction between the 
acid and the coupling agent is carried out at 0°C, followed by amine addition. Furthermore, a 
selected nucleophile can be used as an additive. The nucleophile also prevents the undesired 
product formation, because it reacts faster than the competing acyl transfer and generates the 
intermediate IV on which the nucleophilic substitution by the amine yields the desired amide. 
 
Figure 31 Carbodiimide-assisted amide synthesis, with and without additive 
(HOBt is showed as example of nucleophile) 
 
An attempt was conducted by using the DCC / 2-TT system in dioxane. However, as the 
desired ―di-amide‖ 7a and the resulting dicyclohexylurea byproduct showed similar low 
solubility in common solvents, it was too difficult to separate them.  
This practical problem was solved by the use of EDCI / 2-TT system. The resulting urea 
was water-soluble and thereby could be easily removed by extractive work-up.  
In this third attempt, 1,10-bis(2-thioxothiazolidin-3-yl)decane-1,10-dione 8 was obtained 
by coupling 1,10-decanedioïc acid with 2-TT in the presence of EDCI in dioxane. Unfortunately, 
due to tedious purifications, the yield was very low (8%). The ―di-amide‖ 7a was synthesized by 
the subsequent addition of 8 to a solution of CIP and K2CO3 in acetonitrile (CH3CN) in 39% 
yield. However, the overall yield after these two steps was very low 3% (Scheme 6). This result 
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is apparently due to the wrong choice of the 2-TT in the first step, leading to an intermediate 8 
hard to purify. 
 
Scheme 6 Synthesis of CIP ―di-amide‖ 7a through a 2-TT pathway 
 
3.2.2 Current work 
An attempt conducted by using EDCI / HOBt system was successful and the desired ―di-
amide‖ 7a was easily isolated in 48% yield. This synthetic pathway was then applied to the 
synthesis of the target CIP ―di-amides‖ 7a-f (Scheme 7, Table 44). Initial activation of -
alkanedioïc acid  (1 equivalent) was performed by reacting with EDCI (2.5 equivalents) and 
HOBt (2.5 equivalents) in 1:1 DMF / CH2Cl2 mixture for 30 minutes at room temperature. The 
subsequent addition of CIP (2.3 equivalents) and stirring for 4 hours at room temperature, was 
followed by a precipitation of the compound and water washing. The purification by column 
chromatography on silica provided the corresponding 7-(4-(alkanoyl)piperazin-1-yl))-linked CIP 
―dimers‖ 7a-f in yields ranging from 31 to 66%.  Certain derivatives of this series were difficult 
to purify which explains differences between yields. 
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Scheme 7 Preparation of 4-(alkanoyl)piperazin-1-yl-linked CIP ―dimers‖ 7a-f 
 
Table 44 Yields of CIP ―di-amides‖ derivatives 7a-f 
Compound n Yield, % 
7a 8 48 
7b 10 31 
7c 12 66 
7d 13 61 
7e 14 55 
7f 16 53 
 
In summary, several synthetic methods have been used during our attempts to synthesize 
CIP ―di-amides‖ derivatives. We have faced degradation-related problems using oxalyl chloride 
pathway whereas challenging purification was a major issue when DCC or EDCI / 2-TT systems 
were used. As a result, EDCI / HOBt system was found to be the most efficient in terms of yields 
and practical convenience. Having successfully synthesized the ―di-amide‖ series of CIP 
derivatives we have shifted to the ―di-oxoethylester‖ series which will be discussed in greater 
details in the next section. 
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3.3 Synthesis of 7-(4-(oxoethylalkanoate)piperazin-1-yl)-linked CIP “dimers” 
Keeping in mind that we wanted to establish a SAR of synthetized FQs derivatives, the 
length of the alkyl chain was preserved as before that for ―di-amides‖ series (Figure 32) 
 
Figure 32 Target molecules of 7-(4-(oxoethylalkanoate)piperazin-1-yl)-linked 
CIP ―dimers‖ 
 
The 7-(4-(oxoethylalkanoate)piperazin-1-yl)-linked CIP ―dimers‖ 9a-f, termed ―di-
oxoethylester‖ derivatives were prepared by using the method previously described for ―mono-
oxoethylester‖ analogues 3a-j (Schéma 2, Tableau 42). From the synthetic point of view it 
consists of two classical nucleophilic substitution reactions. 
First step was the substitution of chloroacetyl chloride by the 4-(piperazinyl)nitrogen of 
CIP to afford 7-(4-(2-chloroacetyl)piperazin-1-yl) CIP derivative 2 as described previously in 
Schéma 2. 
The next stage was the condensation of carboxylic diacids with derivative 2. The 
mechanism involves classical nucleophilic attack of the in situ generated dicarboxylate anion on 
the derivative 2 (Figure 33). This step was a subject for condition optimization during 
preliminary studies which were carried out in our group. 
 
Figure 33 Schematic representation for the preparation of CIP ―di-oxoethylesters‖ 
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3.3.1 Optimisation of reaction conditions for 1,12-dodecanoïc diacid 
In order to find the best conditions for the condensation of carboxylic diacids, it was 
decided to perform a series of optimization experiments conducted by using 1,12-dodecanedioïc 
acid (n = 10) to produce 9b derivative (Figure 32). 
All optimization runs involved the following typical procedure : A solution of carboxylic 
diacids (1 equivalent) and M2CO3 (2 equivalents) in DMF or CH3CN under argon was stirred 
during 2 hours. Compound 2 (2 equivalents) and TBAI (none, 0.2 or 2 equivalents) were added 
and was stirred at the mentionned temperature for 3, 5 or 7 days (Table 45). 
Firstly, the conditions previously described for the synthesis of ―mono-oxoethylesters‖ 
3a-j were used, that were K2CO3 as a base and DMF as a solvent. However, in comparison with 
the ―monomer‖ analog, these conditions gave ―di-oxoethylester‖ derivative in lower yield (10-
15% for 9b versus 46% for 3h (n=10)) and required longer reaction time, from 4 hours for 3h to 
5-7 days for 9b (Table 45, entries 1-2). 
Changing the solvent to CH3CN allowed us to slightly decrease the reaction time from 7 
days to 5 days. However, yield (15%) was still poor and additional optimization was needed. 
(Table 45, entry 3). 
We decided to use tetrabutylammonium iodide (TBAI) in order to increase the yield of 
this reaction. TBAI is supposed to in situ convert N-chloroacetylciprofloxacin into the more 
reactive N-iodo-analog. Because iodides are generally more reactive in nucleophilic substitution, 
we expected a faster completion of the reaction. However, when a catalytic amount of TBAI (0.2 
equivalent) was used, no improved yield was observed (Table 45, entry 4). Whereas a 
stoechiometric amount of TBAI (2 equivalents) led to an enhanced yield with a 3-fold increase 
from 15 to 46% and allowed us to reduce the reaction time to a 3 days period (Table 45, entry 
5). However, it was noticed that the crude mixture was more complex when reaction was carried 
out in CH3CN instead of DMF 
It is known that cesium counterion and dipolar aprotic solvents (such as DMF, 
dimethylsulfoxide (DMSO) and hexamethylphosphorotriamide) facilitate nucleophilic 
substitution reactions. The more voluminous cesium cation tends to form weaker ionic bond with 
hard anion, thereby freeing nucleophilic anion from the ionic pair and making it more active. 
DMF, as a polar aprotic solvent, stabilizes free anion thereby promoting the dissociation of the 
carboxylic salt. While having similar yields, the use of cesium carbonate (Cs2CO3) / DMF 
combination (Table 45, entry 6) allowed us to decrease the reaction temperature in comparison 
to K2CO3 / CH3CN conditions. The formation of byproducts were less important in DMF at 50°C 
leading to easier purifications. This effect of the temperature seemed to be important to avoid the 
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formation of byproducts as if the reaction was conducted in DMF at temperature above 60°C 
more complex mixtures were obtained. 
 
Table 45 Optimisation runs for the synthesis of 7-(4-(2-
oxoethyldodecanoate)piperazin-1-yl))-linked CIP ―dimer‖ 9b 
Entry Base Solvent Relative 
amounts of 
TBAI 
Temperature Reaction time Yield (%) 
1 K2CO3 DMF - 80°C 5 days 10 
2 K2CO3 DMF - 80°C 7 days 15 
3 K2CO3 CH3CN - 80°C 5 days 15 
4 K2CO3 CH3CN TBAI (0.2eq) 80°C 5 days 15 
5 K2CO3 CH3CN TBAI (2eq) 80°C 3 days 46 
6 Cs2CO3 DMF TBAI (2eq) 50°C 3 days 50 
 
In summary, after a series of experiments two set of optimized reaction conditions were 
found (Table 45, entries 5-6). They were further applied to the other chain lengths in order to 
compare their effectiveness for the synthesis of both short and long-chain ―dimers‖. These 
studies will be described in the next section. 
3.3.2 Application of optimized runs to the synthesis of 7-(4-
(oxoethylalkanoate)piperazin)-linked CIP “dimers” 
In order to compare the two selected methods according to the chain length, we have 
tested them from 1,12-decanedioïc, 1,14-tetradecanedioïc and 1,16-hexadecanedioïc acids. The 
results, summarized in Table 46 (entries 1-6), showed that both methods provided the desired 
―di-oxoethylester‖ derivatives 9a,c,e in better yields with Cs2CO3/DMF (42, 56 and 41% 
respectively) than K2CO3/CH3CN (37, 29 and 15% respectively) combinations, specially for the 
synthesis of 9e from 1,16-hexadecanedioïc acid. The best conditions were further applied to the 
synthesis of ―di-oxoethylesters‖ 9d,f from 1,15-pentadecanedioïc and 1,18-octadecanedioïc acids 
leading to the desired compounds in good yields of 56 and 70% respectively (Table 46, entries 
7-8) 
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Table 46 Yields of ―di-oxoethylester‖ CIP derivatives 9a,c-f according to 
optimized experimental conditions 
Entry Compound 
(n) 
Base Solvent Catalyst Temp. Time Yield (%) 
1 9a (8) K2CO3 CH3CN TBAI (2eq) 80°C 3 days 37 
2 9a (8) Cs2CO3 DMF TBAI (2eq) 50°C 3 days 42 
3 9c (12) K2CO3 CH3CN TBAI (2eq) 80°C 3 days 29 
4 9c (12) Cs2CO3 DMF TBAI (2eq) 50°C 3 days 56 
5 9e (14) K2CO3 CH3CN TBAI (2eq) 80°C 3 days 15 
6 9e (14) Cs2CO3 DMF TBAI (2eq) 50°C 3 days 41 
7 9d (13) Cs2CO3 DMF TBAI (2eq) 50°C 3 days 56 
8 9f (16) Cs2CO3 DMF TBAI (2eq) 50°C 3 days 70 
 
Finally, the desired series of ―di-oxoethylester‖ CIP derivatives 9a-f were synthesized by 
the following procedure: A solution of -alkanedioïc acid (1 equivalent) and Cs2CO3 (2 
equivalents) was stirred in DMF at 50˚C for 2 hours to obtain the corresponding carboxylate salt. 
Then, TBAI (2 equivalents) and N-chloroacetylciprofloxacin 2 (2 equivalents) were added and 
the reaction mixture was stirred for 3 days at 50°C. After work-up and purification by silica gel 
chromatography desired ―di-oxoethylester‖ CIP derivatives 9a-f were isolated in 41-70 % yields 
(Scheme 8, Table 46, entries 2, 4, 6-8). Yields varied because certain products were difficult to 
purify. 
 
Scheme 8 Preparation of 7-(4-(oxoethylalkanoate)piperazin-1-yl))-linked CIP 
―dimers‖ 9a-f  
 
In summary, we have synthesized the second series of CIP ―dimer‖ derivatives. During 
the optimization process we have found that, among tested combinations, the Cs2CO3 in DMF 
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provides the highest yields for different chain lengths. Having successfully synthesized C-7-
linked CIP ―dimers‖, we have shifted our attention to C-6 modified LEV derivatives. The 
detailed data concerning the synthesis of different LEV derivatives will be discussed in the next 
section. 
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4. Levofloxacin derivatives 
4.1 Choice of compounds to develop 
During the literature overview we have shown that the C-3 position on FQs (C-6 in LEV) 
bears a unique type of substituent which stands out among other positions. From the antibacterial 
point of view, this position has a very low tolerance for structural modifications. To date, 
carboxyl group is the only successful substituent present in currently marketed antibacterial 
quinolones. For antibacterial activity, the carboxyl group plays essential role in drug-enzyme 
interaction and is thought to form multiple hydrogen bonds with a quinolone binding pocket
27
. 
However, concerning the antiproliferative activity, some other substituents are tolerated. 
LEV, as well as CIP, is highly active against wide range of gram-positive and gram-
negative pathogens and is used as a second line drug for the treatment of tuberculosis. LEV also 
possesses some antiproliferative activity against human cancer cell lines. From the chemical 
point of view, the methylated nature of the N-4' nitrogen of C-10-piperazine moiety of LEV 
permits chemical transformations at carboxylic group (Figure 34). These properties make LEV 
an interesting molecule for the synthesis of C-6 modified derivatives. 
 
Figure 34 Structure of LEV 
 
As the upper portion of the molecule which includes the carboxy- and keto moieties is 
required for interactions with DNA bases, they are generally considered as essential and thus 
explains low tolerance for modifications at this point. In order to maintain significant degree of 
activity, the C-6 group of LEV should comprise structural elements with hydrogen atom able to 
mimic carboxyl group. Literature examples include arylamides with some representatives being 
equipotent to LEV towards S. aureus
85
. The amide moiety bears additional hydrogen atom which 
could form hydrogen bonds with enzyme residues. The bonding could be formed with one or 
both tautomeric forms of the amide (Figure 35). 
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In contrast to antibacterial activity, antiproliferative potency tolerates structural changes 
at C-3 carboxylic acid of quinolones with a number of successful examples. 
 
Figure 35 Carboxyl group mimicking by amide group 
 
Taking into account these considerations we synthesized series of alkyl carboxamides 
(termed ―mono-amides‖) and ―dimeric‖ analogs (termed ―di-amides‖) of LEV.  We have also 
decided to synthesize a series of acyloxymethyl esters of LEV that would represent prodrugs of 
LEV. In the literature various acyloxyalkyl ester prodrugs of butyric acid with anticancer activity 
were described.
166
. 
In a similar way to the derivatives synthesized from CIP, varying the chain length should 
result in compounds with different hydrophobicity and steric hindrance, thus providing a useful 
model for SAR studies. 
 
Figure 36 Target molecules of LEV derivatives. 
 
In summary, after reviewing the literature and taking into account previous results of our 
group we have decided to synthesize two types of LEV derivatives: carboxamides and 
acyloxymethyl esters (Figure 36). The detailed synthetic pathway and challenges faced will be 
described in the next section. 
 109 
 
4.2  Synthesis of C-6-acyloxymethyl esters of LEV: Previous attempts 
4.2.1 Synthesis of C-3-acyloxymethyl esters of nalidixic acid 
The FQ modification at C-3 position was first carried out in our group by using NAL, a 
parent compound for the quinolone family
167
. Two possible pathways were evaluated for the 
synthesis of acyloxymethyl esters of NAL (Scheme 9). The pathway A consists in a nucleophilic 
substitution of chloromethyl alkanoates 10, synthesized from alkanoic acids, by NAL 
carboxylate. The first step of the second pathway B consists in synthesis of the chloromethyl 
ester of NAL 11 and in the subsequent nucleophilic substitution by various fatty carboxylates 
(Scheme 9).  
Two methods of chloromethylation of alkanoic acids were employed, either by a phase-
transfert system or by the use of a Lewis acid in presence of 1,3,5-trioxane (pathway A). It was 
shown that that higher yields of alkylcarbonyloxymethyl chlorides 10 could be obtained by the 
phase-transfert system. Unfortunately, when attempting the alkylation of NAL potassium salt 
with one equivalent of these reagents in DMF at 50°C for 24 h, complex mixtures were obtained 
resulting from incomplete reaction (even in the presence of sodium iodide) or decomposition. 
The corresponding acyloxymethyl esters 12a-b were then isolated in poor yields ranging from 
22% to 35% (Table 47). 
On the contrary, the pathway B provided the clean chloromethylation of NAL by using 
chloromethyl chlorosulfate (ClCH2OSO2Cl) in a phase-transfer H2O/CH2Cl2 system. The 
chloromethyl NAL derivative 11 was obtained in a 55% yield. Further condensation with the salt 
of fatty acid in DMF at room temperature for 4 days rendered the corresponding acyloxymethyl 
esters 12a-d in 50-70% yields (Table 47). 
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Reagents and conditions : Pathway A : a) i – CH3(CH2)nCOOH, Na2CO3, H2O (rt or 100°C 
according to n) ii – CH2Cl2, (nBu)4NHSO4, ClO2SOCH2Cl, 0°C (1h) – rt (18h) or a‘) i – 
ClCOCOCl, CH2Cl2, 0°C (1h) – rt (2h), ii- ZnCl2, CaCl2, rt (15‘) iii – 1,3,5-trioxane, 0°C (2h) – 
rt (20h). b) 10, K2CO3, DMF, 50°C (24h). Pathway B : c) i – Na2CO3, H2O, rt (90‘) ii – CH2Cl2, 
(nBu)4NHSO4, ClO2SOCH2Cl, 0°C (1h) – rt (18h). d) i – CH3(CH2)nCOOH, K2CO3, DMF, 50°C 
(5h) ii – 11, rt (4d) 
Scheme 9 Preparation of acyloxymethyl esters of NAL 
 
Table 47 Yields (%) of acyloxymethyl esters of NAL according to pathways A or 
B 
Compound n Pathway A 
(from 10) 
Pathway B 
(from 11) 
12a 6 35 70 
12b 10 22 50 
12c 12 - 60 
12d 14 - 56 
 
The pathway B turned out to be more convenient in terms of purification and yields and 
above all it does not require the synthesis of each chloromethyl alkanoates 10. So, this pathway 
B was chosen for the preparation of a series of acyloxymethyl esters of LEV. 
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4.2.2 Synthesis of acyloxymethyl esters of LEV 
However when this method B was applied to LEV the first stage couldn‘t be completed. 
The two alternative protocols for the chloromethylation were tried, but none of them provided 
the desired chloromethyl ester of LEV 13 (Figure 37).  
 
Figure 37 Unsuccessful attempts for the chloromethylation of LEV 
 
So, it was decided to use the pathway A for the synthesis of acyloxymethyl esters of LEV 
14, that is the direct alkylation of LEV with various chloromethyl alkanoates (Figure 38). In 
order to apply this method to various alkyl chain lengths it was necessary to synthesize a series 
of alkylcarbonyloxymethyl chlorides 10, except for the commercially chloromethyl butyrate (n = 
2) 10a. 
 
Figure 38 Schematic representation of the preparation of acyloxymethyl esters of 
LEV 14 
4.2.3 Synthesis of chloromethyl alkanoates 
Examination of the literature on the preparation of chloromethyl esters revealed two main 
protocols : alkylation of carboxylates with chloromethyl chlorosulfate in phase-transfer 
conditions
168
 (Scheme 9, pathway A a)) and condensation of an aldehyde with acid chlorides in 
the presence of a Lewis acid
169
 (Scheme 9, pathway A a')). Preliminary studies involving the 
synthesis of chloromethyl octanoate 10c (n=6) revealed that the A a) method provides higher 
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yields (60% yield for 10c) but uses hazardous, potentially carcinogenic alkylating agent, that is 
chloromethyl chlorosulfate. In order to improve the A a') procedure, several Lewis acids were 
tried for the preparation of chloromethyl octanoate 10c (Scheme 10, Table 48). It was observed 
that the use of zinc chloride in the presence of calcium chloride improved the yield of reaction to 
52%. 
 
Scheme 10 Procedures for the synthesis of chloromethyloctanoate 10c 
 
Table 48 Optimization of the synthesis of chloromethyl octanoate (n = 6) 
167
 
Pathway A Lewis Acid Yield of 10c, % 
a) – 60a 
a') SnCl4 33
b
 
ZrCl4 9
b
 
AlCl3 16
b
 
ZnCl2 25
b
 
ZnCl2 + CaCl2 57
b
 (52
a
) 
a
Yields after isolation. 
b
Yields calculated from 
1
H NMR (Nuclear Magnetic Resonance) 
spectra of mixtures obtained after usual workup.  
 
After these optimization runs with chloromethyl octanoate, both methods were applied to 
the synthesis of a series of lipophilic alkylating agents. It was observed that the pathway A a) is 
often more effective for the synthesis of chloromethyl alkanoate in comparison with the pathway 
A a') (Table 49). 
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Table 49 Comparative results for the synthesis of chloromethyl alkanoates 
Compound n 
Yield, % 
Pathway A a) Pathway A a') 
10b 4 68% – 
10c 6 60 52 
10d 8 77, 87
a
 – 
10e 10 84, 87
a
 41 
10f 12 82 – 
10g 14 80 56, 69
a
 
10h 16 – 58, 72
a
 
10i 18 81 – 
a
Yields from multiple experiments 
 
In summary, preliminary assays have shown that the pathway B (Scheme 9) 
derivatization worked well with NAL but failed when it was applied to LEV. Alternative A 
pathway comprising the LEV derivatization with various chloromethyl alkanoates was 
promising. Therefore, a series of these lipophilic alkylating esters was prepared for the synthesis 
of various acyloxymethyl esters of LEV. 
 
4.3 Synthesis of C-6-acyloxymethyl esters of LEV: Optimization 
4.3.1 Classical conditions 
The synthesis of acyloxymethyl esters of LEV 14 started from optimization experiments 
with commercially available chloromethyl butanoate 10a. A series of experiments were 
conducted with several experimental conditions including those described by Maeda et al
170
. 
Reactions were conducted by varying solvent (DMF or CH3CN), temperature (from room 
temperature to 80°C), reaction time (from 17 hours to 7 days) and with or without catalyst. The 
results demonstrated that the best conditions were refluxing 1 equivalent LEV in the presence of 
2 equivalents of K2CO3 with 1.2 equivalents of chloromethyl butanoate 10a and 0.1 equivalent 
of TBAI in CH3CN for 7 days (Scheme 11, Table 50). 
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Scheme 11 Synthetic route to the target butanoyloxymethyl ester of LEV 14a 
 
Table 50 Optimization assays for the synthesis of butanoyloxymethyl ester of 
LEV (n = 2) 
Base Solvent 
Catalyst (relative 
amounts/LEV) 
Temperature 
Reaction 
time 
Yield of 14a 
(%) 
K2CO3
a
 DMF – 50ºC 17h traces 
K2CO3
b 
DMF – rt 4d 23 
K2CO3
b
 DMF – 50ºC 7d 28 
K2CO3
b
 CH3CN – rt 4d 15 
K2CO3
b
 CH3CN – 50ºC 7d 36 
K2CO3
b
 CH3CN – Reflux 7d 25 
K2CO3
b
 CH3CN TBAI (0.1 eq) Reflux 7d 48 
a
Experimental conditions described by Maeda et al
170
 
b
Sandra Dorbes, Master 2, 
February-June 2005 
Later on this protocol was applied to the synthesis of long-chain acyloxymethyl esters of 
LEV 14e-i. However, in comparison with short-chain compound 14a, the long-chain analogs 
were obtained with a significant decrease of the yield (0-10% yields) and noticeable quantities of 
methylene dialkanoate by-product 15 (14-35% yields) were isolated (Scheme 12, Table 51). The 
formation of these symmetric double esters may be explained by the hydrolysis of the 
chloromethyl alkanoates 10 leading to the formation of corresponding carboxylates which 
probably react more rapidly with the remaining chloromethyl alkanoate than LEV carboxylate. 
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Scheme 12 Synthesis of acyloxymethyl esters of LEV 14 
 
Table 51 Yields of long-chain acyloxymethyl esters of LEV 14e-i and methylene 
dialkanoate 15e-i.
a
 
n Compound Yield of 14 ( %)b Coumpound Yield of 15 (%)
b
 
10 14e 5 15e 17 
12 14f 10 15f 35 
14 14g 3 15g 14 
16 14h 5 15h 28 
18 14i 0 15i 0 
a
Sandra Dorbes, Master 2, February-June 2005 
b
Isolated yields after purification 
 
In summary, classical conditions for the alkylation of LEV with chloromethyl butanoate 
were optimized and gave a moderate yield of 48%. However, applying these conditions for the 
synthesis of long-chain acyloxymethyl esters of LEV resulted in the significant drop of the yield. 
This was probably due to the hydrolysis of the chloromethyl alkanoates during the prolonged 7 
days heating of the reaction mixture. In order to overcome these difficulties we decided to 
perform microwave-assisted attempts.  
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4.3.2 Microwave-assisted synthesis 
4.3.2.1 Optimization for the commercial chloromethyl butyrate 
The microwave-assisted (MW) synthesis was attractive because of its major advantages 
such as rapid heat transfer and selective heating. This should lower the reaction time and 
therefore decrease the possible hydrolysis of the alkylating agent
171
. 
Initial attempts were carried out with chloromethyl butyrate 10a and showed, in 
comparison with classical oil bath conditions, a significant decrease of the reaction time 
(Scheme 13, Table 52). In an effort to ascertain the reaction parameters governing the 
nucleophilic substitution, for all optimization runs (Table 52, entries 2-13), the reactive 
potassium or cesium salt was always prepared under MW in a discrete step using 20 min 
irradiation time from 1 equivalent of LEV and 2 equivalents of base. In the nucleophilic 
substitution step, 1.5 equivalents of chloromethyl butyrate was used with regard to LEV.  
Reactions were first conducted in DMF at 120°C, by varying reaction time and catalyst 
amounts (Table 52, entries 2-6). Three experiments were conducted to assess the effect of the 
relative amounts of TBAI on the isolated yields while keeping constant the irradiation time (60 
min) (Table 52, entries 2-4). The yield was significantly dependent on the amount of catalyst 
used, the use of 0.2 equivalent of TBAI led to an optimized yield of 46%. Next, the effect of 
irradiation time on the substitution (Table 52, entries 4–6) was assessed and showed that 
increasing the reaction time from 60 to 120 min led to a loss of yield of the expected 14a. 
Esterifications with chloroalkylesters were described as more effective when the reaction was 
conducted in N,N’-dimethylpropyleneurea DMPU172 and we have found out that it gave similar 
yield as in DMF (Table 52, entry 7).  
CH3CN as solvent at 90°C for 60 minutes with 0.2 equivalent of TBAI, led to an enhance 
yield of 56% (Table 52, entry 8). As observed with DMF, an increase of time of reaction from 
60 to 90 minutes led to a loss of yield (Table 52, entry 9). We also assessed the effect of the 
relative amounts of TBAI. When the reaction was carried out with 0.1 equivalent of TBAI, we 
observed a loss of yield and with 0.3 equivalent of TBAI, the yield remained unchanged (Table 
52, entries 10-11). The change of the base by using Cs2CO3 instead of K2CO3, either in DMF or 
CH3CN, did not lead to an improved yield (Table 52, entries 12-13). 
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Scheme 13 MW-assisted synthesis routes of butanoyloxymethyl ester of LEV 14a 
 
Table 52 MW vs classical conditions for the synthesis of butanoyloxymethyl ester 
of LEV 14a 
Entry Heating Solvent Base Temp. Time 
Relative 
amount of 
TBAI/LEV 
Yield 
( %) 
1 Oil bath CH3CN K2CO3 Reflux 7d 
days 
0.1 eq 48 
2 MW
a DMF K2CO3 120°C 60' 0 8
b 
3 MW DMF K2CO3 120°C 60' 1 7
b
 
4 MW DMF K2CO3 120°C 60' 0.2 46
b
 
5 MW DMF K2CO3 120°C 90' 0.2 47
b
 
6 MW DMF K2CO3 120°C 120' 0.2 20
b
 
7 MW DMPU K2CO3 120°C 120' 0.2 16
b
 
8 MW CH3CN K2CO3 90°C 60' 0.2 56 
9 MW CH3CN K2CO3 90°C 90' 0.2 32 
10 MW CH3CN K2CO3 90°C 60' 0.1 46 
11 MW CH3CN K2CO3 90°C 60' 0.3 55 
12 MW DMF Cs2CO3 120°C 60' 0.2 37 
13 MW CH3CN Cs2CO3 90°C 60' 0.2 45 
a
All reactions were performed in 80 mL cylindrical Pyrex open vessels 
b
Previous 
attempts 
 
 118 
 
Then, the optimal MW conditions for the synthesis of butanoyloxymethyl ester 14a were 
found to be the use of 0.2 equivalent of catalyst (TBAI) in CH3CN at 90°C for 60 minutes in the 
presence of K2CO3. 
4.3.2.2 Synthesis of a series of acyloxymethyl esters of LEV 
We then applied this experimental protocol to the synthesis of the series of 
acyloxymethyl esters LEV 14b-i with longer chain lengths. Potassium salt of LEV was prepared 
by reaction of K2CO3 (2 equivalent) on LEV (1 equivalent) in CH3CN at 90°C under MW using 
20 min irradiation time. After the addition of TBAI catalyst (0.2 eq) and chloromethyl alkanoates 
10b-i (1.5 eq), the mixture was irradiated one hour more at 90°C. Though yields were somewhat 
higher (from 10 to 23% yields) for the synthesis of 14e-i than those obtained under oil bath 
heating (from 3 to 10% yields), they were significantly lower than the yields obtained for the 
short chain analog 14a (n=2). (Scheme 14, Table 53) 
 
Scheme 14 MW-assisted synthesis of acyloxymethyl esters of LEV 14b-i 
 
Table 53 Yields of acyloxymethyl esters of LEV 14b-i under MW conditions 
Compound n Yield, % 
14b 4 16 
14c 6 18 
14d 8 16 
14e 10 17 
14f 12 9 
14g 14 11 
14h 16 23 
14i 18 –
a
 
a
Failed to isolate the pure product 
 
In order to investigate the reason for these poor yields, we decided to examine the 
byproduct formation. A representative example of long-chain derivatives was chosen for this 
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study, that was the MW-assisted synthesis of octadecanoyloxymethyl ester of LEV 14h. Indeed, 
during the synthesis of acyloxymethyl esters of LEV conducted under classical oil-bath 
conditions, high quantities of methylene dialkanoates by-product 15 were observed and were 
thought to be the possible cause of the low yield (Table 51). 
In order to clarify the reaction behavior we have evaluated the rate of by-products, that 
were methylene dioctadecanoate 15h, octadecanoic acid (arising from the hydrolysis of 
chloromethyl octadecanoate) along with unreacted reagent 10h and the desired 
octadecanoyloxymethyl ester of LEV 14h (Table 54). After a tedious purification, we have got 
many batches containing pure product or a mixture of two products. In this last case, the yields 
have been estimated by 
1
H NMR spectroscopy. We observed that under MW conditions, much 
less of the symmetric methylene dioctadecanoate 15h and more of the desired 
octadecanoyloxymethyl ester of LEV 14h were produced in a shorter time of reaction comparing 
to classical oil-bath conditions. However, we have seen that the main part of the alkylating agent 
10h remains unreacted or hydrolyzed to octadecanoic acid. In addition, unreacted LEV was also 
detected. 
 
Table 54 Conversion of chloromethyloctadecanoate 10h during the synthesis of 
long-chain compound (n = 16) 
Compound 
Conversion
a
, % 
Microwave, 1 hour Oil-bath, 7 days 
14h 18
b
 3
b
 
n-C17H35CO2CH2Cl, 10h 32
c
 –d 
(n-C17H35COO)2CH2, 15h 5
c
 28
b
 
n-C17H35CO2H 45
e
 –d 
a
Based on the n-C17H35CO2CH2Cl (Its initial quantity is set to 100%) 
b
Isolated product 
c
Estimated by 
1
H NMR spectroscopy for the mixture of 10h and 15h
 d
Was not evaluated during 
experiment 
e
Calculated as a difference between the initial quantity of n-C17H35CO2CH2Cl  and 
other C17 containing components 
 
In summary, the MW-assisted synthesis of acyloxymethyl esters of LEV had some 
advantages over classical conditions (significantly lower reaction time) but the yields were low 
for the long-chain derivatives. This could be explained by the relatively high hydrolysis rate of 
chloromethylalkanoate. The presence of unreacted LEV and alkylating agent may be due to their 
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low reactivity in these conditions, which is supposed to be the second reason for the low yield. 
So we decided to search for alternative conditions in order to optimize this synthetic protocol. 
4.3.3 Modified classical oil-bath conditions: use of cesium salts of LEV 
4.3.3.1 Preliminary attempt for butyloxymethyl ester of LEV (n = 2) 
Cesium salts generally display higher solubility in organic solvents. We first isolated 
LEV cesium salt after refluxing LEV with cesium carbonate in dichloromethane. DMF was first 
evaluated as solvent. The other parameters were kept the same as for the microwave and 
classical conditions: 90 ºC, 0.2 equivalent of TBAI and 1.5 equivalents of chloromethyl butyrate 
10a (Scheme 15). Initial experiment rendered the desired butyloxymethyl ester of LEV 14a  in 
moderate yield (50%) after only 3 hours while classical conditions discussed above required 7 
days under reflux to achieve 48% yield. 
 
Scheme 15 Synthesis of butyloxymethyl ester of LEV in DMF by using cesium 
salt 
 
This reaction conducted with cesium salt of LEV seemed to be faster than the one from 
LEV. However, it should be pointed out that this procedure, when applied to a series of long 
chain derivatives (bearing 11-19 carbon atoms), was always plagued with difficulties during 
purification. Generally, several (2–3) silica gel columns (with different solvent systems) were 
necessary to isolate the lipophilic esters in pure form without any trace of TBAI. Low isolated 
yields were thus obtained. To circumvent this problem, the reaction with chloromethyl 
octadecanoate was further investigated using oil-bath heating and without TBAI. 
4.3.3.2 Preliminary attempts for the synthesis of octadecanoyloxymethyl ester of 
levofloxacin 14h (n = 16) 
We decided to optimize the reaction on a long-chain derivative, as the increase of chain 
length of alkylating agents posed greater problems. The reaction was conducted with 
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chloromethyloctadecanoate 10h in the same conditions, except we did not use any catalyst 
(Scheme 16). In order to evaluate the optimal reaction time, the main product formation was 
monitored by HPLC. Thus, during the first hour, probes were taken each 20 minutes and the 
concentration of cesium salt of LEV was determined at the same time as that of the formed 
compound 14h (Table 55). Conversion of cesium salt of LEV to the main product 14h was 
evaluated to be around 64% after 60 minutes. The mixture was then allowed to react for 2 more 
hours. The isolated yield after this total time of 3 hours was 60% which is significantly higher 
than ever before but was appreciably the same to the evaluated yield after 1 hour of reaction. 
 
Scheme 16 Synthesis of octadecanoyloxymethyl ester of LEV 14h 
 
Table 55 Reaction monitoring for the synthesis of 14h 
 
Concentration ( M) determined by 
HPLC 
Time, min 14h Cesium salt of LEV 
0
a
 0 0.440 
20 0.257 0.186 
40 0.263 0.183 
60 0.263 0.180 
a
Calculated values before the start of the reaction 
 
During the purification of 14h, once more, we have isolated methylene dioctadecanoate 
15h and octadecanoic acid along with unreacted alkylating agent 10h. As shown in Table 56, we 
observed that, in comparison with the previously discussed MW-assited synthesis (Table 54), 
the obtained higher yield could be explained by a two-fold higher conversion of the 
chloromethylalkanoate 10h into the main product 14h. Though we could still observe hydrolysis 
products, the current conditions had positive impact on the yield. 
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Table 56 Comparison of conversion of chloromethyloctadecanoate 10h for the 
current conditions and MW-assisted synthesis of 14h (n = 16) 
Compound 
Conversion
a
, % 
Current conditions, 3 hours MW, 1 hour 
14h 34
b
 18
b
 
n-C17H35CO2CH2Cl, 10h 17
c
 32
c
 
(n-C17H35COO)2CH2, 15h 4
c
 5
c
 
n-C17H35CO2H 45
d
 45
d
 
a
Based on the n-C17H35CO2CH2Cl (Its initial quantity is set to 100%) 
b
Isolated product 
c
Estimated by 
1
H NMR spectroscopy for the mixture of 10h and 15h
 d
Calculated as a difference 
between the initial quantity of n-C17H35CO2CH2Cl (1.5 eq) and other C17 containing 
components 
 
A series of small-scale experiments were conducted in order to find the best conditions of 
reaction. The yields of compound 14h were estimated by HPLC analysis of the crude reaction 
mixture. Thus, we assessed the effect of CH3CN instead of DMF (Table 57, entries 1, 2), the 
time of reaction (Table 57, entries 1, 3) and the amount of chloromethyloctadecanoate (Table 
57, entries 1, 4).  
 
Table 57 Optimization of reaction conditions for the synthesis of 14h 
Entry Time (hour) Solvent RCO2CH2Cl ( eq) Yield
 
(%) 
1 3 DMF 1.5 64 
2 3 CH3CN 1.5 58 
3 1 DMF 1.5 70 
4 1 DMF 1 63 
 
First of all, we observed that CH3CN gave lower yield than DMF. As already observed 
the reaction time in DMF can be decreased to 1 hour. Using 1 equivalent of the alkylating agent 
instead of 1.5 equivalents slightly lowered the yield, but facilitated the purification step. Though 
an increased yield was achieved, this protocol still presented some drawbacks: the step of the 
cesium salt preparation and the moisture sensitivity of the cesium salt making it uneasy to 
handle. The resolution of these issues will be discussed in the next section. 
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4.3.4 Modified classical conditions: in situ formation of LEV salts 
In order to overcome these drawbacks, we decided to prepare in situ the cesium (or 
potassium) salt of LEV. During an optimization study, isolated yields of compound 14h were 
determined. A mixture of LEV and M2CO3 (1 equivalent) was heated in CH3CN or DMF for 20 
minutes. After adding octadecanoyloxymethyl chloride, the reaction was performed during 1 
hour (Scheme 17). The results obtained for various parameters: the solvent (DMF or CH3CN), 
the base (Cs2CO3 or K2CO3) and the quantity of alkylating agent (1 or 1.5 equivalents) are 
presented in Table 58. 
 
Scheme 17 Synthesis of octadecanoyloxymethyl ester of LEV 14h 
 
Table 58 Optimization runs for the synthesis of 14h 
Base, eq Solvent RCO2CH2Cl, eq Yield, % 
Cs2CO3 (1eq) DMF 1 83 
Cs2CO3 (1 eq) CH3CN 1 23 
K2CO3 (1 eq) DMF 1 81 
K2CO3 (1 eq) CH3CN 1 9 
K2CO3 (1 eq) DMF 1.5 86 
 
From obtained results, we observed that the use of in situ salts formation increased the 
yield and favored the conversion of LEV into the desired compound 14h. The nature of the base 
used was not really important in this case as both Cs2CO3 and K2CO3 gave similar yields, if the 
reaction was conducted in DMF. The nature of the used solvent turned out to be the determining 
factor for this reaction: when DMF was used, the isolated yields were four- to eight-folds higher 
than those in CH3CN. This phenomenon could be explained by the preferred cation-solvation by 
DMF, thereby activating the LEV carboxylate-anion. A poor difference was obtained between 
equimolar and 1.5 equivalent quantities of the chloromethyloctadecanoate. We selected as 
optimal conditions for the synthesis of the rest of acyloxymethyl esters of LEV derivatives: 1 
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equivalent of K2CO3 (cheaper and less hygroscopic), DMF as solvent, 1 equivalent of alkylating 
agent RCO2CH2Cl, 1 hour reaction time at 90°C. 
4.3.5 Synthesis of acyloxymethyl esters of LEV derivatives using optimized conditions 
We have synthesized the series of LEV acyloxymethyl esters 14a-i in yields varying from 
59 to 81% depending on the length of the chain (Table 59). 
1
H NMR spectra of the crude 
mixture showed no significant difference between long and short chain derivatives. As the lower 
yields were obtained for compounds with shorter chains, we proposed that as they are more polar 
they are probably held tighter by the silica column during the purification step. 
 
Table 59 Yields of acyloxymethyl esters of LEV 
 
Compound n Yield, % 
14a 2 59 
14b 4 69 
14c 6 75 
14d 8 79 
14e 10 79 
14f 12 77 
14g 14 79 
14h 16 81 
14i 18 79 
 
In summary, we have designed and synthesized the series of acyloxymethyl esters of 
LEV. We have tried three general synthetic protocols while optimizing the experimental 
conditions. During these experiments we have deduced the most important factors influencing 
the reaction: the reaction time (1h) and the nature of the solvent (DMF). The other factors such 
as the nature of the base (K2CO3 vs Cs2CO3) and the quantity of the alkylating agent (1 
equivalent versus 1.5 equivalents) showed minor influence on the yield. As it was previously 
mentioned this compounds could represent prodrugs of LEV. Though acyloxymethyl esters of 
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LEV are more stable than simple esters, they are sensible to hydrolysis. So we have shifted our 
attention to the synthesis of ―mono-‖ and ―di-amide‖ derivatives of LEV with higher stability 
towards enzymatic and chemical hydrolysis. 
 
4.4 Synthesis of C-6-(alkylcarboxamide)-linked LEV “monomers” and “dimers” 
4.4.1 Synthesis of “monomer” dodecylcarboxamide derivative of LEV 
As previously outlined for the synthesis of CIP derivatives, FQs did not tolerate the use 
of thionyl chloride or oxalyl chloride due to the high degree of degradation of FQs with these 
chlorinating agents. 
Carbodiimides were previously used for the synthesis of CIP derivatives. In the previous 
section 3.2 we discussed some methods for formation of the amide bond in peptide chemistry. 
Carbodiimides are often used for the coupling of aminoacids and amide formation from aliphatic 
acids.  
We compared two methods of carboxylic acid activation : i) the use of the salt of uronium 
with a non-nucleophilic anion which exists in the O- and N-forms: 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]pyridinium hexafluorophosphate 3-
oxide (N-HATU) and N-[(1H-1,2,3-triazolo[4,5-b]pyridin-1-yloxy)(dimethylamino)methylene]-
N-methylmethanaminium hexafluorophosphate (O-HATU)
173
 and ii) the use of the 
triphenylphosphine (TPP)  / trichloroacetonitrile
174
 (TCA)  system. 
It was previously reported that HATU is very efficient in solution synthesis
175
 and tertiary 
amines such as diisopropylethylamine (DIPEA) have been considered as practically useful bases 
due to their non-nucleophilic property, while the highly hindered 2,4,6-trimethylpyridine (TMP) 
was recommended by Carpino
176
. Both O- and N-forms serve as excellent coupling agents. 
(Figure 39). 
 
Figure 39 Two isomers of HATU coupling agent 
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The HATU based amide coupling is mediated in two steps, activation and coupling. 
Mechanistically, it is similar to the previously discussed EDCI/HOBt system with the difference 
that the carbodiimide moiety and nucleophilic additive are present in the same molecule of 
HATU (Figure 40). During the activation step that takes place in a basic media, HATU reacts 
with the carboxylate, forming an uronium intermediate, which is subsequently transformed to O- 
and N-acyl species. The more active O-form is generated more rapidly and is subsequently 
isomerized to the less active N-form. During the coupling step created intermediates react with 
the amino component to form the amide bond
177
. 
 
Figure 40 Mode of formation of amide bond by using HATU 
 
TCA is an inexpensive, stable and commercially available compound, which has been 
used as a source of chlorine in synthetic transformations
174, 178
. The reaction of TCA with TPP 
readily generates triarylphosphonium chloride which can react with carboxylic acids to produce 
triphenylacyloxyphosphonium species. The subsequent attack of chloride anion yields acid 
chloride and TPP oxide
178
. This provides a mild and efficient procedure for the conversion of 
carboxylic acids into acid chlorides under neutral conditions (Figure 41)
174, 179
. Obtained acyl 
chloride can used to generate the desired amide by in situ condensation with alkylamines in the 
basic media. 
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Figure 41 Mechanism of formation of amide bond TPP/TCA system 
16 
We applied these two methods to the synthesis of dodecylcarboxamide derivative of LEV 
17f (Scheme 18). 
 
Scheme 18 Synthesis of dodecylcarboxamide derivative of LEV 17f  
 
The initial activation of the LEV by 1 equivalent of HATU and 3 equivalents of DIPEA 
in DMF for 1 hour at room temperature was followed by addition of 1 equivalent of 
dodecylamine. After stirring reaction mixture at room temperature for 8 hours, the target 
compound 17f was isolated with 52% yield. Reaction went smoothly and the purification didn‘t 
pose any problems.  
Acyl chloride of LEV 16 was prepared after the treatment of LEV with TPP/TCA (2 
equivalents / 2 equivalents) in CH2Cl2 for 4 hours at room temperature. This derivative was 
filtered off and used in the next step without purification. Reaction with 1 equivalent of 
dodecylamine in the presence of 3 equivalents of triethylamine for 18 hours in CH2Cl2 at room 
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temperature provided the desired dodecylcarboxamide derivative of LEV 17f with moderate 
overall yield (38%) after an easy purification (Scheme 18). 
TPP/TCA system was chosen for the synthesis of C-6-(alkylcarboxamide)-linked LEV 
―monomers‖ and ―dimers‖ which will be described in the next section. 
4.4.1.1 Synthesis of “monomer” alkylcarboxamide derivatives of LEV 
The series of ―monomer‖ alkylcarboxamide derivatives of LEV 17a-j was obtained, by 
using TPP/TCA system, with moderate yields. The summary of these results is presented in 
Table 60. 
 
Table 60 Synthesis of ―monomer‖ alkylcarboxamide derivatives of LEV 17a-j 
 
Compound n Yield, % 
17a 3 34 
17b 5 37 
17c 6 36 
17d 7 36 
17e 9 35 
17f 11 37 
17g 12 39 
17h 13 39 
17i 14 40 
17j 16 41 
4.4.1.2 Synthesis of “dimer” alkylcarboxamide derivatives of LEV 
For the synthesis of ―di-amide‖ derivatives of LEV 18, the same TPP/TCA system was 
used. The ―dimeric‖ derivatives were obtained with yields somewhat lower (20-41%) than that 
for their ―monomeric‖ analogs 17 (Scheme 19, Table 61). 
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Scheme 19 Synthesis of ―dimer‖ alkylcarboxamide derivatives of LEV 18a-h 
 
Table 61 Yields of ―dimer‖ alkylcarboxamide derivatives of LEV 18a-h 
Compound n Yield 
18a 4 39 
18b 5 29 
18c 6 41 
18d 7 37 
18e 8 23 
18f 9 20 
18g 10 27 
18h 12 27 
 
In summary, during this work, five series of LEV and CIP derivatives were prepared (7, 
9, 14, 17, 18). Several synthetic challenges were faced on the way to these new compounds and a 
number of optimization studies were conducted in order to overcome these problems. 
5. Stability tests 
The stability of the biologically active compounds is a very important physicochemical 
property. It determines the rate of degradation of the products and therefore influences the 
pharmacokinetics: maximum concentration in the serum and AUC (area under the curve 
concentration/time). Therefore stability evaluation step is inevitable during the drug development 
process. Different types of stability tests are necessary for ―hits‖ – newly synthesized compounds 
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with biological activity. The simplest initial tests measure the stability in vitro - in the water 
buffer at physiological pH = 7.4 and 37ºC. These tests could provide some insight into the 
stability of the compounds and select the successful candidates for in vivo testing. 
Though there is no standard universal procedure for stability evaluation of every 
compound, analytical  HPLC is one the most frequently used methods
180
. It is relatively simple 
and quick with a high potential of separating complex mixtures of compounds. The optical 
ultraviolet (UV) detection provides quantification and a high sensitivity of this method. 
So we decided to use the HPLC procedure and UV detection to measure the stability of 
our compounds. 
5.1 Conditions for the stability testing 
Though there are a number of examples of experimental conditions for the stability 
testing
180
 there is no generalized procedure recognized as a standard. We have chosen phosphate 
buffer saline (PBS) as a buffer solution for the testing. Our compounds weren‘t soluble directly 
in the buffer so mixture of PBS/acetonitrile (50:50) was used. Initially compounds were 
dissolved in the DMSO and then they were diluted by the PBS/acetonitrile mixture. 
Experimental evidences from the literature showed that up to 10% of DMSO doesn‘t result in 
significant changes of stability
180a
. However, even in these conditions the most liphophilic 
compounds weren‘t soluble. We decided to test synthesized compounds for 6-7 days with 
intermediate sampling. 
5.2 Results 
5.2.1 CIP derivatives 
We have selected representatives from each series with wide range of chain lengths. In a 
typical experiment 1mM DMSO solution of compound was diluted by PBS to render the final 
concentration 10
-4
M of tested compound and 10% of DMSO. An aliquot was taken and kept at 
4ºC (0 day). Then the vial was sealed and incubated for 6 days at 37ºC (6 days). In order to 
evaluate the degradation degree of tested compounds these two probes were injected. 
Chromatograms were extracted at the wavelength = 280 nm as it represents an absorbance 
maximum for these series of CIP derivatives. By the comparison of the initial chromatogram and 
the one after the incubation we could estimate the percentage of the remaining parent compound 
relative to the initial concentration. Typical chromatograms for 0 day and 6 days probes are 
demonstrated on the Figure 42. The peak with tr = 1.0 min is associated with the dead volume of 
the column. The series of ―monomeric‖ CIP derivatives can provide two possible degradation 
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products: CIP (retention time tr = 1.6 min) and 4 (tr = 2.6 min). The presence of 4 is expected for 
the series of ―mono-oxoethylesters‖ CIP derivatives 3. 
 
 
Figure 42 Representative example of 0 day (A) and 6 days (B) probes for 3b 
 
As we can see from the results the CIP ―monomeric‖ derivatives (1, 2, 3 and 6) are stable 
at described conditions with more than 97% of the unhydrolyzed compound after 6 days of 
incubation (Table 62). 
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Table 62 Stability of CIP ―monomeric‖ derivatives 
 
Compound R 
Stability
a
, % 
6 days 
1f -CO(CH2)5CH3 100 
1h -CO(CH2)8CH3 100 
1k -CO(CH2)14CH3 100 
2 -COCH2Cl >99 
3b -COCH2OCO(CH2)2CH3 100 
3c -COCH2OCO(CH2)4CH3 >99 
3d -COCH2OCO(CH2)6CH3 >97 
6a -C(O)OCH2CH3 100 
6b -C(O)O(CH2)3CH3 100 
6c -C(O)O(CH2)7CH3 100 
6g -C(O)OC(CH3)3 >99 
a
Stability(%) at x day = [mean measured concentration (n = 2) at x day/mean measured 
concentration (n = 2) at 0 day] × 100 
 
During stability studies of ―dimeric‖ CIP derivatives we have monitored the intermediate 
concentration at 3 and 5 days point in order to estimate the rate of hydrolysis. We have also 
evaluated the presence of CIP in the solution during stability testing. However, for all 
compounds the peak corresponding to CIP was not observed (Figure 43) and the data shown on 
the Table 63 proves that CIP ―di-amide‖ derivatives 7 exhibit no hydrolysis after 7 days of 
incubation. 
 
 
A 
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Figure 43 Representative examples of chromatograms for 0 day (A), 3 days (B), 5 
days (C) and 7 days (D) probe for 7c (n = 12). 
 
Table 63 Stability of CIP ―di-amide‖ derivatives 
 
Compound 
Stability, % 
3 days 5 days 7 days 
7b (n = 10) 100 100 100 
7c (n = 12) 100 100 100 
7e (n = 14) 99 >99 >99 
B 
C 
D 
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5.2.2 LEV derivatives 
For the stability testing of LEV derivatives we have utilized similar conditions as for CIP 
derivatives: PBS/acetonitrile buffer (pH = 7.4), 10% DMSO, 7 days incubation at 37ºC. After the 
incubation we have noticed the presence of other peaks which didn‘t correspond to tested 
compounds, nor to the hydrolysis product. Having investigated their UV-spectra it was proposed 
that they are plasticizers from the rubber septum, like o-dialkylphthalates. Also due to the 
overlapping with tested compounds we have to change the detection wavelength to 325 nm for 
14g. Because of the low solubility of the most lipophilic compounds in the series we have to 
increase dilution to 5·10-5M for 14e and 1·10-5M for 14g. We have also monitored the LEV 
(retention time tr = 2.4 min) concentration during the incubation. As we can see from these 
results the LEV ―mono-oxoethylesters‖ series 14 are only slightly hydrolyzed in current 
conditions with more than 92% of the final compound after 7 days of incubation (Figure 44, 
Table 64). 
 
 
 
A 
B 
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Figure 44 Representative examples of chromatograms for 0 day (A), 3 days (B), 5 
days (C) and 7 days (D) probe for 14a (n = 2) 
 
Table 64 Stability of LEV acyloxymethyl esters 
 
Compound 
Stability, % 
0 days 3 days 5 days 7 days 
14a (n = 2) 100 95 93 92 
14c (n = 6) 100 98 94 92 
14e (n = 10) 100 96 93 93 
14g (n = 14) - 95
a
 93
a
 93.0
a
 
C 
D 
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a
The 14g peak was slightly overlapped with impurity peak so we had to change the wavelength 
of the UV detector. 
 
For the LEV ―mono-amide‖ series 17 we have used glass stoppers and didn‘t observe the 
other peaks. The results showed minor LEV quantities or no LEV in the mixture after 7 days, so 
we can conclude that compounds from LEV ―mono-amide‖ series are also stable at these 
conditions (Table 65, Figure 45). 
 
 
 
Figure 45 Representative examples of chromatograms for 0 day (A) and 7 days 
(B) probe for 17d (n = 7) 
 
Table 65 Stability of LEV ―mono-amide‖ derivatives 
 
Compound 
Stability, % 
0 days 7 days 
17a (n = 3) 98 95 
17b (n = 5) 100 100 
17d (n = 7) 99 99 
17h (n = 13) 100 100 
A 
B 
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In summary, all tested compounds were found to be quite stable at pH = 7.4 and 37ºC 
with higher than 92% of unhydrolyzed compound remained after incubation. The least stable 
compounds were LEV acyloxymethyl derivatives which showed noticeable amounts of the 
hydrolysis product. This could be explained by the fact that they possess acyloxymethyl ester 
bound which is more easily hydrolyzed than the amide bond. Indeed, the other series of 
compounds containing amide bond didn‘t exhibit significant hydrolysis. After stability 
evaluation of synthesized compound we have switched on the biological testing which will be 
described in the next chapter. 
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6. Conclusion 
In summary, during the thesis we have prepared five series of LEV and CIP derivatives (7, 
9, 14, 17, 18). During the synthesis of 7-(4-(oxoethylalkanoate)piperazin-1-yl)-linked CIP 
―dimers‖ 9 we have faced the problem of the low reactivity of N-chloroacetylciprofloxacin so we 
conducted optimization studies with varying solvent, temperature, catalyst quantity and base. We 
have found that Cs2CO3 in the DMF with equimolar quantities of TBAI provide the best 
combination in the terms of reaction time and yield. The synthesis of 7-(4-(alkanoyl)piperazin-1-
yl))-linked CIP ―dimers‖ 7 required the implication of EDCI coupling agent with HOBt additive 
to achieve high yields and facilitate the purification. 
The C-6 LEV modification was also complicated by the low reactivity of its carboxyl 
moiety. For the synthesis of C-6-acyloxymethyl esters of LEV 14 we have tried microwave 
conditions to decrease the reaction time in comparison with original thermal pathway. However, 
we have found that after several optimizations (Cs2CO3, DMF) thermal conditions were capable 
to render the desired compounds within 1hour and with good yields (>59%). We have also faced 
several synthetic challenges on the way to C-6-alkylcarboxamides of LEV 17 because of 
inapplicability of classical activation agents, like thionyl and oxalyl chloride. Finally, we found 
an alternative TPP/TCA system which was used for the synthesis of the both C-6-
(alkylcarboxamide)-linked LEV ―monomers‖ and ―dimers‖ 17, 18. 
A range of CIP derivatives and LEV with different chain lengths were also evaluated for 
their stability at PBS buffer at physiological pH = 7.4 and 37ºC for 6-7 days. All tested 
compounds showed significant stability towards hydrolysis (>93% of unhydrolyzed compound 
remained) under present conditions. 
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CHAPITRE III ÉVALUATION BIOLOGIQUE DES DÉRIVÉS 
SYNTHÉTISÉS 
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1. Introduction 
Ce chapitre sera consacré à l'évaluation in vitro de l'activité biologique des dérivés de la 
CIP et de la LEV. 
Tout d'abord, un criblage initial de l'activité antimicrobienne des dérivés synthétisés 
contre des souches à Gram-positif et à Gram-négatif sera décrit. Nous présenterons également les 
études concernant l‘activité de certains dérivés contre les souches de S. aureus Méticilline 
Résistantes (SAMR) et MultiDrogues Résistantes (SAMDR) . Aux vues des résultats d‘activités 
antimicrobiennes obtenues, nous avons essayé de réaliser une relation structure-activité pour les 
différents dérivés de la CIP et de la LEV testés. 
Dans la deuxième partie de ce chapitre, l'activité antimycobactérienne des composés 
synthétisés sera présentée. Nous discuterons l'influence des modifications structurales sur 
l'activité contre M. tuberculosis. 
La dernière partie de ce chapitre sera dédiée à l‘évaluation de l'activité antiproliférative 
des dérivés de la CIP et de la LEV. Nous discuterons les résultats concernant leur cytotoxicité 
sur cinq lignées cancéreuses humaines. Nous mettrons en évidence l'influence des modifications 
structurales de la CIP et de la LEV sur leur potentialité et leur spectre d‘activité cytotoxique. 
En conclusion, nous donnerons un aperçu de l'ensemble des propriétés biologiques et 
nous essayerons de décrire les relations structure-activité générales concernant l'influence du 
type de substitution, de la nature du noyau quinolone et de la structure ―monomère‖ ou ―dimère‖ 
sur la sélectivité et la potentialité des dérivés contre ces cibles biologiques. 
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2. L'activité antibactérienne 
De part la propriété antibiotique majeure des composés parents, la CIP et LEV, les 
activités antimicrobiennes des composés synthétisés ont été déterminées. Cette étude a été 
effectuée par le Professeur Christine Roques au Laboratoire de Microbiologie Industrielle, UFR 
des Sciences Pharmaceutiques, Université Paul Sabatier, Toulouse. 
Un premier criblage contre quatre souches standards de bactéries sélectionnées a été 
effectué. Cette étude a été réalisée sur deux souches Gram-négatifs : E. coli (bactérie impliquée 
dans la diarrhée et autres infections gastro-intestinales) et P. aéruginosa (bactérie impliquée dans 
les infections de blessures par brûlures et de l'oreille externe), ainsi que deux souches Gram-
positifs : S. aureus (bactérie impliquée dans les infections de la peau et des plaies, les abcès, la 
pneumonie, la méningite ou l'ostéomyélite) et Enterococcus hirae (E. hirae, bactérie impliquée 
dans les infections de plaies). Les composés les plus actifs contre S. aureus ont été également 
testés sur un ensemble des souches SAMR et SAMDR qui représentent une cause majeure des 
maladies nosocomiales. 
2.1 Activité antimicrobienne in vitro des dérivés de la CIP 
Les concentrations minimales inhibitrices (CMI) et les concentrations minimales 
bactéricides (CMB) de certains composés synthétisés parmi les dérivés de la CIP ont été 
évaluées, comparativement à celles de la CIP (Tableau 66). La CMI est déterminée comme la 
concentration minimale de l‘agent antibactérien qui inhibe la croissance visible de la souche. La 
CMB est déterminée comme la concentration minimale de l‘agent antibactérien qui tue >99.9% 
de la souche. Ces concentrations sont déterminées par des techniques des dilution consécutives. 
On définit les antibiotiques comme bactéricides lorsque le rapport CMB/CMI est égal à 4, et les 
antibiotiques bactériostatiques, lorsque ce rapport est compris entre 8 et 16. 
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Tableau 66 Activité antimicrobienne in vitro des dérivés de la CIP 
 
   CMI (CMB), M 
   Gram-négatif Gram-positif 
Comp R CLogP
a
 E. coli
b
 
P. 
aéruginosac 
S. aureus
d
 E. hirae
e
 
CIP H -0,72 0,97(0,97) 0,97 (1,95) 0,97 (0,97) 0,97 (1,95) 
2 COCH2Cl 1,75 <0,97(<0,97) 27,8 (250) <0,97 (<0,97) 3,9 (3,9) 
1a COCH3 1,14 1,95 (1,95) 31,2 (31,2) <0,97 (1,95) 7,8 (7,8) 
1b COCH2CH3 1,67 3,9 (>500) 31,2 (250) <0,97 (<0,97) 3,9 (3,9) 
1c CO(CH2)2CH3 2,19 7,8 (7,8) 62,5 (250) <0,97 (<0,97) 7,8 (7,8) 
1d COC(CH3)3 2,37 15,6 (31,2) 62,5 (250) <0,97 (<0,97) 7,8 (7,8) 
1e CO(CH2)3CH3 2,72 7,8 (15,6) 62,5 (250) <0,97 (<0,97) 7,8 (7,8) 
1f CO(CH2)5CH3 3,78 31,2 (31,2) 62,5 (250) <0,97 (<0,97) 31,2 (31,2) 
1g CO(CH2)7CH3 4,84 31,2 (>500) 62,5 (250) <0,97 (<0,97) 31,2 (31,2) 
1h CO(CH2)8CH3 5,37 125 (>500) 125 (250) 7,8 (62,5) 15,6 (15,6) 
1i CO(CH2)10CH3 6,43 7,8 (7,8) 62,5 (250) 3,9 (7,8) 7,8 (7,8) 
1j CO(CH2)12CH3 7,48 125 (500) 125 (250) 125 (125) 62,5 (250) 
1k CO(CH2)14CH3 8,54 125 (250) 125 (250) 125 (250) 62,5 (250) 
1l COCH2C6H5 3,19 9,3 (7,8) 62,5 (250) <0,97 (<0,97) 3,9 (7,8) 
4 COCH2OH 1,35 <0,97 (1,95) 15,6 (250) <0,97 (1,95) 7,8 (7,8) 
5 COCH2OCH2Ph 3,31 7.8 (15.6) 62,5 (250) <0.97 (>500) 15,6 (62,5) 
3a COCH2OCOCH3 1,71 7,8 (15,6) 62,5 (250) <0,97 (<0,97) 15,6 (15,6) 
3b COCH2OCO(CH2)2CH3 2,77 31,2 (31,2) 62,5 (250) <0,97 (<0,97) <0,97 (<0,97) 
3c COCH2OCO(CH2)4CH3 3,83 31,2 (31,2) 62,5 (250) <0,97 (<0,97) <0,97 (<0,97) 
3d COCH2OCO(CH2)6CH3 4,89 31,2 (62,5) 31,2 (250) <0,97 (<0,97) <0,97 (<0,97) 
3e COCH2OCO(CH2)7CH3 5,41 62,5 (500) 31,2 (250) <0,97 (<0,97) <0,97 (<0,97) 
3f COCH2OCO(CH2)8CH3 5,95 15,6 (15,6) 31,2 (250) <0,97 (<0,97) 7,8 (15,6) 
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   CMI (CMB), M 
   Gram-négatif Gram-positif 
Comp R CLogP
a
 E. coli
b
 
P. 
aéruginosac 
S. aureus
d
 E. hirae
e
 
3g COCH2OCO(CH2)9CH3 6,47 62,5 (250) 62,5 (250) <0,97 (<0,97) <0,97 (1,95) 
3h COCH2OCO(CH2)10CH3 7,00 125 (250) 62,5 (250) <0,97 (<0,97) 7,8 (7,8) 
3i COCH2OCO(CH2)12CH3 8,06 125 (>500) 125 (250) 7,8 (7,8) 31,2 (31,2) 
3j COCH2OCO(CH2)14CH3 9,12 125 (250) 125 (250) 62,5 (500) 125 (500) 
6a C(O)OCH2CH3 2,82 7,8 (31,2) 62,5 (250) <0,97 (<0,97) 3,9 (3,9) 
6b C(O)O(CH2)3CH3 3,88 7,8 (31,2) 62,5 (250) <0,97 (<0,97) 3,9 (7,8) 
6c C(O)O(CH2)7CH3 5,99 125 (500) 125 (250) 7,8 (62,5) 125 (125) 
6d C(O)O(CH2)8CH3 6,52 125 (500) 125 (250) 62,5 (125) 62,5 (250) 
6e C(O)O(CH2)9CH3 7,05 125 (500) 125 (250) 62,5 (62,5) 62,5 (500) 
6f C(O)O(CH2)11CH3 8,11 125 (125) 125 (250) 125 (125) 62,5 (>500) 
6g C(O)OC(CH3)3 3,53 1,95 (1,95) 15,6 (250) <0,97 (<0,97) 15,6 (15,6) 
7a (CH2)8 n.d. >250(>250) 62,5 (>125) 250 (<0, 48) 250 (250) 
7b (CH2)10 n.d. 62,5 (62,5) 62,5 (250) <0,97 (<0,97) 125 (500) 
7c (CH2)12 n.d. 62,5 (500) 62,5 (250) <0,97 (1,95) 125 (500) 
7d (CH2)13 n.d. 62,5 (500) 62,5 (250) <0,97 (3,9) 125 (500) 
7e (CH2)14 n.d. 62,5 (500) 62,5 (250) 1,95 (15,6) 62,5 (500) 
7f (CH2)16 n.d. 125 (500) 125 (250) 125 (500) 125 (500) 
9a (CH2)8 n.d. 31,2 (62,5) 31,2 (125) 31,2 (>250) 62,5 (>250) 
9b (CH2)10 n.d. 31,2 (62,5) 62,5 (125) < 0,48 (0,97) 31,2 (31,2) 
9c (CH2)12 n.d. 31,2 (62,5) 62,5 (125) < 0,48 (<0,48) 15,6 (15,6) 
9d (CH2)13 n.d. 31,2 (62,5) 62,5 (250) <0,97 (<0,97) 7,8 (15,6) 
9e (CH2)14 n.d. 7,8 (15,6) 62,5 (250) <0,97 (<0,97) 31,2 (62,5) 
9f (CH2)16 n.d. 15,6 (31,2) 62,5 (250) 7,8 (15,6) 62,5 (125) 
aLa lipophilie (CLogP) a été évaluée par un calcul in silico avec le logiciel (ChemDraw 
Ultra 10,0) 
b
E. coli CIP 53126 
c
P. aeruginosa CIP 82118 
d
S. aureus CIP 4.83 
e
E. hirae CIP 
5855. 
 
Quelle que soit la souche testée, les composés actifs (CMI ≤ 7,8 M) présentent tous un 
rapport CMB / CMI inférieur à 4 indiquant que ce sont des bactéricides comme la CIP. 
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D'une manière générale, les activités inhibitrices et bactéricides des composés évalués 
contre la souche Gram-positif S. aureus ont été conservées. Parmi les 45 composés testés, 
l'activité antibactérienne in vitro pour 29 d'entre eux est équivalente à celle de la CIP (CMI: 0,97 
M) contre S. aureus. L'activité contre la souche Gram-positif E. hirae est plus aléatoire ; seuls 5 
composés, appartenant à la série 7-(4-(2-oxoéthylalkanoate)pipérazin-1-yl) 3, présentent la 
même activité antibactérienne in vitro comparé à la CIP. 
En revanche, l'activité antibactérienne in vitro de tous les composés synthétisés sont 20 à 
128 fois moins actifs contre P. aeruginosa et de 2 à 250 fois moins actifs contre E. coli que la 
CIP (CMI: 0,97 M). Seuls les composés 2 (ClogP: 1,75) et 4 (1,35), qui sont les dérivés les plus 
polaires, montrent une activité antibactérienne in vitro contre E. coli équivalente à celle de la 
CIP. 
Rappelons que le composé 4 est le produit issu d‘une possible hydrolyse enzymatique ou 
chimique des dérivés de la série 7-(4-(2-oxoéthylalkanoate)pipérazin-1-yl) 3. Le composé 4 est 
actif contre les deux souches Gram-positifs (S. aureus et E. hirae) avec des valeurs de CMI et 
CMB équivalentes à celles des dérivés 3a-l. En revanche, alors que les dérivés 3a-j ne sont pas 
actifs contre les deux souches Gram-négatifs (E. coli et P. aeruginosa), le composé 4 présente 
une activité conte E. coli équivalente à celle de la CIP. Il semblerait donc que les dérivés de la 
série 3 ne subissent pas d‘hydrolyse dans ces milieux cellulaires. 
Une activité contre S. aureus comparable à celle de la CIP a été conservée :  
 pour les dérivés de la CIP ―monomères‖ 7-(4-(oxoéthylalcanoate) pipérazin-1-
yl) 3a-h possédant des valeurs de ClogPs comprises entre 1,71 et 7,00;  
 pour les dérivés 7-(4-(alkyloxyoxycarbonyle)pipérazin-1-yl) 6a (ClogP: 2,82); 
6b (3,88) et 6g (3,53) ;  
 pour les dérivés 7-(4-(alcanoyle)pipérazin-1-yl) 1a-g,k (1,14<ClogP < 4,84). 
 
Pour ces trois séries homogènes, les composés présentant les plus hautes valeurs de 
ClogP ne sont pas actifs contre S. aureus. 
Parmi les dérivés ―dimères‖ de la CIP 7a-f et 9a-f, les composés 7b, 9b ; 7c, 9c ; 7d, 9d 
et 7e, 9e sont aussi actifs ou deux fois moins actifs pour le dérivé 7e (CMI: 1,95 M) contre S. 
aureus par rapport à la CIP. 
Les FQs sont connues pour traverser la membrane cytoplasmique des bactéries Gram-
positifs par diffusion passive. Seules les formes non chargées de ces composés peuvent diffuser à 
travers la bicouche lipidique des membranes biologiques
45a, 181. Les FQs pénètrent dans les 
bactéries Gram-négatifs par une voie essentiellement hydrophile grâce aux porines ou par une 
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voie hydrophobe à travers la bicouche lipidique182. Il en découle que plus un médicament est 
hydrophile, plus la pénétration cellulaire se fera par la voie des porines alors que plus un 
médicament est hydrophobe, plus la diffusion au travers de la bicouche lipidique aura lieu.  
La modification structurale de la CIP en position C-7 entraîne une rupture des propriétés 
zwittérioniques des dérivés synthétisés. Ainsi, pour ces dérivés de la CIP, seul l‘équilibre non-
chargé / déprotoné peut se produire, facilitant la diffusion passive à travers la bicouche lipidique, 
ce qui est cohérent avec les activités observées contre la souche Gram-positif S. aureus au 
détriment des souches Gram négatifs. Ces résultats sont en accord avec les travaux reportés dans 
la littérature par Foroumadi et coll.67, 158, 183. 
2.2 Activité antimicrobienne in vitro des dérivés de la LEV 
Les résultats de l'évaluation des CMIs et des CMBs de certains dérivés de la LEV contre 
S. aureus, E. hirae, P. aeruginosa et E. coli ainsi que ceux de la LEV sont résumés dans le 
Tableau 67. 
Tableau 67 Activité antimicrobienne in vitro des dérivés de la LEV 
 
   CMI (CMB), M 
   Gram-negatif Gram-positif 
Comp R CLogP E. coli P. aeruginosa S. aureus E. hirae 
LEV OH -0,51 0,97(0,97) 0,97 (0,97) 0,97 (0,97) 0,97 (0,97) 
14d OCH2OCO(CH2)8CH3 4,84 <0,97(<0,97) < 0,97 (3,9) < 0,97 (< 0,97) 0,97 (1,95) 
14e OCH2OCO(CH2)10CH3 5,90 3,9 (3.9) < 0,97 (< 3,9) < 0,97 (< 0,97) 1,95 (1,95) 
14f OCH2OCO(CH2)13CH3 6,96 15,6 (15,6) 62,5 (250) 7,8 (3,9) 15,6 (15,6) 
17a NH(CH2)3CH3 2,13 62,5 (62,5) 62,5 (250) 125 (125) 125 (250) 
17b NH(CH2)5CH3 3,19 125 (500) 62,5 (250) 250 (250) 125 (250) 
17d NH(CH2)7CH3 4,25 125 (500) 62.5 (250) 31,2 (31,2) 31,2 (31,2) 
17e NH(CH2)9CH3 5,31 125 (500) 62,5 (250) 7,8 (7,8) 7,8 (15,6) 
17f NH(CH2)11CH3 6,36 125 (500) 62,5 (250) 3,9 (15,6) 3,9 (3,9) 
17h NH(CH2)13CH3 7,42 125 (500) 62,5 (250) 7,8 (31,2) 3,9 (3,9) 
17i NH(CH2)14CH3 7,95 125 (500) 62,5 (250) 15,6 (62,5) 7,8 (7,8) 
18b (CH2)5 n.d. 62,5 (62,5) 62,5 (250) 125 (500) 125 (250) 
18c (CH2)6 n.d. 62,5 (62,5) 62,5 (250) 125 (500) 125 (125) 
18e (CH2)8 n.d. 3,9 (3,9) 62,5 (250) 15,6 (15,6) 62,5 (125) 
18f (CH2)9 n.d. 3,9 (3,9) 62,5 (250) 31,2 (31,2) 31,2 (31,2) 
18g (CH2)10 n.d. <0,97(<0,97) 31,2 (62,5) 7,8 (7,8) 31,2 (62,5) 
18h (CH2)12 n.d. <0,97(<0,97) 31,2 (31,2) 1,95 (1,95) 3,9 (3,9) 
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As outlined in the introduction, the upper portion of the molecule which includes the C-3 
carboxy and C-4 keto moieties of FQs is considered as essential for the antibacterial activity. 
Pyvaloyloxymethyl ester of ofloxacin, the racemate LEV, synthesized as prodrug by Maeda et 
al.
170
 did not exhibit antibacterial activity against a panel of Gram-positive and Gram-negative 
strains (MIC > 25 g/mL). Our previous report concerning the in vitro antimicrobial evaluation 
of various alkanoyloxymethyl esters of NAL ranging from 3 to 15 carbon units
167
 showed that 
this chemical modification of the C-3 carboxylic group of NAL led to the loss of the antibacterial 
activity, as expected (CMI > 128 g/mL). We however evaluated the in vitro antibacterial 
activity of 3 ―monomer‖ alkanoyloxymethyl esters of LEV, 14d, 14e and 14f, selected 
depending on their ClogPs which were included in the same range (from 4.84 to 6.96) than the 
most potent ―monomer‖ CIP derivatives. 
Surprisingly, these latter derivatives and in particular 14d and 14e, retained an 
antibacterial activity against the Gram-positive and Gram-negative standard strains. These 
activities could be due to the hydrolysis of the compounds into the parent LEV and therefore 
compounds could act as prodrugs. If hydrolyse occurs, this one should be more important as the 
alkyl chain length decreases and can explain that 14d and 14e are more potent against bacteria 
strains than 14f. However, as we will discuss in next sections, acyloxymethyl ester derivatives 
14a (n=2), 14c (n=6), 14d (n=8) and 14f (n=12) showed IC50 and MIC value against M. 
tuberculosis, roughly similar to that of LEV whatever the chain length. Moreover, 14a (n=2) 
exhibited an antiproliferative activity with IC50 values against cancer cell lines lower than those 
of LEV, whilst 14b (n=4), 14c (n=6) and 14d (n=8) didn‘t inhibit the cancer cell lines growth. 
Compounds 14e-h (10<n<16) displayed antiproliferative activities against U373-MG, LoVo and 
MCF-7 cancer cell lines with IC50 values for 14e 200- to 2000-fold lower than that of LEV. So, 
these observations don‘t seem to be in favour of a hydrolyse for compounds 14e and 14f. 
Some authors reported the synthesis and antimicrobial activities of carboxamide 
derivatives of LEV and CIP and showed that they displayed antibacterial activities, contradicting 
the dogma that C-3 carboxylic acid is required
85, 184
. In our case, the alkylcarboxamide 
―monomer‖ derivatives of LEV 17 were inactive against Gram-positive and Gram-negative 
strains. Compounds 17e-h (5.31<ClogP<7.42) showed moderate activities against Gram-positive 
strains with MICs higher than LEV. But interestingly, when increasing the linker length of the C-
6-(N-alkylcarboxamide)-linked LEV ―dimers‖ 18, an antibacterial activity in particularly against 
the Gram-negative E. coli strain was observed for compounds 18g-h.  
One time more, the active compounds (CMI ≤ 7.8 M) are bactericides as their native 
parent, LEV, as they displayed a MBC / MIC ratio less than 4. 
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By considering ―monomer‖ and ―dimer‖ derivatives of LEV, for which the acidic 
function is modified, only the uncharged/protonated equilibria can occur. Even if the 
hydrophobicity of carboxamide ―monomer‖ derivatives 17 allows them to diffuse through the 
membrane, they seem not to act effectively on the enzymatic target. The mechanism of 
antibacterial activity of C-6-(N-alkylcarboxamide)-linked LEV ―dimers‖ 18 seem to differ as by 
increasing the alkyl chain length, not only the activity against Gram-positive strains increases but 
also the activity against Gram-negative strains. These results also show that amide function can 
act as a bioisostere of carboxylic acid and therefore new derivatives of FQ can be envisaged for 
the future as antibacterials. 
2.3 In vitro antimicrobial activities of CIP derivatives against standard S. aureus, MRSA and 
MDRSA strains 
Due to the observed in vitro activities against S. aureus of CIP derivatives, we selected 
the most potent derivatives to be tested against a standard strain of S. aureus (CIP4.83), two 
MRSA strains (ATCC33591 and ATCC33592) and two clinical isolates MDRSA strains 
(MDRSA1 and MDRSA2). The MICs and the MBCs of all the 29 selected compounds against 
these different strains of S. aureus are shown in Table 68 along with those of CIP. 
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Table 68 In vitro antimicrobial activity (MIC(MBC) in M) of selected 
coumpounds against the S. aureus standard strain (Sa CIP 4.83), two MRSA 
strains (Sa ATCC33591 and Sa ATCC33592) and two MDRSA clinical isolates 
(Sa MDRSA1 and Sa MDRSA2) 
  MIC (MBC), M 
  S. aureus strains Clinical isolates 
Comp CLogP
a
 CIP 4.83 MRSA1 MRSA2 MDRSA1 MDRSA2 
CIP -0.72 0.97 (1.95) 0.97 (1.95) 0.48 (0.97) 31.2 (62.5) 31.2 (31.2) 
2 1.75 0.97 (1.95) 0.97 (0.97) 0.48 (0.97) 125 (500) 62.5 (62.5) 
1a 1.14 0.48 (0.48) 0.97 (0.97) 0.48 (0.97) 62.5 (500) 31.2 (62.5) 
1b 1.67 0.48 (0.97) 0.48 (0.97) 0.24 (0.48) 62.5 (500) 31.2 (31.2) 
1c 2.19 0.48 (0.48) 0.48 (0.48) 0.24 (0.48) 31.2 (62.5) 31.2 (62.5) 
1d 2.37 0.48 (0.97) 0.48 (0.48) 0.24 (0.48) 31.2 (500) 31.2 (31.2) 
1e 2.72 0.24 (0.48) 0.48 (0.48) 0.24 (0.48) 62.5 (500) 31.2 (31.2) 
1l 3.19 0.12 (0.24) 0.12 (0.24) 0.12 (0.24) 31.2 (62.5) 15.6 (15.6) 
1f 3.78 0.03 (0.12) 0.061 (0.48) 0.061 (0.24) 62.5 (500) 250 (>500) 
1g 4.84 
7.6·10-3 
(0.03) 
0.015 (0.24) 0.12 (0.24) 31.2 (500) 31.2 (500) 
3a 1.71 1.95 (3.9) 3.9 (3.9) 0.97 (1.95) 125 (500) 125 (125) 
3b 2.77 0.24 (0.48) 0.48 (0.97) 0.061 (0.12) 15.6 (62.5) 15.6 (15.6) 
3c 3.83 0.03 (0.24) 0.03 (0.061) 3.8·10
-3
 (7.6·10-3) 15.6 (500) 7.8 (15.6) 
3d 4.89 
<9.5·10-4 
(<9.5·10-4) 
<9.5·10-4 
(1.9·10-3) 
<9.5·10-4 
(<9.5·10-4) 
7.8 (500) 15.6 (15.6) 
3e 5.41 
3.8·10-3 
(0.12) 
0.03 (0.24) 0.015 (0.015) 7.8 (15.6) 7.8 (15.6) 
3f 5.95 0.12 (0.97) 0.24 (0.48) 3.8·10
-3
 (7.6·10-3) 7.8 (15.6) 7.8 (15.6) 
3g 6.47 0.97 (0.97) 0.97 (1.95) 3.8·10
-3 
(0.03)
 
15.6 (500) 7.8 (15.6) 
3h 7.00 0.97 (1.95) 1.95 (3.9) 0.061 (0.97) 125 (500) 62.5 (250) 
4 1.35 0.97 (1.95) 0.97 (1.95) 0.24 (1.95) 125 (500) 62.5 (62.5) 
5 3.31 0.12 (0.24) 0.48 (0.97) 0.24 (0.97)  125 (500) 62.5 (125) 
6a 2.82 0.97 (0.97) 0.97 (1.95) 0.48 (1.95) 125 (500) 62.5 (125) 
6b 3.88 0.061 (0.12) 0.03 (0.12) 7.6·10
-3
 (0.12) 62.5 (500) 31.2 (31.2) 
6g 3.53 0.12 (0.24) 0.061 (0.48) 0.12 (0.48) 31.2 (500) 15.6 (31.2) 
7b n.d. 0.12 (7.8) 0.48 (3.9) 0.12 (1.95) 125 (500) 125 (500) 
7c n.d. 0.12 (1.95) 0.061 (3.9) 0.12 (0.97) 7.8 (500) 7.8 (15.6) 
7d n.d. 0.061 (1.95) 0.061 (0.97) 0.061 (0.48) 1.95 (500) 15.6 (31.2) 
9b n.d. 1.95 (3.9) 3.9 (7.8) 0.48 (0.97) 250 (500) 125 (500) 
9c n.d. 1.95 (1.95) 1.95 (7.8) 0.015 (0.97) 125 (500) 62.5 (125) 
9d n.d. 0.12 (0.48) 0.48 (1.95) 0.12 (0.97) 62.5 (500) 31.2 (62.5) 
9e n.d. 1.95 (7.8) 7.8 (15.6) 0.97 (1.95) 125 (500) 125 (500) 
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The first group of ―mono-amide‖ derivatives displayed increased activity against both 
standard and methicillin-resistant strains. Compounds 1a-e,l displayed MIC values somewhat 
equivalent with an improvement of MIC and MBC values towards standard, MRSA1 and 
MRSA2 strains than those of CIP. The most lipophilic (CLogPs = 3.78 and 4.84) compounds 
1f,g displayed interesting activities against standard and MRSA strains with a 60-fold decrease 
of MICs compared to CIP. However, none of compounds from the ―mono-amide‖ group 
exhibited significant activity against MDR clinical isolates. 
Considering the 7-(4-(alkanoyl)piperazin-1-yl) derivatives 1a-g and 1l, we observed a 
significant increase of activity only for two of them, that were compounds 1f (ClogP = 3.78;  Mw 
= 443.5 g·mol-1; MICs from 0.03 to 0.061 M) and 1g (4.84 ; 471.6 g·mol-1; 0.12 M to 7.6 nM).  
As shown in Table 69, representing the MICs values of 1a-g, 1l homologous derivatives 
along with those of CIP against the standard CIP4.83 and the two MRSA strains, we observed a 
constant improvement of MIC and MBC values, comparing to CIP, for compounds 1b-e and 1l 
with ClogP values varying from 1.67 to 3.19. The two last and most lipophilic compounds 1f-g 
(CLogPs = 3.78 and 4.84) turned out to be the most potent derivatives of this series. 
 
Table 69 MICs values of CIP and homologous derivatives 1 against standard 
strains CIP4.83 and the two MRSA strains 
 
Cmpd 1a 1b 1c 1d 1e 1l 1f 1g 
n 0 1 2 -* 3 -* 5 7 
CLogP 1.14 1.67 2.19 2.37 2.72 3.19 3.78 4.84 
Mw, g·mol-1 373.4 387.4 401.4 415.5 415.5 449.5 443.5 471.6 
* R = t-Bu for 1d and R = CH2Ph for 1l 
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Compounds 1f (n = 5; cLogP = 3.78; Mw = 443.5 g.mol-1) and 1g (7; 4.84; 471.6 g.mol-
1) exhibited respectively MICs values 8- to 32- fold and 4- to 128- fold lower than those of CIP 
against standard CIP4.83 and the two MRSA strains. 
The ―mono-oxoethylester‖ CIP derivatives exhibited the highest degree of activity among 
all ―monomeric‖ series. Compound 4, resulting from a possible hydrolyse of derivatives 3, 
displayed IC50 values equivalent to those of CIP. Once more, it seems that no hydrolyse of 
derivatives 3 occurs in bacterial cellular media.  
The eight 7-(4-(oxoethylalkanoate)piperazin-1-yl) derivatives 3a-h (2.77 < ClogPs < 
5.95) displayed MICs and MBCs equivalent or lower than CIP. Among them, compounds 3d 
(ClogP = 4.89; Mw = 515.6 g·mol-1; MIC<0.95 nM) and 3e (5.41 ; 529.6 g·mol-1; from 0.03 M 
to 3.8 nM) exhibited very good in vitro activities. 
 
Table 70 MICs values of CIP and homologous derivatives 3 against standard 
strains CIP4.83 and the two MRSA strains 
 
Cmpd 3a 3b 3c 3d 3e 3f 3g 3h 
n 0 2 4 6 7 8 9 10 
CLogP 1.71 2.77 3.83 4.89 5.41 5.95 6.47 7.00 
Mw, g·mol-1 431.4 459.5 487.5 515.6 529.6 543.6 557.7 571.7 
 
We observed a clear minimum on the curve representing MICs values of CIP and 3a-h 
homologous derivatives against standard strains CIP4.83 and the two MRSA strains (Table 70) 
Compound 3d (n = 6; cLogP = 4.89; Mw = 516.6 g.mol
-1
), with subnanomolar MIC and MBC (< 
0.95 nM) values against standard and methicillin-resistant strains, turned out to be the most 
potent derivatives with MICs values 500- to 1000- fold lower than those of CIP. 
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Among the 7-(4-(alkoxycarbonyl)piperazin-1-yl) derivatives 6, only compound 6b (n = 3; 
ClogP = 3.88; Mw = 431.5 g.mol
-1
) exhibited lowest MICs than CIP and was found to be 16- to 
63- fold more potent than CIP with a MIC value of 7.6 nM against MRSA strain ATCC33592.  
In a general way, 7-(4-(alkanoyl)piperazin-1-yl))-linked CIP ―dimers‖ 7, displayed more 
potent activities against the standard and MRSA strains. Compound 7d (n = 13) was found to be 
8- to 16- fold more potent than CIP against these strains.  
7-(4-(2-Oxoethylalkanoate)piperazin-1-yl))-linked CIP ―dimers‖ 9 didn‘t show any 
significant enhancement of the activity against the standard and MRSA strains compared to CIP. 
Only compound 9d (n = 13) was found to be 2- to 8- fold more potent than CIP.  
For these two series of C7-C7-linked CIP ―dimers‖, it would seem that the required 
conformation for an interaction with the enzymatic target is reached for a chain length of 13 
carbon units. 
On the other hand, even if some compounds exhibited better inhibitory activities against 
the two clinical isolates MDRSA (MDRSA1 and MDRSA2) than CIP, the benefit was less 
important.  
No compounds from 7-(4-alkanoyl)piperazin-1-yl) 1, 7-(4-alkoxycarbonyl)piperazin-1-
yl) 6 and 7-(4-(2-oxoethylalkanoate)piperazin-1-yl))-linked 9 CIP derivatives were active against 
MDRSA strains.  
7-(4-(Oxoethylalkanoate)piperazin-1-yl) derivatives 3b-g (2 < n < 9; 2.77 < ClogPs < 
6.47; 459.5 < Mw < 557.7 g.mol
-1
) showed MICs from 7.8 to 15.6 M against these two clinical 
isolates that is 2- to 4-fold more potent than CIP. From all series of tested ―monomer‖ CIP 
derivatives, this series of derivatives 3 exhibited the more potent activities against the tested S. 
aureus strains.  
7-(4-(Alkanoyl)piperazin-1-yl))-linked CIP ―dimer‖ 7c was found to be 4- fold more 
potent than CIP against the two clinical isolates with MICs of 7.8 M. The most potent 
compound against MDRSA1 was found to be the ―di-amide‖ derivative 7d (MIC: 1.95 M), that 
is 16- fold lower than that of CIP.  
We can also notice that if active compounds against standard and MRSA strains retained 
a bactericide activity, this is not always true for MDRSA strains.  
To conclude, for the most potent compounds against S. aureus, the activity is also 
maintained for MRSA strains. For each series of ―monomer‖ derivatives the activity against 
standard and MRSA strains increases with ClogP until an optimal value of ClogP (Tableau 66, 
Table 68). We observed an optimal value for ClogP = 4.84 for the alkanoyl 1 CIP derivatives, 
4.89 for the oxoethylalkanoate 3 and 3.88 for the alkoxycarbonyl 6. The more potent antibacterial 
compounds were found in the oxoethylalkanoate 3 series, but whatever the considered 
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―monomer‖ series, all of them showed better activities against S. aureus strains than ―dimer‖ CIP 
derivatives. 
 
2.4 SAR attempts 
Several general trends in antibacterial activity were deduced from these studies. 
 
 Both active CIP or LEV derivatives (―monomeric‖ and ―dimeric‖ structures) against 
bacterial strains (with CMIs values ≤ 7.8 M) were bactericides (CMB / CMI < 4). So, 
they displayed the same antimicrobial profile than their native parents, CIP and LEV. It is 
nevertheless necessary to specify that this observation is not general for the antibacterial 
activities observed against MDRSA strains. 
 Tested compounds were significantly less active towards Gram-negative species in 
comparison with the native parents CIP and LEV. 
 Nevertheless, CIP and LEV derivatives didn‘t display the same antimicrobial profile of 
activity. 
 CIP derivatives showed a selectivity of the antimicrobial activity against S. 
aureus.  
 LEV derivatives showed various antimicrobial profile according to the structure. 
2.4.1 SAR on CIP derivatives 
The substitution of the distal nitrogen-4 atom at C-7 position of CIP resulted in an 
increased activity specifically towards S. aureus along with a significant decrease against other 
pathogens in comparison with the broad-spectrum activity of CIP. 
The most active CIP derivatives against the various studied strains of S. aureus are 
represented in Table 71 
The degree of activity is strongly dependent on the nature of attached functional group 
and decreases in the following order:  
 for ―monomers‖: oxoethylesters > amides ≈ carbamates,  
 and the reversed order for ―dimers‖: amides > oxoethylesters. 
 
There is also a strong influence of the chain length on MIC values. The highest activity 
could be achieved with values of methylene groups of respectively n = 7 and 6 for ―mono-
amide‖ and ―mono-oxoethylesters‖ derivatives. For these two series, the activities against S. 
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aureus evolve in the same way according to the chain length and the ClogP. As outlined before, 
too short or too long attached moieties was not beneficial. The optimal CLogP values were 
situated within a close range for the most active ―monomers‖ 1g and 3d (CLogP = 4.84 and 4.89 
respectively). These observations can‘t be done for the series of ―mono-carbamates‖ derivatives 
6 as the highest activity is achieved with a chain length of n = 3 and a ClogP = 3.88. In fact, no 
derivatives with a chain length included between n = 3 (ClogP = 3.88) and n = 7 (5.99) were 
synthesized.  
Concerning the ―dimer‖ CIP derivatives, it seems that the optimal chain length ranges 
around 12-13 methylene groups and that the presence of two quinolone cores in the molecule 
leads to an enhanced activity against MDRSA clinical isolates. 
 
Table 71 Most active CIP derivatives against the various strains of S. aureus 
   MIC, M 
   S. aureus strains 
Structure Comp (n) CLogP CIP 4.83 MRSA1 MRSA2 MDRSA 
 
1f (5) 3.78 0.03 0.061 0.061 Non active 
1g (7) 4.84 7.6.10
-3 
0.015 0.12 Non active 
 
3c (4) 3.83 0.03 0.03 3.8.10
3 
7.8-15.6 
3d (6) 4.89 < 9.5.10
-4 
< 9.5.10
-4
 < 9.5.10
-4
 7.8-15.6 
3e (7) 5.41 3.8.10
-3
 0.03 0.015 7.8-7.8 
3f (8) 5.95 0.12 0.24 3.8.10
-3
 7.8-7.8 
3g (9) 6.47 0.97 0.97 3.8.10
-3
 7.8-15.6 
 
6b (3) 3.88 0.061 0.03 7.6.10
-3
 Non active 
 
7c (12) Nd 0.12 0.061 0.12 7.8-7.8 
7d (13) Nd 0.061 0.061 0.061 1.95-15.6 
 
9c (12) Nd 1.95 1.95 0.015 Non active 
9d (13) Nd 0.12 0.48 0.12 Non active 
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2.4.2 SAR on LEV derivatives 
Concerning LEV derivatives only preliminary screening against the four Gram-positive 
and Gram-negative standard strains were conducted. 
In summary, the C-6 carboxyl group modification of LEV led to antibacterial profile and 
potency somewhat different than C-7 piperazine modification of CIP.  
The degree of activity is also dependent on the nature of attached functional group and 
decreases in the following order: 
 ―mono-acyloxymethyl ester‖ derivatives 14 which displayed a broad spectrum 
of activity, 
 ―di-amides‖ derivatives 18 for which an antimicrobial activity was observed 
for compounds owning a chain length more than 10 methylene groups, 
 ―mono-amides‖ derivatives 17 were inactive. 
Taking in account the possible hydrolysis of acyloxymethyl ester of LEV, it cannot be 
rational to conclude to a lead compound in this series without supplementary physico-chemical 
and biological evaluations. 
The observed antibacterial activities of ―di-amides‖ derivatives of LEV 18 can be due to 
the fact that amide function can act as a bioisostere of carboxylic acid for the formation of the 
drug-enzyme complex or to a modified mechanism of action of these compounds. 
The C-6-(N-dodecylcarboxamide)-linked LEV ―dimers‖ 18 seems to be the most 
promising compounds of all LEV derivatives for further antimicrobial studies (Figure 46). 
 
 
MIC S. aureus: 1.95 M 
MIC E. hirae: 3.9 M 
MIC P. aeruginosa: 31.2 M 
MIC E. coli: ≤0.97 M 
Figure 46 Lead compound of the series C-6-(N-acylcarboximide)-linked LEV ―dimers‖ 
  
18h 
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3. Antimycobacterial activity 
We have also explored the effect of increasing the lipophilic character of CIP and LEV 
on activity against M. Tuberculosis (H37Rv strain) as penetration is crucial for FQ activity against 
this strain. The antimycobacterial activity of synthesized derivatives was evaluated by Patricia 
Constant at IPBS (Group of Dr. Mamadou Daffé, Institut de Pharmacologie et Biologie 
Structurale), Département Mécanismes Moléculaires des Infections Mycobactériennes, 
Toulouse. 
 
3.1 In vitro antimycobacterial inhibitory activities of CIP derivatives 
The percentage of inhibition of M. tuberculosis growth was first determined for some 
selected compounds, along with those of CIP at concentrations of 10 and 1 M and 0.1  The 
percentage of inhibition of H37Rv obtained at 10 and 1 M are summarized inTable 72. 
 
Table 72 Percentage of inhibition of M. Tuberculosis growth for selected CIP 
derivatives 
 
Comp R CLogP 
% inhibition of 
H37Rv at 10 M 
% inhibition of 
H37Rv at 1 M 
CIP
a
 H -0.72 98 95 
2 COCH2Cl 0.343 95 6 
1a COCH3 1.14 92 0 
1b COCH2CH3 1.67 93 3 
1c CO(CH2)2CH3 2.19 93 3 
1d COC(CH3)3 2.37 93 2 
1e CO(CH2)3CH3 2.72 92 0 
1f CO(CH2)5CH3 3.78 96 0 
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Comp R CLogP 
% inhibition of 
H37Rv at 10 M 
% inhibition of 
H37Rv at 1 M 
1g CO(CH2)7CH3 4.84 95 2 
1h
b
 CO(CH2)8CH3 5.37 97 14 
1i
b
 CO(CH2)10CH3 6.43 96 16 
1j CO(CH2)12CH3 7.48 47 3 
1k CO(CH2)14CH3 8.54 14 0 
1l COCH2C6H5 3.19 92 0 
4 COCH2OH 1.35 88 2 
5 COCH2OCH2Ph 3.31 93 3 
3c COCH2OCO(CH2)4CH3 3.83 96 5 
3d COCH2OCO(CH2)6CH3 4.89 96 4 
3f COCH2OCO(CH2)8CH3 5.95 96 5 
3g COCH2OCO(CH2)9CH3 6.47 95 7 
3h COCH2OCO(CH2)10CH3 7.00 95 4 
3i COCH2OCO(CH2)12CH3 8.06 93 2 
3j COCH2OCO(CH2)14CH3 9.12 85 0 
6a C(O)OCH2CH3 2.82 92 0 
6b C(O)O(CH2)3CH3 3.88 95 0 
6c C(O)O(CH2)7CH3 5.99 96 7 
6d C(O)O(CH2)8CH3 6.52 78 8 
6e C(O)O(CH2)9CH3 7.05 71 7 
6f C(O)O(CH2)11CH3 8.11 80 0 
6g C(O)OC(CH3)3 3.53 64 0 
7a (CH2)8 n.d. 0 0 
7c (CH2)12 n.d. 11 2 
7d (CH2)13 n.d. 40 5 
7f (CH2)16 n.d. 3 0 
9a (CH2)8 n.d. 62 0 
9b (CH2)10 n.d. 26 4 
9c (CH2)12 n.d. 87 6 
9f (CH2)16 n.d. 1.5 2 
a
MIC/IC50 values ( M) from the literature 0.16-12
185
/1.15
185a
 
 b
IC50 values were 
evaluated for the most active 1h (0.91/8.45) and 1i (0.65/>10) 
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At 10 M, several ―monomer‖ CIP derivatives displayed a percentage of inhibition of 
H37Rv growth more than 95% comparable to that of CIP (98%). 
Concerning the 7-(4-alkanoyl)piperazin-1-yl) derivatives 1, the percentage of inhibition 
was optimal in a ClogP range from 3.78 (1f, n = 5, Mw = 463.5 g.mol
-1
) to 6.43 (1i, n = 10, 
513.7 g.mol
-1
) and decreased for higher ClogP (1j and 1k, owning longer chain length (n = 12 
and 14 respectively). 
Among the tested 7-(4-(oxoethylalkanoate)piperazin-1-yl) derivatives 3, this optimum 
was reached for ClogP ranging from 3.83 (3c, n = 4, Mw = 487.5 g.mol
-1
) to 8.06 (3i, n = 12, 
599.7 g.mol
-1
) and in a similar manner decreased for derivatives with longer chain length (3j, n = 
14). The results obtained for compound 4 resulting from the possible hydrolysis of derivatives 3 
showed once again that no hydrolysis occured in the cellular media. 
7-(4-(Alkoxycarbonyl)piperazin-1-yl) derivatives 6 are less potent as only compounds 6b 
(ClogP = 3.88: n = 3, Mw = 431.5 g.mol
-1
) and 6c (5.99; n = 7, 487.6 g.mol
-1
) exhibited a 
percentage of inhibition ≥ 95%. 
The more potent CIP derivatives from series 1 and 3 displayed the best percentages of 
inhibition of H37Rv growth for CLogP and molecular weight values situated within a relatively 
large range (3.78 < ClogP < 8.06 and 463.51 < Mw < 599.7 g.mol
-1
) and for a range of chain 
length between 4 to 12 methylene groups. For the CIP derivatives from series 6, these ranges of 
values were more limited (3.88 < ClogP < 5.99; 3 < n < 7; 431.5 < Mw < 487.6 g.mol
-1
) and we 
observed a decrease of inhibition of H37Rv growth from a ClogP value of 6.52 (6d, n=8; Mw = 
501.6 g.mol
-1
). 
It could be notice that the ―dimer‖ derivatives 7 and 9 of CIP were few active or inactive 
as the highest percentages of inhibition of H37Rv growth for these two series were 40% (7d) and 
87% (9c).  
At 1 M, most of the ―monomer‖ and ―dimer‖ CIP derivatives were inactive as only 
compounds 1h and 1i showed percentages of inhibition around 15% while CIP inhibited the 
mycobacterial growth at 95%. 
At 0.1 M (data not shown), all compounds including CIP, didn‘t inhibit the 
mycobacterial growth. 
This first screening has shown that increasing lipophilicity of CIP by a C-7 piperazine 
modification does not lead to an increase of the antimycobacterial activity as the more potent 
CIP derivatives are less potent than their native parent CIP at 1 M. 
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3.2 In vitro antimycobacterial inhibitory activities of LEV derivatives 
Derivatives of LEV were also evaluated for their inhibitory activity against M. 
tuberculosis at concentrations of 10, 1 and 0.1 M along with those of LEV. These results are 
summarized in Table 73 
 
Table 73 Percentage of inhibition of M. Tuberculosis growth for selected LEV 
derivatives 
 
Comp R CLogP 
% inh. 
at 10 M 
% inh. 
at 1 M 
MIC, 
M 
IC50, 
M 
LEV
a
 OH -0.51 96 85 2.10 
b 
0.78
 b
 
14a OCH2OCO(CH2)2CH3 1.67 96 74 3.33
 b
 1.60
 b
 
14c OCH2OCO(CH2)6CH3 3.79 96 89 3.33 
b
 1.40
 b
 
14e OCH2OCO(CH2)10CH3 5.68 97 89 3.33 
b
 1.26 
b
 
14f OCH2OCO(CH2)12CH3 6.74 96 6 2.50 
c 
1.50 
c 
14g OCH2OCO(CH2)14CH3 7.79 95 0   
14i OCH2OCO(CH2)18CH3 n.d. 0 0   
17b NH(CH2)5CH3 3.19 15 0   
17d NH(CH2)7CH3 4.25 98 0   
17e NH(CH2)9CH3 5.31 97 5 10 5.10 
c 
17g NH(CH2)12CH3 6.89 97 6 > 10 n.d.
 
17i NH(CH2)14CH3 7.95 96 6 10 4.00 
c 
17j NH(CH2)16CH3 9.00 93 3   
18b (CH2)5 n.d. 77 5   
18c (CH2)6 n.d. 60 0 >10 n.d
 
18f (CH2)9 n.d. 98 20 5.00
 b
 1.96
 b
 
18g (CH2)10 n.d. n.d. n.d. 5.00 
c 
1.90 
c 
18h (CH2)12 n.d. n.d. n.d. 2.50 
c 
1.60 
c 
a 
MIC/IC50 values from the literature
 
0.18-2.76
185a, b, 185e, f
 / 1.8
185a, b
 Mean of three 
experiments 
c
 Values from two different experiments 
 
At 10 M, several ―monomer‖ LEV derivatives displayed a percentage of inhibition more 
than 95% comparable to that of LEV (96%).  
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Concerning the acyloxymethyl ester LEV derivatives, the percentage of inhibition was 
optimal in a ClogP range from 1.67 (14a, n = 2, Mw = 461.7 g.mol
-1
) to 7.79 (14g, n = 14, 629.8 
g.mol
-1
) and the compound with the higher chain length (14h, n = 18, 685.9 g.mol
-1
) did not 
inhibit at all the growth of M. tuberculosis.  
Among the tested alkylcarboxamide LEV derivatives, this optimum was reached for 
ClogP ranging from 4.25 (17d, n = 7, Mw = 472.3 g.mol
-1
) to 9.00 (17j, n = 16, 598.4 g.mol
-1
). 
The ―dimer‖ alkylcarboxamide LEV derivatives 18f (n = 9, Mw = 845.0 g.mol-1) 
displayed a percentage of inhibition of the mycobacterial growth of 98%. Compounds with 
shorter chain length (18b and 18c, n = 5 and 6) were less potent against M. Tuberculosis. 
At 1 M, only three compounds from the acyloxymethyl ester series, 14a (74%), 14c 
(89%) and 14e (89%) displayed an activity similar to that of LEV (85%). However, the 
possibility of a hydrolysis of these compounds into the parent LEV remained even if this 
hydrolysis should be more important for 14a (n = 2) than for 14c (n = 6) or 14e (n = 10). 
At 0.1 M (data not shown), all compounds including LEV, didn‘t inhibit the 
mycobacterial growth. 
 
3.3 In vitro determination of MIC and IC50 against M. tuberculosis 
This first screening permitted us to select some compounds for a determination of their 
MIC and/or IC50 values against M. tuberculosis. We have selected, for these tests, the most 
potent CIP and LEV derivatives at 10 and 1 M. 
For CIP derivatives, only two compounds were selected that were 1h and 1i. As we have 
seen, more LEV derivatives were active at 1 M, so MIC and IC50 of several compounds of each 
series were evaluated including C-6-(N-acylcarboxamide)-linked LEV dimers 18g and 18h that 
were synthesized in the group after the evaluation of inhibitory activities. The results obtained 
for these various compounds are reported in Table 72 and Table 73 along with those of CIP and 
LEV. 
These preliminary studies confirmed the observed results about the inhibition of M. 
tuberculosis growth, that were a more potent activity of derivatives of LEV than those of CIP. 
The MIC and IC50 values of CIP and LEV against H37Rv are in accordance with those of 
literature. Nevertheless, these studies are currently carried out as only one experiment had been 
done for some compounds and as derivatives 1h and 1i of CIP showed two very different values 
from the two separate experiments. 
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3.4 SAR on CIP derivatives 
A SAR study is somewhat difficult to establish as, concerning the antimycobacterial 
activity, a C-7 modification of CIP was not beneficial as all ―monomers‖ and ―dimers‖ were less 
or as active as than their parent CIP. We also observed that ―monomers‖ were much more active 
than the corresponding ―dimers‖.  
If we consider the ―monomer‖ CIP derivatives we can conclude the following order of 
relative antimycobacterial activity: amides > oxoethylesters > carbamates. 
The maximum percentages of inhibition of M. tuberculosis were observed for the most 
active compounds for whom ClogP values were included between 3.78 and 8.06, n between 4 
and 12 and molecular weights between 463.5 and 599.7 g.mol
-1
.  
The most active compounds 1h and 1i belong to the amide series with ClogP values of 
5.37 and 6.43; n = 8 and 10 and Mw = 485.6 and 513.7 g.mol
-1
 (Table 74). 
 
Table 74 The most active CIP derivatives against H37Rv strain 
 
Comp n CLogP 
% inhibition 
at 10 M 
% inhibition 
at 1 M 
IC50, M 
1h 8 5.37 97 14 0.91/8.45 
1i 10 6.43 96 16 0.65 
 
 SAR on LEV derivatives 1.1
A C-6 modification of LEV was more beneficial than C-7 modification of CIP with 
higher number of active compounds. The most potent derivatives of LEV, that were 
alkanoyloxymethyl esters LEV derivatives 14 and C-6(N-alkylcarboxamide)-linked LEV 
―dimers‖ 18 exhibited  IC50 ≤ 2 M and MIC ≥ 2.5 M. Alkylcarboxamide LEV derivatives 17 
were the least active. Compound 14e (IC50 = 1.26 M; n = 10; ClogP = 5.68; Mw = 513.7 g.mol
-
1
) from alkanoyloxymethyl esters of LEV seems to be the more potent against M. tuberculosis 
among all ―monomer‖ derivatives of LEV, while compound 18h (IC50 = 1.60 M; n = 12; Mw = 
845.0 g.mol
-1
) seems to be the more potent against M. tuberculosis among C-6(N-
alkylcarboxamide)-linked LEV ―dimers‖ (Table 75). 
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Table 75 The most active derivatives of LEV against H37Rv strain  
Comp Ref n CLogP 
% 
inhibition 
at 10 M 
% 
inhibition 
at 1 M 
IC50, M 
 
14a 2 1.67 96 74 1.6 
14c 6 3.79 96 89 1.4 
14e 10 5.68 97 89 1.26 
14f 12 6.74 96 6 1.50 
 
 
18f 9 n.d. 98 20 1.9 
18g 10 n.d. - - 1.90 
18h 12 n.d. - - 1.60 
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4. Antiproliferative activity 
The antiproliferative activity of synthesized compounds together with parent LEV and 
CIP was evaluated in vitro against five human cancer cell lines. For each of the compounds 
under study, nine concentrations were tested on two human apoptosis-resistant glioblastoma 
U373-MG
186
, non-small cell lung cancer A549
187
 cell lines and three apoptosis-sensitive prostate 
PC-3
188
, colorectal LoVo
189
, breast MCF-7
188
 cancer cell lines. We made use of the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay, which 
indirectly assesses the effect of the potentially anticancer compounds on the overall growth of 
adherent cell lines
190
. The IC50 values, which are the concentrations that reduce the mean growth 
value of the cell lines by 50% (after having cultured the cells for 5 days in presence of the 
investigational compound), were determined for each drug and compared to the mean control 
growth value. The in vivo tolerance of some selected derivatives in mice was also determined as 
a maximum tolerated dose (MTD) which represents the highest single dose of the compound that 
can be administered acutely to healthy animals. This evaluation was conducted by Pr. Robert 
Kiss et al., at Laboratoire de Toxicologie, Institut de Pharmacie, Université Libre de Bruxelles, 
Belgium. 
4.1 In vitro antiproliferative activities of CIP derivatives 
4.1.1 In vitro antiproliferative activities of “monomer” derivatives 
The IC50 values, which are the concentrations that reduce the mean growth value of the 
cells by 50%, were determined for each drug and compared to the mean control growth value 
and are listed in Table 76.  
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Table 76 In vitro antiproliferative activity of CIP ―monomer‖ derivatives 
   IC50 ( M) 
   Apoptosis-sensitive Apoptosis-resistant 
Comp. n CLogP PC-3 LoVo MCF-7 U373-MG A549 
CIP - -0.72 143 ± 1 89 ± 2 476 ± 13 96 ± 4 280 ± 11 
2 - 0.78 8 ± 0.1 17 ± 0.3 23 ± 0.2 4 ± 0.3 10 ± 0.2 
1a 0 1.14 680 ± 33 323 ± 8 803 ± 15 535 ± 13 584 ± 14 
1b 1 1.67 352 ± 7 306 ± 6 727 ± 17 279 ± 6 402 ± 21 
1c 2 2.19 85 ± 2 148 ± 2 172 ± 9 104 ± 2 697 ± 18 
1d - 2.37 246 ± 4 93 ± 5 85 ± 1 67±3 509 ± 11 
1e 3 2.72 73 ± 0.7 87 ± 2 316 ± 11 86 ± 2 64 ± 0.8 
1f 5 3.78 779 ± 21 793 ± 14 754 ± 12 729 ± 9 808 ± 12 
1g 7 4.84 7 ± 0.1 30 ± 0.4 26 ± 0.3 24 ± 0.3 6 ± 0.1 
1h 8 5.37 4 ± 0.1 7 ± 0.2 20 ± 0.4 5 ± 0.2 3 ± 0.1 
1i 10 6.43 4 ± 0.1 45 ± 0.9 108 ± 2 18 ± 0.2 7 ± 0.1 
1j 12 7.48 94 ± 1 101 ± 0.9 96 ± 1 205 ± 3 56 ± 0.4 
1k 14 8.54 114 ± 0.6 290 ± 4 145 ± 1 16 ± 0.1 65 ± 0.7 
1l - 3.19 243 ± 2 41 ± 0.6 32 ± 0.5 34 ± 0.7 29 ± 0.3 
4 - 1.35 433 ± 19 408 ± 12 985 ± 26 294 ± 4 456 ± 8 
5 - 3.31 692 96 242 85 82 
3a 0 1.71 176 ± 2 268 ± 4 279 ± 6 99 ± 2 373 ± 8 
3b 2 2.77 715 ± 10 613 ± 6 1000 ± 11 586 ± 6 456 ± 5 
3c 4 3.83 14 ± 0.1 27 ± 0.8 72 ± 2 28 ± 0.7 20 ± 0.3 
3d 6 4.89 23 ± 0.3 29 ± 0.4 818 ± 17 53 ± 0.7 16 ± 0.2 
3e 7 5.41 257 ± 4 267 ± 2 255 ± 3 272 ± 7 216 ± 1 
3f 8 5.95 416 ± 8 317 ± 2 353 ± 4 291 ± 5 273 ± 4 
3g 9 6.47 nd
a
 828 ± 13 816 ± 17 >1000 >1000 
3h 10 7.00 3 ± 0.1 39 ± 0.7 621 ± 12 49 ± 2 15 ± 0.2 
3i 12 8.06 745 ± 14 766 ± 12 828 ± 14 748 ± 23 742 ± 18 
3j 14 9.12 30 ± 0.4 75 ± 2 56 ± 0.8 119 ± 0.6 112 ± 1 
6a 1 2.34 385 ± 14 272 ± 8 455 ± 12 228 ± 3 >1000 
6b 3 3.40 9 ± 0.3 52±1 14 ± 0.2 31 ± 0.5 42 ± 1.3 
6c 7 5.52 24 ± 0.6 43 ± 1 23 ± 1 79 ± 0.7 21 ± 0.5 
6d 8 6.05 30 ± 0.5 30 ± 0.1 35 ± 2 283 ± 9 38 ± 2 
6e 9 6.58 24 ± 0.7 32 ± 0.1 20 ± 1 401 ± 44 44 ± 5 
6f 11 7.63 217 ± 2 347 ± 6 200 ± 3 94 ± 7 273 ± 7 
6g - 3.06 26 ± 0.6 40 ± 0.4 13 ± 0.3 35 ± 0.9 18 ± 0.2 
a
Not determined 
 165 
 
 
In a general way, no clear correlation between CLogP values or chain length and in vitro 
cytotoxic activity was observed for ―monomers‖ CIP derivatives. 
The synthesized 7-(4-(substituted)piperazin-1-yl) derivatives and the native 
pharmacophore CIP, evaluated in vitro for their antitumor activity, displayed IC50 values ranging 
from M to mM concentrations.  
Compound 2 (N-(chloroacetyl)-CIP; ClogP = 0.78; Mw = 407.8 g.mol
-1
) showed higher 
antitumor activity in vitro than CIP with mean IC50 values of 9 M (mean IC50 values = 250 M 
for CIP) and exhibited IC50 values 5- to 28-fold lower than that of CIP depending on human 
cancer cell lines.  
Among the series of 7-(4-(alkanoyl)piperazin-1-yl) CIP derivatives (1a-l) with different 
chain lengths from one to fifteen carbon atoms (ClogP ranging from 1.14 to 8.54), only three 
compounds (1g (ClogP = 4.84; n = 7; Mw = 471.6 g.mol
-1
; mean IC50; 15 M), 1h (5.37; 8; 
485.6 g.mol
-1
; 5 M) and 1i (6.43; 10; 471.6 g.mol
-1
; 10 M)) showed ICs50 15 M (Table 76). 
The most potent compound against all cancer cell lines was 1h, which exhibited IC50 values from 
13- to 93-fold lower than that of CIP. 
Among the series of 7-(4-(2-oxoethylalcanoate)piperazin-1-yl) CIP derivatives (3a-j) 
with increasing lipophilicity of the alkyl chain bearing one to fifteen carbon atoms (ClogP 
ranging from 1.71 to 9.12), only three derivatives (3c (ClogP = 3.83; n = 4; Mw = 487.5 g.mol
-1
;
 
mean IC50; 26 M); 3d (4.89; 6; 515.6 g.mol
-1
;
 
32 M); 3h (7.00; 10; 571.4 g.mol
-1
; 37 M)) 
showed higher activities than CIP but none of them showed higher activity when compared to 
compounds from the ―mono-amide‖ series 1. The most interesting compound of this series was 
3h whose IC50 value on the prostate cancer cell line (3 M) was 47-fold lower than that of CIP. 
Stability tests of some compounds from series 3 in phosphate buffer at pH 7.4 have shown no 
degradation into 4. As compound 4 had a very weak in vitro antitumor activity (mean IC50: 484 
M), the observed antitumor activities recorded for 3c, 3d and 3h are thus not related to a 
degradation of these compounds.  
Compounds from the series of 7-(4-(alkoxycarbonyl)piperazin-1-yl) CIP derivatives (6a-
g) with different length chains from two to twelve carbon atoms (ClogP ranging from 2.34 to 
7.63) showed few or no in vitro antitumor activities. Indeed, compounds 6b-e, g (3.40 < ClogP < 
6.58; 1< n < 9; 431.46< Mw < 515.62 g.mol
-1
; 33 <
 
mean IC50 < 26 M) presented in vitro 
antitumor activity against the five cancer cell lines that is weaker than series 1 and 3. The most 
active compound 6b (IC50 = 9 M for PC-3) with a n-Butyl chain displayed IC50 values 
somewhat similar than its analog 6g with a t-Butyl moiety. 
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In summary, among the three series of ―monomer‖ CIP derivatives, some compounds 
displayed increased in vitro antitumor activity in comparison to their parent CIP regardless the 
type of cancer cell line (both resistant and sensitive to apoptosis). No clear dependence between 
cLogP and cytotoxicity was observed since the most active compounds 2 and 1h greatly differed 
with their cLogP values (0.78 and 4.40 respectively). However, there was a strong influence of 
the type of attached group on the potency with the following order ―amide‖ > ―oxoethyl ester‖ ≈ 
―carbamate‖. We can conclude that the modification of the distal nitrogen at C-7 piperazine of 
CIP lead to more cytotoxic compounds with a homogenous activity profile for the two more 
potent derivatives.  
4.1.2 In vivo maximum tolerated dose (MTD) in healthy mice 
The in vivo tolerance of CIP, compound 2 and derivatives from series 1 and 6 with the 
lowest or highest in vitro activity (1f, 1h, 1k, 6a, 6b, 6c and 6g) was determined as the MTD 
index, which represents the highest single dose of the compound that can be administered i.p. to 
experimental groups of three healthy mice per group over a maximum period of 28 days without 
causing their death
191
. All of which displayed MTD indices >80 mg/kg. 
4.1.3 In vitro antiproliferative activities of “dimer” derivatives 
C-7-((4-substitued)piperazin-1-yl)-linked CIP ―dimers‖ were analogously evaluated in 
regards to their antiproliferative activity (Table 77). 
 
Table 77 In vitro antiproliferative activity of CIP ―dimer‖ derivatives 
  IC50 ( M) 
  Apoptosis-sensitive Apoptosis-resistant 
Comp. n PC-3 LoVo MCF-7 U373-MG A549 
CIP – 143 89 476 96 280 
7a 8 350 339 826 358 423 
7b 10 > 1000 > 1000 > 1000 141 > 1000 
7c 12 175 15 5 5 82 
7d 13 246 88 81 60 249 
7e 14 8 6 8 3 7 
7f 16 69 29 28 48 43 
9a 8 358 389 > 1000 291 428 
9b 10 454 476 > 1000 71 680 
9c 12 281 43 9 3 437 
9d 13 734 41 694 78 125 
9e 14 0.2
 
0.1 1.0 0.8 8.7 
9f 16 785 514 > 1000 516 838 
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The same antiproliferative profile was obtained for ―dimers‖ of CIP 7a-f and 9a-f.  
The 7-(4-(alkanoyl)piperazin-1-yl)-linked CIP 7c (n = 12) and 7e (n = 14) and the 7-(4-
(oxoethylalcanoate)piperazin-1-yl)-linked CIP 9c (n = 12) and 9e (n = 14) were the more potent 
derivatives of these two series (Table 77). Compounds 7e and 9e displayed ICs50 ≤ 10 M 
against all cancer cell lines, whereas compounds 7c and 9c showed an in vitro inhibition of the 
human apoptosis-resistant U373-MG (5 and 3 M respectively) and apoptosis-sensitive MCF-7 
(5 and 9 M respectively) cancer cell lines. Compounds 7e and 9e exhibited respectively IC50 
values from 3 to 8 M and from 0.1 to 8.7 M that are 15- to 40-fold and 32- to 890-fold lower 
than that of CIP. For other compounds, no pharmacological benefit, in term of in vitro antitumor 
activity, was observed compared to CIP. The ―dimer‖ 9e turned out to be the most potent 
compound among the C-7/C-7-linked CIP ―dimers‖. 
4.1.4 General conclusion on antiproliferative activity of CIP derivatives 
Several of the novel CIP derivatives displayed higher in vitro antitumor activity than 
parent CIP. By increasing lipophilicity of CIP, we could expect an increase in the affinity of the 
compounds for the cell membrane and thus an easier penetration into the cell. However, if 
substitutions on the piperazinyl group of CIP can lead to an increase in antitumor activity, this is 
not dependent on the lipophilicity. In comparing each homologous series or each cancer cell line 
independently, no correlation between ClogP and IC50 values can be observed.  
However, in comparing the same chain length but with a different functional linker to 
CIP, the ―monomer‖ alkanoyl derivatives 1 seem to be more potent than the alkoxycarbonyl 6 or 
oxoethylalcanoate 3 derivatives. For example, the most potent antiproliferative derivative 1h, 
with a chain length of nine carbon atoms, is more active than the corresponding alkoxycarbonyl 
6d or oxyethylalcanoate 3f derivatives.  
In a general way, piperazinyl-linked CIP ―dimers‖ displayed more potent antiproliferative 
effect than the monomers derivatives. For the most interesting ―dimer‖ derivative 9e, the two CIP 
moities are tethered by an oxoethylalcanoate linker whereas for the most interesting monomer 
derivative 1h, an alkanoyl functionnal group is linked to CIP.  
In comparing ―mono-amide‖ versus ―di-amide‖ series, the most active ―mono-amide‖ 1h 
(n = 8) showed the same homogeneous antiproliferative profile than the most active ―di-amide‖ 
derivative 7e (n = 14) (Figure 47, A) 
In comparing ―mono-oxoethylester‖ versus ―di-oxoethylester‖ series, the most active 
―mono-oxoethylester‖ derivatives (3c (n = 4); 3d (n = 6) and 3h (n = 10)) showed a low activity 
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against all cancer cell lines while the most active ―di-oxoethylester‖ derivative 9e (n = 14) 
displayed a homogeneous antiproliferative profile with IC50 values < 10 M (Figure 47, B). 
 
 
Figure 47 IC50 values ( M) of ―monomer‖ and ―dimer‖ CIP derivatives (A) : 
―mono-amide‖ 1h versus ―di-amide‖ 7e CIP derivatives. (B) ―mono-
oxoethylester‖ 3h versus ―di-oxoethylester‖ 9e CIP derivatives 
 
In conclusion, the antiproliferative activity of CIP derivatives decreases in the following 
order : ―di-oxoethylester‖  > ―di-amide‖ > ―mono-amide‖ > ―mono-carbamate‖ ~ ―mono-
oxoethylester‖. 
The ―di-oxoethylester‖ 9e displayed the highest cytotoxic activity among all CIP 
derivatives. 
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4.2 In vitro antiproliferative activities of LEV derivatives 
4.2.1 In vitro antiproliferative activities of “monomer” LEV derivatives 
Some C-6 substituted LEV derivatives were tested for their antiproliferative activity 
against the panel of five cancer cell lines (Table 78).  
 
Table 78 Antiproliferative activity of ―monomer‖ LEV derivatives 
   IC50 ( M) 
   Apoptosis-sensitive Apoptosis-resistant 
Comp. n CLogP PC-3 LoVo MCF-7 U373-MG A549 
LEV - -0.51 238 ± 12 67 ± 5 622 ± 19 188 ± 13 70 ± 6 
14a 2 1.67 31 ± 4 5 ± 1 35 ± 3 40 ± 3 3 ± 1 
14b 4 2.73 207 ± 12 162 ± 15 183 ± 12 199 ± 22 235 ± 16 
14c 6 3.79 230 ± 14 209 ± 12 238 ± 13 243 ± 15 289 ± 12 
14d 8 4.84 >1000 >1000 >1000 >1000 >1000 
14e 10 5.90 86 ± 6 0.3 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 65 ± 5 
14f 12 6.96 71 ± 7 21 ± 3 6 ± 1 8 ± 2 617 ± 15 
14g 14 8.02 56 ± 5 6 ± 1 8 ± 1 4 ± 1 46 ± 4 
14h 16 nd 100 ± 6 4 ± 1 12 ± 2 0.9 ± 0.2 593 ± 34 
17a 3 2.13 30 ± 2 24 ± 3 55 ± 4 113 ± 18 46 ± 1 
17b 5 3.19 12 ± 2 5 ± 1 16 ± 2 4 ± 1 6 ± 1 
17c 6 3.72 4 ± 1 1 ± 1 5 ± 1 3 ± 1 3 ± 1 
17d 7 4.25 1.5 ± 0.2 0.8 ± 0.4 2.1 ± 0.2 2.3 ± 0.1 2.2 ± 0.1 
17e 9 5.31 3 ± 1 3 ± 1 5 ± 1 3 ± 1 3 ± 1 
17f 11 6.36 5 ± 1 3 ± 1 10 ± 1 5 ± 1 5 ± 1 
17h 13 7.42 3 ± 1 3 ± 1 5 ± 1 3 ± 1 5 ± 1 
17i 14 7.95 5 ± 1 6 ± 1 15 ± 2 7 ± 1 8 ± 1 
 
Although the ―mono-acyloxymethyl ester‖ derivatives 14 of increasing lipophilicity 
(ClogP ranging from 1.67 to 8.02) showed different antiproliferative effects depending on the 
substituent grafted on the carboxylic acid, there was no clear-cut relationship between in vitro 
antitumor activity and lipophilicity. Among the ―mono-amide‖ derivatives 17 of increasing 
lipophilicity (ClogP ranging from 2.13 to 7.95), only the less lipophilic compound 17a displayed 
IC50 values >10 M; the introduction of a group with higher lipophilicity led to derivatives 17b-
f, 17h-i that exhibited IC50 values in the micromolar range.  
Only three ―mono-esters‖ (14b, 14c, 14d) possessed poor activity (IC50 >100 M) against 
all cell lines (Table 78). As far as the A549 lung cell line is concerned, the ―mono-esters‖ (with 
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the exception of 14a) generally displayed poor growth inhibition or an effect comparable to that 
of parent LEV; the ―mono-amides‖ 17 were more potent. 
―Mono-ester‖ 14e (n = 10) was the most active compound against U373-MG, LoVo and 
MCF-7 cell lines, with IC50 values below the micromolar range, that were 220-2000-fold lower 
than that of LEV. ―Mono-amide‖ 17d (n = 7) displayed IC50 values in the micromolar range, 30-
150-fold lower than that of LEV, in PC-3 and A549 NSCLC cell lines, and turned out to be the 
most potent derivative in this series. 
A difference in selectivity was observed between ―mono-ester‖ and ―mono-amide‖ series. 
For example, esters 14e-h (5.90 < ClogP < 8.02; 10 < n < 16) displayed a growth inhibitory 
effect against both the apoptosis-resistant U373-MG and apoptosis-sensitive LoVo and MCF-7 
cancer cell lines, whereas they were not active against both apoptosis-sensitive PC-3 and 
apoptosis-resistant A549 cell lines. In contrast, amides 17b-f, 17h-i (3.19 < ClogP < 7.95; 5 < n 
< 14) produced similar effects irrespective of the cell lines.  
As shown in Figure 48, the various cancer cell lines showed an heterogeneous profile of 
sensitivity to the lead ester 14e in relation to apoptosis sensitivity versus resistance, while they 
all displayed similar sensitivity to the lead amide 17d. 
 
Figure 48 In vitro IC50 of compounds 14e and 17d with respect to apoptosis-
resistant and sensitive cancer cell lines 
 
In terms of antitumor activity, these data suggest that the ―mono-amide‖ derivative 17d 
was able to overcome the natural resistance of certain cancer cell types to apoptosis. The active 
derivatives under study could exert their antitumor activity through activation of apoptotic or 
non-apoptotic cell death processes. 
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Mondal et al.
192
 and Yamakuchi et al.
193
 evaluated the antiproliferative and apoptotic 
activities of LEV on human NSCLC and transitional bladder carcinoma cells in culture 
respectively. These investigators demonstrated that LEV caused cellular growth inhibition in a 
time-dependent manner. We also investigated the time course of the increase on growth 
inhibition of the stable ―mono-amide‖ derivatives that exhibited similar antitumor effect against 
all the cell lines under study. In agreement with previous reports,
192-193
 we observed significant 
increases in growth inhibition, on all tumor cell lines, from 3 to 5 days of exposure. For example, 
the cell number declines from 30-60% to 1-3% for the ―mono-amide‖ 17d, depending on the cell 
line (Figure 49). 
 
 
Figure 49 Time-dependent growth inhibition observed with LEV and ―mono-
amide‖ 17d in human tumor cell. The cells were cultured for 3 (purple bars) or 5 
(blue bars) days with compounds LEV or 17d 
 
4.2.2 In Vivo Maximum Tolerated Dose (MTD) in Healthy Mice 
The in vivo tolerance of LEV and ―mono-esters‖ 14 was determined as the MTD index, 
all of which displayed MTD indices >80 mg/kg. 
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4.2.3 In vitro antiproliferative activity of “dimer” LEV derivatives 
IC50 values of ―di-amide‖ derivatives along with those of LEV are summarized in Table 
79.  
 
Table 79 In vitro antiproliferative activity of LEV ―di-amides‖ 
  IC50 ( M) 
  Apoptosis-sensitive Apoptosis-resistant 
Comp. n PC-3 LoVo MCF-7 U373-MG A549 
LEV – 238±12 67±5 622±19 188±13 70±6 
18a 4 20 ± 2 19± 2 36 ± 2 30 ± 2 64.7 ± 1.5 
18b 5 14 ± 2 9 ± 1 33 ± 5 23 ± 1 85 ± 13 
18c 6 0.7 ± 0.1 1.2 ± 0.1 1.8±  0.1 2.4 ± 0.1 2.9 ± 0.2 
18d 7 1.7 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 2.1 ± 0.1 2.3 ± 0.1 
18e 8 1.6 ± 0.1 0.4 ± 0.1 1.8 ± 0.1 2 ± 60 2.2 ± 10 
18f 9 0.3 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 0.2 ± 0.1 0.7 ± 0.1 
18g 10 120 ± 10 130 ± 20 360 ± 30 270  ± 10 480  ± 20 
18h 12 2.8 ± 0.1 2.2 ± 0.1 3.8 ± 0.5 2.4 ± 0.1 4.5 ± 0.6 
 
A homogeneous antiproliferative profile was obtained for C-6-(N-alkylcarboxamide)-
linked LEV ―dimers‖ 18a-h. For each human cancer cell lines, there was a good correlation 
between the antiproliferative activities and the alkyl linker length. C-6-(N-butylcarboxamide)-
linked LEV 18a and C-6-(N-pentylcarboxamide)-linked LEV 18b ―dimers‖ exhibited ICs50 ≥ 9 
M, whereas IC50 values were in the range from 0.2 to 4.5 M against all cancer cell lines for 
compounds 18c-f, h (chain length with n ≥ 6). Thus, IC50 values decreased when the chain length 
increased, however we observed a break between C-6-(N-nonylcarboxamide)-linked LEV 18f 
which exhibited the most potent antiproliferative activities against all cancer cell lines and C-6-
(N-dodecanoylcarboxamide)-linked LEV 18h as compound C-6-(N-decanoylcarboxamide)-
linked LEV 18g was inactive. These observed results led us to study the solubility of these 3 
compounds (18f, 18g, 18h) in the cellular media for 24 hours at 37°C (Figure 50). 
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Figure 50 Solubility tests in cellular media for compound 18f (n=9) at 5 M (A, 
no precipitation) and 50 M (A‘), compound 18g (n=10) at 50 M (B) and 500 
M (B‘) and compound 18h (n=12) at 5 M (C) and 50 M (C‘) 
 
Compound 18f didn‘t precipitate at concentrations of 5 and 50 M while compound 18h 
precipitated at 50 M and also, but with less importance, at 5 M. On the other hand, we 
observed a precipitation of compound 18g at 500 or 50 M. These results could explain why 
compound 18f exhibited the most potent antiproliferative activities while there was a loss of 
activity for compound 18h and no antiproliferative activity for compound 18g. Nevertheless, the 
―dimer‖ 18f exhibited the most potent activities against all cancer cell lines with IC50 values 
ranging from 0.2 to 0.7 M, that is 100- to 1240-fold lower than that of LEV. 
A A’ 
B B’ 
C C’ 
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4.3 Conclusion on antiproliferative activity of LEV derivatives 
We showed that ―mono-amide‖ derivatives of LEV 17 exhibited better antiproliferative 
activities than the ―mono-oxymethylester‖ 14. The monomer (N-octyl)carboxamide derivative 
17d (0.8 < ICs50 < 2.3 M) was more potent than the most interesting monomer 
dodecanoyloxymethyl ester derivative 14e (0.2 < ICs50 < 86 M). By analogy with C-6(N-
alkylcarboxamide)-linked LEV ―dimers‖ 18, we also observed a decrease of the antiproliferative 
effect when the alkyl chain length was less than 6 methylene groups as the (N-butyl)carboxamide 
17a derivative of LEV was inactive (24 < IC50 < 113 M). The alkylcarboxamide derivatives 17b-
h exhibited a homogeneous antiproliferative profile with IC50 values ranging from 0.8 to 16 M 
against all the human cancer cell lines. On the other hand, alkanoyloxymethyl ester derivatives 14 
exhibited a heterogeneous antiproliferative profile with ICs50 ranging from 0.2 to > 500 M 
depending on the cancer cell lines. The ―monomer‖ 17d and the most potent antiproliferative 
―dimer‖ 18f (0.2 < ICs50 < 0.7 M), are both alkylcarboxamide derivatives of LEV.  
Once more, ―dimer‖ derivatives are more potent antiproliferative agents than ―monomers‖ 
derivatives of LEV (Figure 51).  
 
Figure 51 IC50 values ( M) of ‗mono-amide‖ 17d and ―di-amide‖ 18f derivatives 
of LEV 
 
4.4 General conclusion on antiproliferative activity 
This study thus has demonstrated that the cytotoxicity of CIP or LEV can be positively 
modulated through the introduction of simple substituents. 
The derivatisation of C-6 LEV turned out to be more potent with regards to cytotoxic 
activity than C-7 modification of CIP. We can also notice the increased cytotoxicity of ―dimer‖ 
compounds in comparison to ―monomers‖ whatever the parent FQ. As we have previously noted 
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for the whole series of synthesized compounds we couldn‘t establish a clear-cut dependence 
between the chain length and the antiproliferative activity.  
For ―monomers‖ derivatives, we observed a profile of activity which was highly 
influenced by the functional group linked to FQ: 
 
 The most active ―mono-oxoethylester‖ CIP derivatives (3c, 3d or 3h) and ―mono-
acyloxymethylester‖ derivatives of LEV (14e-h) displayed a heterogeneous 
antiproliferative profile of activity towards the different cancer cell lines. However, ―mono-
acyloxymethylester‖ derivatives of LEV were found to be more potent than ―mono-
oxoethylester‖ CIP derivatives. 
 The most active ―mono-amide‖ derivative of CIP 1h and ―mono-amide‖ derivatives of 
LEV (17c-h) both displayed homogeneous antiproliferative. Again, ―mono-amide‖ 
derivatives of LEV were found to be more potent than ―mono-amide‖ CIP derivatives. 
 
Whatever the parent FQ, the dimerization of monomeric molecules led to an increase of 
the antiproliferative activity: 
 
 The most active ―di-amide‖ derivative of CIP 7e was more potent than the most active 
―mono-amide‖ derivative of CIP 1h. They both showed a homogeneous antiproliferative 
profile. 
 The most active ―di-oxoethylester‖ derivative of CIP 9e was more potent than the most 
active ―mono-oxoethylester‖ CIP derivatives (3c, 3d or 3h). ―Monomer‖ derivatives 
showed a heterogeneous antiproliferative profile while ―dimer‖ derivatives showed a 
homogeneous one. 
 The most active ―di-amide‖ derivatives of LEV 18c-f, 18h were more potent than the most 
active ―mono-amide‖ derivatives of LEV 17c-h. They both showed a homogeneous 
antiproliferative profile. 
 
As seen in literature, the mechanisms of action by which some FQ antibiotics exert 
antitumor effects on various human cancer cell lines were determined to be through pro-
apoptotic effects.  
In terms of antitumor activity, these data suggest that the ―amide‖ CIP derivatives and 
LEV and the ―di-oxoethylester‖ derivative of CIP are able to overcome the natural resistance of 
certain cancer cell types to apoptosis as they all exhibited a homogeneous antiproliferative 
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profile. The active derivatives could exert their antitumor activity through activation of apoptotic 
or non-apoptotic cell death processes. 
The most potent antiproliferative compounds are represented in Table 80. 
 
Table 80 In vitro antiproliferative activity of the most active synthesized 
derivatives 
 IC50 ( M) 
 Apoptosis-sensitive Apoptosis-resistant 
Structure PC-3 LoVo MCF-7 
U373-
MG 
A549 
 
4 7 20 5 3 
 
8 6 8 3 7 
 
0.2 0.1 1.0 0.8 8.7 
 
1.5 0.8 2.1 2.3 2.2 
 
0.3 0.2 0.5 0.2 0.7 
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5. General overview of biological activity 
The synthesized compounds displayed different level of specificity towards different 
biological targets. 
 
Concerning the C-7 modification of CIP, it was beneficial with regards to antibacterial 
and antiproliferative activity while being less effective in the case of antimycobacterial potency. 
In a general way, ―monomer‖ CIP derivatives were more potent as antibacterials against S. 
aureus while ―dimers‖ were more potent as antiproliferative agents. ―Monomer‖ derivatives 
showed a moderate activity against M. tuberculosis while ―dimer‖ derivatives were inactive. 
The antibacterial activity of ―monomer‖ derivatives was optimal for a chain length 
ranging from n = 3 to 9 according to the linking group. Even if several ―monomer‖ derivatives 
displayed antiproliferative activities greater than CIP, only the derivative 1h (n = 8) showed 
significant IC50 values ranging from 3 to 20 M depending on the cancer cell lines.  
The antibacterial activity of ―dimer‖ derivatives was optimal for n = 12 and mainly for n 
= 13 whatever the linking group while their antiproliferative activity was optimal for n = 12 and 
mainly n = 14. We could notice the most potent antibacterial compounds 7d and 9d (n = 13) 
were inactive against the cancer cell lines and that the most potent antiproliferative compounds 
7e and 9e (n = 14) were few active against the S. aureus strain. (Figure 52). 
 
Figure 52 Influence of the chain length on the biological activity of CIP 
derivatives. 
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The C-6 modification of LEV was more beneficial with regards to cytotoxicity than for 
antibacterial and antimycobacterial activities.  
The antibacterial activity of ―mono-acyloxymethyl esters‖ derivatives was optimal for 
chain lengths equal to n = 8 (14d) and 10 (14e) while the antimycobacterial activity was optimal 
for n = 6 (14c) and 10 (14e). We could notice that these optimums were close for these two 
biological activities. On the other hand, the antiproliferative activity was optimal for longer chain 
lengths that were n = 12 (14f), 14 (14g) and 16 (14h) (Figure 47). 
 
Figure 53 Influence of the chain length on the biological activity of LEV ―mono-
acyloxymethyl esters‖ 
 
The introduction of an amide function at C-6 position of LEV led to a loss of activity of 
―mono-amide‖ derivatives against bacteria strains. The antimycobacterial activity was moderate 
as the most potent compound 17i (n = 14) showed an IC50 value against M. tuberculosis of 4 M, 
that is 5-fold less potent than LEV. On the other hand, a significant enhancement of the 
antiproliferative activity was observed for chain lengths ranging from n = 6 (17c) to n = 14 (17i) 
with a maximum of activity for n = 7 (17d) (Figure 54). 
 
Figure 54 Influence of the chain length on the spectrum biological of activity for 
LEV ―mono-amides‖ 
 
―Di-amide‖ derivatives of LEV were the most interesting compounds whatever the 
biological activity. For compounds 18g (n = 10) and mainly 18h (n = 12), a broad spectrum of 
activity, as for the parent LEV, against Gram-positive and Gram-negative bacteria strains was 
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observed. A significant antimycobacterial activity was observed from n = 9 (18f) to n = 12 (18h) 
with IC50 values against M. tuberculosis < 2 M. The best antiproliferative activities were 
observed for chain lengths ranging from n = 6 (18c) to n = 12 (18h) with an optimum for n = 9 
(18f) (Figure 55). 
 
Figure 55 Influence of the chain length on the biological activity of LEV ―di-
amides‖ 
 
Considering now the enzymatic target depending on the studied biological activity, 
remember that FQs corrupt the activities of DNA gyrase and topoisomerase IV. However, 
depending upon FQ employed and the bacterial species, either DNA gyrase or topoisomerase IV 
serves as the primary cytotoxic target of drug action.
 
For most older FQ, including CIP and LEV, 
DNA gyrase in Gram-negative bacteria and topoisomerase IV in Gram-positive bacteria are 
often found to be the primary targets. Each quinolone drug appears to have a preferred target and 
the target selection can be altered by changes in quinolone structure. Moreover, Kerns et al. 
showed that DNA gyrase became the primary target for their synthetized ―dimers‖ in Gram-
positive S. aureus and S. pneumoniae strains
74-75
. 
DNA gyrase is the only type II topoisomerase present in M. tuberculosis and hence is the 
only target for FQ action. 
FQs and their derivatives can exert their antitumor activity either by pro-apoptotic or 
through non-apoptotic-dependent mechanisms. As outlined in the introduction, FQs can act on 
human topoisomerase I or II and on several other biological targets. 
We have reported in the following table (Table 81) the level of each biological activity 
for the most potent CIP derivatives and LEV against the Gram-positive S. aureus strain. 
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Table 81 Level of biological activity for selected most potent derivatives against 
S. aureus strain 
 
Antibacterial 
Antimycobacterial Antiproliferative 
Gram + Gram - 
Postulated enzymatic target 
Topo IV > 
Gyrase 
Gyrase > 
Topo IV 
Gyrase Topo I, Topo II 
Entry Compd. ClogP (n)     
1 1f 3.78 (5) ++
a - +/- - 
2 1g 4.84 (7) ++ - +/- + 
3 3c 3.83 (4) ++ - +/- + 
4 3d 4.89 (6) +++ - +/- +/- 
5 3e 5.41 (7) ++ - n.d.
b 
- 
6 3f 5.95 (8) ++ - +/- - 
7 3g 6.47 (9) + - +/- - 
8 7c n.d. (12) ++ - - +/- 
9 7d n.d. (13) ++ - - +/- 
10 14d 4.84 (8) + + n.d. - 
11 14e 5.90 (10) + + ++ ++ 
12 18g n.d. (10) +/- + + c 
13 18h n.d. (12) + + + ++ 
a
 - : inactive +/- to +++ : from few active to more active than the parent CIP or LEV. 
b 
n.d. not determined. 
c
 problem of precipitation in the cellular media 
 
Some trends can be extracted from this table: 
 The more potent compounds from CIP derivatives (Table 81, entries 1-9) 
against the Gram-positive S. aureus strain are inactive against the other 
biological target. 
 The more potent compounds from LEV derivatives (Table 81, entries 10-13) 
are generally less potent against the Gram-positive S. aureus strain than CIP 
derivatives. However, they showed an activity against Gram-negative strain and 
compounds 14e (entry 11) and 18h (entry 13) also displayed antimycobacterial 
and antiproliferative activities. 
 The most potent compounds, from LEV series, against M. Tuberculosis are also 
active against Gram-negative strain. We can then suppose, that for these 
compounds, the enzymatic target could be DNA gyrase. 
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It would be so interesting to evaluate the IC50 values of these compounds against gyrase 
and topoisomerase IV from S. aureus and E. coli. So, we could determine if topoisomerase IV in 
Gram-positive and gyrase in Gram-negative remain to be the primary targets for the studied 
compounds. And mainly to determine if DNA gyrase didn‘t become the primary target for ―di-
amide‖ LEV derivatives 18g-h (Table 81, entries 12-13) in Gram-positive strain. 
 
In the next table (Table 82) are summarized the level of each biological activity for the 
most potent CIP derivatives and LEV against the cancer cell lines. 
 
Table 82 Level of biological activity for selected most potent derivatives against 
cancer cell lines 
 
Antibacterial 
Antimycobacterial Antiproliferative 
Gram + Gram - 
Postulated enzymatic target 
Topo IV > 
Gyrase 
Gyrase > 
Topo IV 
Gyrase Topo I, Topo II 
Entry Compd. ClogP (n)     
1 1h 5.37 (8) - 
a 
- + ++ 
2 3h 7.00 (10) +/- - +/- + 
3 7c n.d. (12) ++ - - + 
4 7e n.d. (14) +/- - - ++ 
5 9c n.d. (12) +/- - +/- + 
6 9e n.d. (14) +/- - n.d. 
b 
+++ 
7 14e 5.90 (10) + + ++ ++ 
8 14f 6.96 (12) - - + + 
9 17d 4.25 (7) - - +/- +++ 
10 17e 5.31 (9) - - +/- ++ 
11 17f 6.36 (11) +/- - n.d. ++ 
12 17h 7.42 (13) +/- - n.d. ++ 
13 17i 7.95 (14) - - + ++ 
14 18c n.d. (6) - - - ++ 
15 18e n.d. (8) - +/- n.d. ++ 
16 18f n.d. (9) - +/- + +++ 
17 18h n.d. (12) + + + ++ 
a
- : inactive +/- to +++ : from few active to more active than the parent CIP or LEV. 
b
n.d. 
not determined.  
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Some trends can be extracted from this table: 
 Except compound 7c (Table 82, entry 3), no compound possessing an 
antibacterial activity showed an antiproliferative activity. Only ―dimer‖ CIP 
derivatives 7e and 9e (entries 4, 6) displayed a good antiproliferative activity. 
 More compounds from LEV derivatives (Table 82, entries 7-17) were found to 
have a good antiproliferative activity than an antibacterial one (Table 82, entries 
10-13). Only LEV derivatives 14e and 18h showed these two biological activities. 
 LEV derivatives are generally more potent as antiproliferative agents than CIP 
derivatives. However, we can notice that, except for compound 18h (entry 17), 
they didn‘t display an antibacterial activity but some of them showed an 
antimycobacterial activity.  
 
The mechanism of action by which these derivatives exert their antiproliferative activity 
will be more difficult to establish. In fact, the time- and dose-dependent pro-apoptotic effects of 
FQ were observed at higher doses than in vitro growth inhibition values. For example, it have 
been shown that most FQ required concentrations (IC50s) to inhibit the human topoisomerase II of 
HeLa cells that were higher than those needed to inhibit bacterial type II topoisomerases. 
Moreover, no significant correlation was observed between the inhibition of HeLa cell 
topoisomerase II and that of S. aureus topoisomerase IV as well as E. coli DNA gyrase
194
. For 
CIP, the IC50 values to inhibit the topoisomerase II of Hela cells was found to be 3 and 478 higher 
than those needed to inhibit bacterial type II topoisomerases. So, the human polymerase II test 
can only be valuable if our compounds have IC50 values lower than CIP or LEV themselves.  
So, mechanistic studies to investigate as whether our lead compounds induce either pro-
apoptotic, pro-autophagic or cell proliferation inhibition should be envisaged. But, before 
proceeding with a genomic approach to identify the molecular pathways activated or inhibited by 
our compounds, we have to select a lead compound through the characterization of in vivo 
activity on a broad panel of biologically aggressive human xenograft models. 
 
In summary, many CIP and LEV derivatives have been synthetized and evaluated for 
their biological activity. Some of these derivatives are non-toxic in vivo according to their MTD.  
This study thus demonstrates that the biological activity of CIP and LEV could be 
positively modulated through the introduction of simple substituents on C-6 or C-7 positions.  
 
Primary investigations have shown that a modification on the N-4 piperazinyl group of 
CIP can influence the biological activity: the main activity is specifically oriented against the 
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inhibition of S. aureus growth or oriented against the inhibition of cancer cell lines growth. No 
significant activity against M. tuberculosis was observed. 
The most potent CIP derivatives against standard and MRSA strains displayed high MIC 
against standard E. coli strain and were inactive for the inhibition of human cancer cell lines 
growth. On the other hand, the most potent CIP derivatives as antiproliferative agents displayed 
moderate to poor activities as antibacterial agents.  
The activity against S. aureus is greater for ―monomeric‖ CIP derivatives as the 
antiproliferative effect is greater for ―dimeric‖ ones.  
 
A modification on the C-6 carboxylic group of LEV, and especially the substitution of 
this group by an alkylcarboxamide one, led to the most potent antiproliferative and 
antimycobacterial agents. So, we can conclude that C-6-carboxylic group of LEV is not required 
for the antiproliferative and antimycobacterial activities.  
In a general way, the derivatives of LEV are less potent as antibacterial agents against S. 
aureus than CIP derivatives. However, some of them display an antibacterial activity against E. 
coli. For some ―monomer‖ and ―dimer‖ derivatives of LEV, the MICs values against S. aureus 
and E. coli are comparable to those of LEV, suggesting that this carboxylic acid modification is 
allowed for the antibacterial activity. These results could be useful for the development of new 
quinolone-based antibacterial agents. 
One LEV derivative, that is C-6-(N-dodecanoylcarboxamide)-linked LEV 18h, was found 
be be particulary interesting as it was the only one derivative showing a broad activity on the 
three biological target. 
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 CONCLUSION GÉNÉRALE 
En résumé, nous avons synthétisé par une procédure efficace cinq séries de dérivés 
―dimères‖ et ―monomères‖ de la LEV et de la CIP. Nous avons mis au point de nouvelles 
conditions de réaction pour les dérivés ―dimères‖ de la CIP parce que les conditions utilisées 
pour la synthèse des ―monomères‖ de la CIP n‘étaient pas efficaces et ont conduit à de faibles 
rendements. L‘optimisation des conditions de réaction pour les "diesters" de CIP ont permis, 
avec l'utilisation de TBAI comme un catalyseur, de préparer ces composés avec de bons 
rendements. Les "di-amides" de CIP ont été obtenus en utilisant le carbodiimide EDCI soluble 
dans l‘eau, ce qui a facilité le processus de purification. Les études les plus approfondies ont été 
menées au cours de la synthèse des "monoester" de la LEV lorsque les deux types de conditions 
par voie thermique et micro-ondes ont été évaluées. Après un examen détaillé de la réaction dans 
le cas des composés à chaîne courte et longue, nous avons obtenu une amélioration du 
rendement, un temps de réaction plus court et diminué la formation de sous-produit (conditions 
thermiques, DMF, Cs2CO3). Pour les "mono-"et "di-amides" de LEV deux méthodes ont été 
comparées: l‘utilisation de l‘agent de couplage HATU et du système  TPP / TCA. Le mélange 
TPP / TCA s'est avéré être plus pratique avec des réactifs disponibles et par conséquent a été 
appliqué pour ces séries de composés. 
En ce qui concerne l'activité biologique, notre travail a démontré que l‘activité native 
(antibactérienne) de CIP et LEV pouvait être modulée par la simple modification des substituants 
en C-6 et en C-7. La modification sur la position C-7 semble être plus bénéfique pour l'activité 
antibactérienne, notamment contre S. aureus pour les composés ―monomères‖ et contre les 
souches résistantes de S. aureus pour les dérivés ―dimères‖. Contrairement à la position C-7, la 
substitution de la LEV en position C-6 a considérablement augmenté l'activité antiproliférative. 
L'influence de la fonction introduite a également été démontrée: le groupement amide fourni une 
large gamme de composés à spectre d‘activité homogène tandis qu‘un groupement ester a 
conduit à des composés à spectre d‘activité hétérogène. 
Nos travaux ont démontré le potentiel des modifications en position C-7 et C-3 des FQs 
et fourni la base pour de nouvelles recherches dans ce domaine. 
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EXPERIMENTAL PART 
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1. Chemistry 
All reagents were of commercial quality, reagent grade and were used as supplied 
without further purification. LEV and CIP (>98%) were purchased from Fluka; chloromethyl 
alkanoates were prepared as previously described
167
. Microwave synthesis was performed in the 
CEM Discover® reactor at open-vessel mode. Merck silica gel 60 F254 plates were used for 
analytical TLC with UV light detection (  = 254 nm). Preparative column chromatography 
purifications were performed on silica 60 Å (Merck) finer than 70 m means of the solvent 
systems indicated. Melting points (mp) were determined on a Kofler hot stage apparatus and are 
uncorrected. 
1
H NMR spectra were recorded on a Bruker AC-300 spectrometer. Data are 
reported in the following order: chemical shift d in ppm, signal multiplicity, value(s) of coupling 
constant(s), number of protons and assignment. 
13
C NMR spectra and 
19
F NMR spectra were 
recorded on a Bruker Avance-300 spectrometer. NMR spectra were recorded in 
deuteriochloroform unless indicated otherwise. The chemical shifts  are expressed relative to 
TMS or CFCl3. The attributions are reported according to the atom numbering indicated at the 
corresponding figures. Mass spectra were recorded on a Perkin Elmer SCIEX API 365 operating 
in electrospray mode. Elemental analyses were carried out by the ―Service Inter-universitaire de 
l‘ENSIACET‖ in Toulouse, on an EA 1110 Thermo. 
 
Figure 56 Atom numbering of CIP ―di-amides‖ 
 
General procedure for the synthesis of bis(7-(4-(alkanoyl)piperazin-1-yl)) CIP 
derivatives (7a-f) termed CIP “di-amides”: To a solution of carboxylic diacid (0.65 mmole) in 
1:1 mixture of DMF and methylenechloride (10 mL), HOBt (0.22 g, 1.63 mmole) and EDCI 
(0.31g, 1.63 mmole) were added and the reaction mixture was stirred at room temperature for 30 
min. Then CIP (0.5 g, 1.51 mmole) was added and the mixture was stirred at r. t. for 4h. The 
solvent was removed under reduced pressure and the solid residue was washed with water (3 × 
20 mL), mixed with 40 mL of methylenechloride. Obtained solution was filtered, filtrate was 
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evaporated. Crude product was purified by column chromatography on silica gel (40g,  CH2Cl2/ 
MeOH, 10:0.1 – 10:1).  
 
bis(7-(4-Decanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7a). Purification provided the desired compound (251 mg, 
48% yield) as a pale yellow solid. m.p. >260 ºC (decomp.). Rf 0.19 (CH2Cl2/MeOH, 10/0.75). 
1
H 
NMR (500 MHz): 1.21 (dd, 
3
Jcis=10.5 Hz, 
3
Jtrans=6 Hz, 4H, C2‖-H and C3‖-H), 1.35 (m, 8H, Cd-
H, Ce-H), 1.40 (dd, 
3
Jcis=13.5 Hz, 
3
Jtrans=6 Hz, 4H, C2‖-H and C3‖-H), 1.66 (quint, 
3
Jb-c=7.5 Hz, 
3
Jc-d=6 Hz, 4H, Cc-H), 2.38 (t, 
3
J=7.5 Hz, 4H, Cb-H), 3.28 (t, 
3
J=5 Hz, 4H, C3'-H), 3.35 (t, 
3
J=5 
Hz, 4H, C5'-H), 3.54 (sept, 
3
J=4 and 7 Hz, 2H, C1''-H), 3.71 (t, 
3
J =5 Hz, 4H, C2'-H), 3.87 (t, 
3
J =5 
Hz, 4H, C6'-H), 7.38 (d, 
4
JH-F=7 Hz, 2H, C8-H), 8.07 (d, 
3
JH-F=13 Hz, 2H, C5-H), 8.79 (s, 2H, C2-
H), 14.89 (br s, 2H, O3a'-H). 
13
C NMR (125 MHz): 8.3 (C2'', C3''), 25.2, 29.2, 29.4, 33.2 (Cb-e), 
35.3 (C1''), 41.1 (C3'), 45.4 (C5'), 49.4 (C6'), 50.4 (C2'), 105.1 (d, 
3
JC-F = 2.8 Hz, C8), 108.4 (C3), 
112.8 (d, 
2
JC-F = 23.3 Hz, C5), 120.5 (d, 
3
JC-F = 7.9 Hz, C4a), 139 (C8a), 145.4 (d, 
2
JC-F = 10.5 Hz, 
C7), 147.6 (C2), 153.6 (d, 
1
JC-F = 249.6 Hz, C6), 166.9 (C3a), 171.8 (Ca), 177.1 (d, 
4
JC-F = 2.5 Hz, 
C4). 
19
F NMR (282 MHz): -121.18 – -121.25 (dd, 3JH-F = 12.6 Hz, 
4
JH-F = 6.9 Hz). MS CI 
(DCI/NH3): C44H50F2N6O8, m/z 829.5 [M+H]
+
. Elemental Anal. (C44H50F2N6O8 · H2O) C, H, N: 
calcd, 62.40, 6.19, 9.92; found, 62.41, 6.12, 9.90. 
 
bis(7-(4-Dodecanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7b). Purification provided the desired compound (174 mg, 
31% yield) as a pale yellow solid. m.p. >260 ºC (decomp.). Rf 0.21 (CH2Cl2/MeOH, 10/0.75). 
1
H 
NMR (500 MHz): 1.21 (dd, 
3
Jcis=10.5 Hz, 
3
Jtrans=6.5 Hz, 4H, C2‖-H and C3‖-H), 1.29 – 1.36 (m, 
12H, Cd-f-H), 1.40 (dd, 
3
Jcis = 13.5 Hz, 
3
Jtrans = 6.5 Hz, 4H, C2‖-H and C3‖-H), 1.65 (quint, 
3
Jb-c = 
8 Hz, 
3
Jc-d = 7 Hz, 4H, Cc-H), 2.37 (t, 
3
J = 8 Hz, 4H, Cb-H), 3.28 (t, 
3
J = 5 Hz, 4H, C3'-H), 3.35 (t, 
3
J = 4.5 Hz, 4H, C5'-H), 3.54 (sept, 
3
J = 4 and 7.5 Hz, 2H, C1''-H), 3.72 (t, 
3
J = 4.5 Hz, 4H, C2'-
H), 3.86 (t, 
3
J = 5 Hz, 4H, C6'-H), 7.37 (d, 
4
JH-F = 7 Hz, 2H, C8-H), 8.03 (d, 
3
JH-F = 12.5 Hz, 2H, 
C5-H), 8.77 (s, 2H, C2-H), 14.90 (br s, 2H, O3a'-H). 
13
C NMR (125 MHz): 8.3 (C2'', C3''); 25.2, 
29.4, 29.4, 33.2 (Cb-f); 35.3 (C1''); 41.1 (C3'); 45.4 (C5'); 49.4 (C6'); 50.3 (C2'); 105.1 (d, 
3
JC-F = 2.8 
Hz, C8); 108.3 (C3); 112.6 (d, 
2
JC-F = 23.1 Hz, C5); 120.4 (d, 
3
JC-F = 7.8 Hz, C4a); 138.9 (C8a); 
145.4 (d, 
2
JC-F = 10.4 Hz, C7); 147.6 (C2); 153.5 (d, 
1
JC-F = 249.7 Hz, C6); 166.9 (C3a); 171.9 
(Ca), 177.1 (d, 
4
JC-F = 2.5 Hz, C4). 
19
F NMR (282 MHz, CDCl3): -121.14 – -121.21 (dd, 
4
JF-H = 
7.0 Hz, 
3
JF-H = 12.8 Hz). MS CI (DCI/NH3): C46H54F2N6O8, m/z 857.7 [M+H]
+
. Elemental Anal. 
(C48H58F2N6O8 · 2.8H2O) C, H, N: calcd, 60.90, 6.58, 9.27; found, 60.93, 6.13, 9.94. 
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bis(7-(4-Tetradecanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7c). Purification provided the desired compound (400 mg, 
66% yield) as a pale yellow solid. m.p. 250 ºC. Rf 0.22 (CH2Cl2/MeOH, 10/0.75). 
1
H NMR (300 
MHz): 1.20 (m, 4H, C2''-H, C3''-H); 1.26 – 1.32 (m, 16H, Cd-g-H); 1.39 (dd, 
3
Jcis = 13.8 Hz, 
3
Jtrans 
= 6.9 Hz, 4H, C2''-H, C3''-H); 1.65 (quint, 
3
Jb-c = 7.8 Hz, 
3
Jc-d = 6.9 Hz, 4H, Cc-H); 2.37 (t, 
3
JH-H = 
7.8 Hz, 4H, Cb-H); 3.29 (m, 4H, C3‘'-H); 3.35 (m, 4H, C5'-H); 3.55 (m, 2H, C1''-H); 3.7 (t, 
3
J = 4.5 
Hz, 4H, C2'-H); 3.86 (m, 4H, C6'-H); 7.35 (d, 
4
JH-F = 6.6 Hz, 2H, C8-H); 7.98 (d, 
3
JH-F = 12.9 Hz, 
2H, C5-H); 8.72 (s, 2H, C2-H); 14.88 (br s, 2H, O3a'-H). 
13
C NMR (75 MHz): 8.2 (C2'', C3''); 25.2, 
29.4, 29.4, 29.5, 33.2 (Cb-g); 35.3 (C1''); 41.0 (C3'); 45.3 (C5'); 49.3 ( C6'); 50.3 ( C2'); 105.0 (d, 
3
JC-
F = 3.0 Hz, C8); 108.1 (C3); 112.5 (d, 
2
JC-F = 23.2 Hz, C5); 120.2 (d, 
3
JC-F = 7.7 Hz, C4a); 138.9 
(C8a); 145.4 (d, 
2
JC-F = 10.2 Hz, C7); 147.5 (C2); 153.5 (d, 
1
JC-F = 249.7 Hz, C6); 166.8 (C3a); 
171.8 (Ca), 176.9 (d, 
4
JC-F = 2.3 Hz, C4). 
19
F NMR (282 MHz): -121.04 – -121.11 (dd, 4JF-H = 7.0 
Hz, 
3
JF-H = 12.9 Hz). MS CI (DCI/NH3): C48H58F2N6O8, m/z 885.8 [M+H]
+
. Elemental Anal. 
(C48H58F2N6O8 · H2O) C, H, N: calcd, 63.86, 6.65, 9.31; found, 63.90, 6.19, 10.04. 
 
bis(7-(4-Pentadecanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7d). Purification provided the desired compound (318 mg, 
61% yield) as a pale yellow solid. m.p. 178 ºC. Rf 0.20 (CH2Cl2/MeOH, 10/0.75). 
1
H NMR (300 
MHz): 1.19 (m, 4H, C2''-H, C3''-H); 1.24 – 1.30 (m, 18H, Cd-h-H); 1.37 (dd, 
3
Jcis=13.5 Hz, 
3
Jtrans=6.9 Hz, 4H, C2''-H, C3''-H); 1.63 (quint, 
3
Jb-c=7.5 Hz, 
3
Jc-d=6.9 Hz, 4H, Cc-H); 2.36 (t, 
3
JH-H 
= 7.5 Hz, 4H, Cb-H); 3.29 (m, 4H, C3'); 3.36 (m, 4H, C5'); 3.55 (m, 2H, C1''-H); 3.71 (m, 4H, C2'); 
3.85 (m, 4H, C6'); 7.33 (d, 
4
JH-F = 7.5 Hz, 2H, C8-H); 7.87 (d, 
3
JH-F = 12.9 Hz, 2H, C5-H); 8.65 (s, 
2H, C2-H); 14.87 (br s, 2H, O3a'-H). 
13
C NMR (75 MHz): 8.2 (C2'', C3''); 25.2, 29.3, 29.4, 29.5, 
29.6 (Cc-h); 33.2 (Cb); 35.3 (C1''); 41.0 (C3'); 45.3 (C5'); 49.3 (C6'); 50.2 (C2'); 105.0 (d, 
3
JC-F = 3.0 
Hz, C8); 107.9 (C3); 112.2 (d, 
2
JC-F = 23.2 Hz, C5); 119.8 (d, 
3
JC-F = 7.8 Hz, C4a); 138.9 (C8a); 
145.3 (d, 
2
JC-F = 10.3 Hz, C7); 147.3 (C2); 153.5 (d, 
1
JC-F = 249.7 Hz, C6); 166.7 (C3a); 171.8 
(Ca), 176.7 (d, 
4
JC-F = 2.5 Hz, C4). 
19
F NMR (282 MHz): -120.93 – -121.00 (dd, 4JF-H = 6.8 Hz, 
3
JF-H = 12.9 Hz). MS CI (DCI/NH3): C49H60F2N6O8, m/z  899.7 [M+H]
+
. Elemental Anal. 
(C49H60F2N6O8 · H2O) C, H, N: calcd, 64.19, 6.77, 9.17; found, 64.15, 6.76, 9.41. 
 
bis(7-(4-Hexadecanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7e). Purification provided the desired compound (326 mg, 
55% yield) as a pale yellow solid. m.p. 144 ºC. Rf 0.20 (CH2Cl2/MeOH, 10/0.75). 
1
H NMR (300 
MHz): 1.20 (m, 4H, C2''-H, C3''-H); 1.24 – 1.32 (m, 20H, Cd-h-H); 1.39 (dd, 
3
Jcis=13.5 Hz, 
3
Jtrans=6.9 Hz, 4H, C2''-H, C3''-H); 1.65 (quint, 
3
Jb-c=7.5 Hz, 
3
Jc-d=7.0 Hz, 4H, Cc-H); 2.37 (t, 
3
JH-H 
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= 7.5 Hz, 4H, Cb-H); 3.29 (m, 4H, C3'-H); 3.36 (m, 4H, C5'-H); 3.55 (m, 2H, C1''-H); 3.72 (m, 4H, 
C2'-H); 3.86 (m, 4H, C6'-H); 7.35 (d, 
4
JH-F = 7.2 Hz, 2H, C8-H); 7.94 (d, 
3
JH-F = 12.9 Hz, 2H, C5-
H); 8.69 (s, 2H, C2-H); 14.88 (br s, 2H, O3a'-H). 
13
C NMR (75 MHz): 8.3 (C2'', C3''); 25.2, 29.4, 
29.4, 29.4, 29.6, 29.6 (Cc-h); 33.2 (Cb); 35.4 (C1''); 41.1 (C3'); 45.4 (C5'); 49.4 (C6'); 50.3 (C2'); 
105.1 (d, 
3
JC-F = 3.0 Hz, C8); 107.9 (C3); 112.4 (d, 
2
JC-F = 23.2 Hz, C5); 120.1 (d, 
3
JC-F = 7.8 Hz, 
C4a); 139.0 (C8a); 145.4 (d, 
2
JC-F = 10.3 Hz, C7); 147.5 (C2); 153.5 (d, 
1
JC-F = 249.8 Hz, C6); 
166.8 (C3a); 171.9 (Ca), 176.9 (d, 
4
JC-F = 2.6 Hz, C4). 
19
F NMR (282 MHz): -121.00 – -121.07 
(dd, 
4
JF-H = 7.0 Hz, 
3
JF-H = 12.7 Hz). MS CI (DCI/NH3): C50H62F2N6O8, m/z 913.7 [M+H]
+
. 
Elemental Anal. (C50H62F2N6O8 · 2H2O) C, H, N: calcd, 63.29, 6.96, 8.86; found, 63.28, 6.85, 
9.22. 
 
bis(7-(4-Octadecanoyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (7f). Purification provided the desired compound (325 mg, 
53% yield) as a pale yellow solid. m.p. 138 ºC. Rf 0.22 (CH2Cl2/MeOH, 10/0.75). 
1
H NMR (300 
MHz): 1.20 (m, 4H, C2''-H, C3''-H); 1.23 – 1.32 (m, 24H, Cd-i-H); 1.39 (dd, 
3
Jcis=13.5 Hz, 
3
Jtrans=6.9 Hz, 4H, C2''-H, C3''-H); 1.64 (quint, 
3
Jb-c=7.5 Hz, 
3
Jc-d=6.6 Hz, 4H, Cc-H); 2.37 (t, 
3
JH-H 
= 7.5 Hz, 4H, Cb-H); 3.29 (m, 4H, C3'-H); 3.36 (m, 4H, C5'-H); 3.55 (m, 2H, C1''-H); 3.72 (m, 4H, 
C2'-H); 3.86 (m, 4H, C6'-H); 7.33 (d, 
4
JH-F = 6.9 Hz, 2H, C8-H); 7.89 (d, 
3
JH-F = 12.9 Hz, 2H, C5-
H); 8.66 (s, 2H, C2-H); 14.88 (br s, 2H, O3a'-H). 
13
C NMR (75 MHz): 8.2 (C2'', C3''); 25.2, 29.4, 
29.4, 29.4, 29.5, 29.6 (Cc-i); 33.2 (Cb); 35.3 (C1''); 41.0 (C3'); 45.3 (C5'); 49.3 (C6'); 50.1 (C2'); 
105.0 (d, 
3
JC-F = 3.0 Hz, C8); 107.9 (C3); 112.2 (d, 
2
JC-F = 23.2 Hz, C5); 119.9 (d, 
3
JC-F = 7.8 Hz, 
C4a); 138.9 ( C8a); 145.3 (d, 
2
JC-F = 10.3 Hz, C7); 147.4 (C2); 153.5 (d, 
1
JC-F = 249.8 Hz, C6); 
166.7 (C3a); 171.9 (Ca); 176.8 (d, 
4
JC-F = 2.6 Hz, C4). 
19
F NMR (282 MHz): -120.94 – -121.01 
(
4
JF-H = 7.0 Hz, 
3
JF-H = 12.7 Hz). MS CI (DCI/NH3): C52H66F2N6O8, m/z 941.8 [M+H]
+
. 
Elemental Anal. (C52H66F2N6O8 · 2H2O) C, H, N: calcd, 63.93, 7.17, 8.61; found, 63.94, 7.01, 
9.22. 
 
Figure 57 Atom numbering of CIP ―di-oxoethyl esters‖ 
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General procedure for the synthesis of bis(7-(4-(2-Oxoethylalcanoate)piperazin-1-
yl)) CIP derivatives (9a-f) termed CIP “di-oxoethyl esters”. To a solution of carboxylic diacid 
(0.5 mmole) in DMF (10 mL), Cs2CO3 (0.32 g, 1.00 mmole) was added and the reaction mixture 
was stirred at 50-60ºC for 1 hour. Then N-chloroacetylciprofloxacin (0.42 g, 1.03 mmole) and 
TBAI (0.37 g, 1.00 mmole) were added and the mixture was stirred at the previously mentioned 
temperature for 72h. The solvent was removed under reduced pressure and 20 mL of aqueous 
HCl 1M was added to the residue. The obtained solid was filtered and washed with aqueous HCl 
1M, water, ethanol and petroleum ether. The remaining solid residue was purified by column 
chromatography (CH2Cl2/MeOH from 10/0.3 to 10/0.5). 
 
bis(7-(4-Oxoethyldecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (9a). Obtained from decanedioïc acid (n=8) as a pale yellow 
solid in 42 % yield (200 mg). Due to the low solubility of this compound, even in DMSO-d6, no 
13
C NMR could be obtained. 
1
H NMR (300 MHz, DMSO-d6): 1.21-1.34 (m, 12H, C2''-H, C3''-H, 
Cf-H, Cg-H); 1.40 (dd, 
3
Jcis=13.5 Hz, 
3
Jtrans=6.9 Hz, 4H, C2''-H, C3''-H);  1.67 (quint, 
3
Jd e=7.5 Hz, 
3
Je f=7.0, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.5Hz, 4H, Cd-H); 3.32 – 3.37 (m, 8H, C3'-H, C5'-H); 3.54 
(m, 2H, C1''-H); 3.66 (m, 4H, C2'-H); 3.87 (m, 4H, C6'-H); 4.78 (s, 4H, Cb-H); 7.38 (d, 
4
JH-F = 6.6 
Hz, 2H, C8-H); 8.07 (d, 
3
JH-F = 12.6Hz, 2H, C5-H); 8.79 (s, 2H, C2-H); 14.86 (br s, 2H, O3a'-H). 
19
F NMR (282 MHz, DMSO-d6): -121.28 – -121.35 (dd, 
3
JH-F = 12.7 Hz, 
4
JH-F = 7.0 Hz). MS CI 
(DCI/NH3): C48H54F2N6O12, m/z 945.6 [M+H]
+
. Elemental Anal. (C48H54F2N6O12 · 1.2 H2O); C, 
H, N: calcd, 59.68, 5.88, 8.70; found, 59.65, 5.96, 8.67. 
 
bis(7-(4-Oxoethyldodecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-
oxoquinoline-3-carboxylic acid) (9b). Obtained from dodecanedioïc acid (n=10) as a pale 
yellow solid in 47 % yield (200 mg). 
1
H NMR (300 MHz, DMSO-d6): 1.21 – 1.32 (m, 16H, C2''-
H, C3''-H, Cf-h-H); 1.40 (dd, 
3
Jcis=13.2 Hz, 
3
Jtrans=6.6 Hz, 4H, C2''-H, C3''-H); 1.70 (quint, 
3
Jd e=7.5 Hz, 
3
Je f=7.0 Hz, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.5 Hz, 4H, Cd-H); 3.32 – 3.37 (m, 8H, C3'-
H,  C5'-H); 3.55 (m, 2H, C1''-H); 3.66 (m, 4H, C2'-H); 3.88 (m, 4H, C6'-H); 4.78 (s, 4H, Cb-H); 
7.38 (d, 
4
JH-F = 6.5 Hz, 2H, C8-H); 8.07 (d, 
3
JH-F = 12.6 Hz, 2H, C5-H); 8.78 (s, 2H, C2-H); 14.89 
(br s, 2H, O3a'-H).
 13
C NMR (125 MHz, DMSO-d6): 8.0 (C2'', C3''); 24.9 (Ch); 29.2, 29.1, 28.8 (Ce-
g); 33.7 (Cd); 36.3 (C1''); 41.5 (C3'); 44.5 (C5'); 48.9 (C2'); 49.2 (C6'); 61.6 (Cb); 107.1 (d, 
3
JC-F = 3 
Hz, C8); 107.4 (C3); 111.5 (d, 
2
JC-F = 24 Hz, C5); 119.7 (d, 
3
JC-F = 8 Hz, C4a); 139.6 (C8a); 145.3 
(d, 
2
JC-F = 10.4 Hz, C7); 148.5 (C2); 153.4 (d, 
1
JC-F = 249.0 Hz, C6); 165.5 (Cc); 166.3 (C3a);  
172.9 (Ca); 176.8 (d, 
4
JC-F = 2.3 Hz, C4). 
19
F NMR (282 MHz, DMSO-d6): -121.31 – -121.38 (dd, 
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3
JH-F=12.5 Hz, 
4
JH-F=6.6Hz). MS CI (DCI/NH3): C50H58F2N6O12, m/z found, 973.6 [M+H]
+
 
Elemental Anal. (C50H58F2N6O12 · 1.9 H2O); C, H, N: calcd, 59.65, 6.18, 8.35; found, 59.49, 
5.94, 8.56. 
 
bis(7-(4-Oxoethyltetradecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-
dihydro-4-oxoquinoline-3-carboxylic acid) (9c). Obtained from tetradecanedioïc acid (n=12) 
as a pale yellow solid in 56% yield (250 mg). 
1
H NMR (500 MHz): 1.20 – 1.32 (m, 20H, C2''-H, 
C3''-H, Cf-i-H); 1.43 (dd, 
3
Jcis = 13.2 Hz, 
3
Jtrans = 6.6 Hz, 4H,  C2''-H, C3''-H); 1.69 (quint, 
3
Jd-e=7.5 
Hz, 
3
Je-f = 6.9 Hz, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.5 Hz, 4H, Cd-H); 3.32 – 3.37 (2m, 8H, C3'-H, C5'-
H);  3.55 (m, 2H, C1''-H); 3.66 (m, 4H, C2'-H); 3.87 (m, 4H, C6'-H); 4.78 (s, 4H, Cb-H); 7.38 (d, 
4
JH-F = 6.6 Hz, 2H, C8-H); 8.05 (d, 
3
JH-F = 12.6 Hz, 2H, C5-H); 8.79 (s, 2H, C2-H); 14.87 (br s, 
2H, O3a'-H). 
13
C NMR (125 MHz): 8.2 (C2'', C3''); 24.9 (Ci); 29.5, 29.5, 29.4, 29.3 (Ce-h); 33.9 
(Cd); 35.3 (C1''); 41.5 (C3'); 44.5 (C5'); 49.3 (C2'); 50.0 (C6'); 58.6 (Cb); 105.3 (d, 
3
JC-F = 2.9 Hz, 
C8); 108.2 (C3); 112.7 (d, 
2
JC-F = 23.3 Hz, C5); 120.5 (d, 
3
JC-F = 7.9 Hz, C4a); 138.9 (C8a); 145.2 
(d, 
2
JC-F = 10.5 Hz, C7); 147.6 (C2); 153.5 (d, 
1
JC-F = 251.4 Hz, C6); 165.3 (Cc); 166.8 (C3a); 
173.5 (Ca); 177.1 (d, 
4
JC-F = 2.5 Hz, C4). 
19
F NMR (282 MHz): 121.28 – -121.35 (dd, 3JH-F = = 
12.9 Hz, 
4
JH-F = 7.0 Hz). MS CI (DCI/NH3): C52H62F2N6O12, m/z 1001.7 [M+H]
+
. Elemental 
Anal. (C52H62F2N6O12 · 0.9 H2O); C, H, N: calcd, 61.39, 6.32, 8.26; found, 61.22, 6.24, 8.66. 
 
bis(7-(4-Oxoethylpentadecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-
dihydro-4-oxoquinoline-3-carboxylic acid) (9d). Obtained from pentadecanedioïc acid (n=13) 
as a pale yellow solid in 56% yield (260 mg). 
1
H NMR (300 MHz): 1.21 – 1.45 (m, 26H, C2''-H, 
C3''-H, Cf-j-H,); 1.65 (quint, 
3
Jd-e = 7.8 Hz, 
3
Je-f = 7.2 Hz, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.8 Hz, 4H, 
Cd-H); 3.32 – 3.38 (2m, 8H, C3'-H, C5'-H); 3.56 (m, 2H, C1''-H); 3.66 (m, 4H, C2'-H); 3.87 (m, 
4H, C6'-H); 4.78 (s, 4H, Cb-H); 7.37 (d, 
4
JH-F = 6.9 Hz, 2H, C8-H); 8.00 (d, 
3
JH-F = 12.6 Hz, 2H, 
C5-H); 8.74 (s, 2H, C2-H); 14.87 (br s, 2H, O3a'-H).
 13
C NMR (75 MHz): 8.2 (C2'', C3''); 24.7 (Cj); 
29.0, 29.2, 29.3, 29.4, 29.5 (Ce-i); 33.9 (Cd); 35.3 (C1''); 41.5 (C3'); 44.2 (C5'); 49.2 (C2'); 49.8 ( 
C6'); 60.9 (Cb); 105.2 (d, 
3
JC-F = 2.7 Hz, C8); 107.9 (C3); 112.3 (d, 
2
JC-F = 23.1 Hz, C5); 120.1 (d, 
3
JC-F = 7.7 Hz, C4a); 138.9 ( C8a); 145.2 (d, 
2
JC-F = 10.4 Hz, C7); 147.4 (C2); 153.5 (d, 
1
JC-F = 
249.8 Hz, C6); 165.2 (Cc); 166.6 (C3a); 173.4 (Ca); 176.8 (d, 
4
JC-F = 2.4 Hz, C4). 
19
F NMR (282 
MHz): -121.06 – -121.13 (dd, 3JH-F = 12.7 Hz, 
4
JH-F = 6.0 Hz); MS CI (DCI/NH3): 
C53H64F2N6O12, m/z 1015.4 [M+H]
+
. Elemental Anal. (C53H64F2N6O12 · 1H2O) C, H, N: calcd, 
61.62, 6.44, 8.13; found, 61.78, 6.56, 8.12. 
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bis(7-(4-Oxoethylhexadecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-
4-oxoquinoline-3-carboxylic acid) (9e). Obtained from hexadecanedioïc acid (n=14) as a pale 
yellow solid in 41% yield (190 mg). 
1
H NMR (500 MHz) : 1.21 (dd, 
3
Jcis = 10.5 Hz, 
3
Jtrans = 7.5 
Hz, 4H, C2''-H, C3''-H); 1.24 –1.34 (m, 20H, Cf-j-H); 1.40 (dd, 
3
Jcis = 14.0 Hz, 
3
Jtrans = 7.5 Hz, 4H, 
C2''-H, C3''-H); 1.67 (quint, 
3
Jd-e = 7.5 Hz, 
3
Je-f = 7.5 Hz, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.5 Hz, 4H, 
Cd-H); 3.31 – 3.38 (2 m, 8H, C3'-H, C5'-H); 3.55 (quint, 
3
J = 3.5 and 7.5 Hz, 2H, C1''-H); 3.66 (m, 
4H, C2'-H); 3.87 (m, 4H, C6'-H); 4.78 (s, 4H, Cb-H); 7.37 (d, 
4
JH-F = 7.0 Hz, 2H, C8-H); 8.00 (d, 
2H, 
3
JH-F = 12.5 Hz, C5-H); 8.74 (s, 2H, C2-H); 14.87 (br s, 2H, O3a'-H). 
13
C NMR (125 MHz): 
8.3 (C2'', C3''); 24.8 (Cj); 29.6, 29.5, 29.4, 29.2, 29.0 (Ce-i); 33.9 (Cd); 35.3 (C1''); 41.0 (C3'); 45.3 
(C5'); 49.2 (C2'); 49.9 ( C6'); 60.9 (Cb); 105.2 (d, 
3
JC-F = 3.0 Hz, C8); 108.2 (C3); 112.6 (d, 
2
JC-F = 
23.1 Hz, C5); 120.4 (d, 
3
JC-F = 7.8 Hz, C4a); 138.9 (C8a); 145.2 (d, 
2
JC-F = 10.3 Hz, C7); 147.6 
(C2); 153.5 (d, 
1
JC-F = 249.8 Hz, C6); 165.3 (Cc); 166.8 (C3a); 173.5 (Ca); 177.0 (d, 
4
JC-F = 2.5 Hz, 
C4). 
19
F NMR (282 MHz): -121.20 – -121.27 (dd, 3JH-F  = 12.7 Hz, 
4
JH-F = 7.0 Hz); MS CI 
(DCI/NH3): C54H66F2N6O12, m/z 1029.6 [M+H]
+
. Elemental Anal. (C54H66F2N6O12 · 2.6H2O) C, 
H, N: calcd, 60.28, 6.67, 7.81; found, 60.20, 6.50, 7.51. 
 
bis(7-(4-Oxoethyloctadecanoate)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-
4-oxoquinoline-3-carboxylic acid) (9f). Obtained from octadecanedioïc acid (n=16) as a pale 
yellow solid in 75% yield (330 mg). 
1
H NMR (500 MHz) : 1.21 (dd, 
3
Jcis = 10.5 Hz, 
3
Jtrans = 7.0 
Hz, 4H, C2''-H, C3''-H); 1.24 – 1.34 (m, 24H, Cf-k-H), 1.40 (dd, 
3
Jcis = 13.5 Hz, 
3
Jtrans = 7.0 Hz, 
4H, C2''-H, C3''-H), 1.68 (quint, 
3
Jd-e = 7.5 Hz, 
3
Je-f = 7.0 Hz, 4H, Ce-H); 2.45 (t, 
3
JH-H = 7.5 Hz, 
4H, Cd-H); 3.31 – 3.38 (2 m, 8H, C3'-H, C5'-H); 3.55 (quint, 
3
J = 3.5 and 7.0 Hz, 2H, C1''-H); 3.66 
(m, 4H, C2'-H); 3.87 (m, 4H, C6'-H); 4.78 (s, 4H, Cb-H); 7.37 (d, 
4
JH-F = 7.0 Hz, 2H, C8-H); 8.05 
(d, 
3
JH-F = 12.5 Hz, 2H, C5-H); 8.78 (s, 2H, C2-H); 14.87 (br s, 2H, O3a'-H). 
13
C NMR (125 
MHz): 8.3 (C2'', C3''); 24.8 (Ck); 29.1, 29.2, 29.4, 29.5, 29.6, 29.7 (Ce-j); 33.9 (Cd); 35.3 (C1''); 
41.5 (C3'); 44.5 (C5'); 49.3 (C2'); 50.0 ( C6'); 60.9 (Cb); 105.2 (d, 
3
JC-F = 2.9 Hz, C8); 108.3 (C3); 
112.7 (d, 
2
JC-F = 23.1 Hz, C5); 120.6 (d, 
3
JC-F = 7.8 Hz, C4a); 138.9 (C8a); 145.2 (d, 
2
JC-F = 10.5 
Hz, C7); 147.7 (C2); 153.6 (d, 
1
JC-F = 249.8 Hz, C6); 165.3 (Cc); 166.8 (C3a); 173.5 (Ca); 177.1  
(d, 
4
JC-F = 2.4 Hz, C4). 
19
F NMR (282 MHz): -121.23 – -121.30 (dd, 3JH-F = 12.7 Hz, 
4
JH-F = 7.0 
Hz); MS CI (DCI/NH3): C56H70F2N6O12, m/z 1057.6 [M+H]
+
. Elemental Anal. (C56H70F2N6O12 · 
1H2O) C, H, N: calcd, 62.56, 6.75, 7.82; found, 62.29, 6.78, 7.92. 
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Figure 58 Atom numbering for LEV ―mono-acyloxymethyl esters‖ 
 
General procedure for the synthesis of (3S)-6-[(Alkanoyloxy)methyl]9-fluoro-2,3-
dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-
6-carboxylates termed LEV “acyloxymethyl esters” (14a-i) under thermal conditions ( ): 
LEV (180 mg, 0.5 mmol) and grinded K2CO3 (69 mg, 0.5 mmol) were mixed with 20 mL of dry 
DMF and left stirring at 90ºC for 20 min. The corresponding chloromethyl alkanoate was added 
(0.5 mmol) and reaction mixture was stirred at 90ºC for 1h. Then it was diluted with 
dichloromethane to 50 mL, washed by 5% aqueous solution of sodium chloride (5×100 mL). 
Organic layer was dried over anhydrous MgSO4 and concentrated on rotary evaporator to 
provide crude product which was further purified by column chromatography. 
 
Procedure for the synthesis of 14a under microwave activation (MW): A mixture of 
LEV (100 mg, 0.276 mmol) and K2CO3 (76 mg, 0.552 mmol) in acetonitrile (2.5 mL) was heated 
to 300 W/ 90 ºC and maintained at this temperature for 20 min. After cooling, (n-Bu)4NI (20 mg, 
0.055 mmol) and chloromethylpropanoate (52 L, 0.414 mmol) were added. The reaction 
mixture was vigorously stirred at 300 W/90 ºC for 1 h. The mixture was cooled and concentrated 
in vacuo. Water (50 mL) and CH2Cl2 (50 mL) were then added to the residue. The organic layer 
was washed with water (2 × 50 mL). This aqueous layer was extracted with CH2Cl2 (30 mL). 
The organic layers were separated, washed with water (3 × 30 mL), dried over anhydrous 
Na2SO4 and evaporated. The remaining residue was purified by flash chromatography on silica 
gel. 
 
(3S)-6-[(Butanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14a). The procedure 
described above ( ) applied to C3H7COOCH2Cl (62 L, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 35-70μm; NEt3/Acetone 2/100) and subsequent acetone wash (10 
mL) 143 mg (59%) of the title compound as a white solid. Rf 0.19 (CH2Cl2/MeOH, 90/10). m.p. 
210ºC. 1H NMR (300 MHz): 0.96 (t, 3JH-H = 7.2 Hz, 3H, Ce-H); 1.52 (d, 
3
JH-H = 6.8  Hz, 3H, C3a-
H); 1.68 (sext, 
3
JH-H = 7.4 Hz, 2H, Cd-H); 2.37 (s, 3H, C4'a-H); 2.39 (t, 
3
JH-H = 7.4 Hz, 2H, Cc-H); 
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2.55 (m, 4H, C3'-H, C5'-H); 3.35 (m, 4H, C2'-H, C6'-H); 4.28 – 4.61 (m, 3H, C2-H, C3-H); 5.95 
(AB system, 
2
JH-H = 5.6 Hz, 2H, Ca-H); 7.38 (d, 
3
JH-F = 12.5 Hz, 1H, C8-H); 8.17 (s, 1H, C5-H). 
13
C NMR (75 MHz): 13.5 (Ce); 18.1 (Cd); 18.3 (C3a); 35.8 (Cc); 46.4 (C4'a); 50.5 (d, 
4
JC-F = 4.2 
Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.2 (d, 
2
JC-F = 24.1 Hz, C8); 107.9 
(C6); 122.9 (d, 
3
JC-F = 8.5 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.9 (d, 
2
JC-F = 14.4 Hz, 
C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 163.4 (C6a); 
172.5 (d, 
4
JC-F = 2.7 Hz, C7); 172.6 (Cb). 
19
F NMR (282 MHz): -120.9 (d, 
3
JF-H = 12.4 Hz). MS-
ESI (positive mode, MeOH) m/z 462.5 [M+H
+
]. Elemental Anal. (C23H28FN3O6); C, H, N: calcd, 
59.86, 6.12, 9.11; found, 59.57, 5.88, 9.02. 
 
(3S)-6-[(Hexanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14b). The procedure 
described above ( ) applied to C5H11COOCH2Cl (82 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 35-70μm; NEt3/Acetone 1/100) 171 mg (69%) of the title compound 
as a white solid. Rf 0.22 (CH2Cl2/MeOH, 90/10). m.p. 190ºC. 
1
H NMR (300 MHz): 0.89 (t, 
3
JH-H 
= 6.9 Hz, 3H, Cg-H); 1.22 – 1.37 (m, 4H, Ce-H, Cf-H); 1.53 (d, 
3
JH-H = 6.8 Hz, 3H, C3a-H); 1.66 
(m, 2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 (t, 
3
JH-H = 7.4 Hz, 2H, Cc-H); 2.57 (m, 4H, C3'-H, C5'-
H); 3.36 (m, 4H, C2'-H, C6'-H); 4.32 – 4.55 (m, 3H, C2-H, C3-H); 5.95 (AB system, 
2
JH-H = 5.6 
Hz, 2H, Ca-H); 7.44 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.21 (s, 1H, C5-H). 
13
C NMR (75 MHz): 
13.9 (Cg); 18.3 (C3a); 22.3 (Cf); 24.3 (Ce); 31.2 (Cd); 34.0 (Cc); 46.4 (C4'a); 50.5 (d, 
4
JC-F = 4.2 
Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.4 (d, 
2
JC-F = 23.7 Hz, C8); 108.0 
(C6); 123.0 (d, 
3
JC-F = 7.8 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.9 (d, 
2
JC-F = 14.2 Hz, 
C10); 139.6 (d, 
3
JC-F = 6.7 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 163.4 (C6a); 
172.5 (d, 
4
JC-F = 2.3 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -121.0 (d, 
3
JF-H = 11.4 Hz). MS-
ESI (positive mode, MeOH) m/z 490.8 [M+H
+
]. Elemental Anal. (C25H32FN3O6); C, H, N: calcd, 
61.34, 6.59, 8.58; found, 61.52, 6.48, 8.49. 
 
(3S)-6-[(Octanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14c). The procedure 
described above ( ) applied to C7H15COOCH2Cl (96 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 35-70μm; NEt3/Acetone 1/100) 192 mg (75%) of the title compound 
as a white solid. Rf 0.23 (CH2Cl2/MeOH, 90/10). m.p. 189ºC. 
1
H NMR (300 MHz): 0.86 (t, 
3
JH-H 
= 6.8 Hz, 3H, Ci-H); 1.21 – 1.36 (m, 8H, Ce-h-H);1.53 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.60 – 1.70 
(m, 2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 (t, 
3
JH-H = 7.2 Hz, 2H, Cc-H); 2.56 (m, 4H, C3'-H, C5'-
H); 3.36 (m, 4H, C2'-H, C6'-H); 4.33 – 4.54 (m, 3H, C2-H, C3-H); 5.96 (AB system, 
2
JH-H = 5.7 
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Hz, 2H, Ca-H); 7.41 (d, 
3
JH-F = 12.0 Hz, 1H, C8-H); 8.19 (s, 1H, C5-H). 
13
C NMR (75 MHz): 
14.0 (Ci); 18.3 (C3a); 22.6 (Ch); 24.6 (Cg); 28.9, 29.0 (Cf, Ce); 31.6 (Cd); 34.0 (Cc); 46.4 (C4'a); 
50.5 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.3 (d, 
2
JC-F = 
24.0 Hz, C8); 107.9 (C6); 123.0 (d, 
3
JC-F = 8.5 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.9 (d, 
2
JC-F = 14.2 Hz, C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 
163.4 (C6a); 172.5 (d, 
4
JC-F = 2.6 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -120.9 (d, 
3
JF-H = 
11.3 Hz). MS-ESI (positive mode, MeOH) m/z 518.8 [M+H]
+
. Elemental Anal. (C27H36FN3O6); 
C, H, N: calcd, 62.65, 7.01, 8.12; found, 62.67, 6.86, 8.12. 
 
(3S)-6-[(Decanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14d). The procedure 
described above ( ) applied to C9H19COOCH2Cl (110 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 35-70μm; NEt3/Acetone 1/100) 215 mg (79%) of the title compound 
as a white solid. Rf 0.24 (CH2Cl2/MeOH, 90/10). m.p. 189ºC. 
1
H NMR (300 MHz): 0.86 (t, 
3
JH-H 
= 6.8 Hz, 3H, Ck-H); 1.19 – 1.36 (m, 12H, Ce-j-H);1.53 (d, 
3
JH-H = 6.9 Hz, 3H, C3a-H); 1.64 (m, 
2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 (t, 
3
JH-H = 7.5 Hz, 2H, Cc-H); 2.57 (m, 4H, C3'-H, C5'-H); 
3.36 (m, 4H, C2'-H, C6'-H); 4.32 – 4.55 (m, 3H, C2-H, C3-H); 5.95 (AB system, 
2
JH-H = 5.7 Hz, 
2H, Ca-H); 7.41 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.20 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 
(Ck); 18.3 (C3a); 22.6 (Cj); 24.6 (Ci); 29.0, 29.2, 29.2, 29.4 (Ce-h); 31.8 (Cd); 34.0 (Cc); 46.4 (C4'a); 
50.5 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.3 (d, 
2
JC-F = 
24.1 Hz, C8); 107.9 (C6); 123.0 (d, 
3
JC-F = 8.5 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.9 (d, 
2
JC-F = 14.2 Hz, C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 
163.4 (C6a); 172.5 (d, 
4
JC-F = 2.7 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -121.0 (d, 
3
JF-H = 
11.3 Hz). MS-ESI (positive mode, MeOH) m/z 546.5 [M+H]
+
. Elemental Anal. (C29H40FN3O6 · 
1.2H2O); C, H, N: calcd, 61.40, 7.53, 7.41; found, 61.33, 7.00, 7.39. 
 
(3S)-6-[(Dodecanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14e). The procedure 
described above ( ) applied to C11H23COOCH2Cl (124 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 35-70μm; NEt3/Acetone 1/100) 233 mg (79%) of the title compound 
as a white solid. Rf 0.25 (CH2Cl2/MeOH, 99/1). m.p. 189ºC. 
1
H NMR (300 MHz): 0.88 (t, 
3
JH-H 
= 6.6 Hz, 3H, Cm-H); 1.21 – 1.35 (m, 16H, Ce-l-H); 1.53 (d, 
3
JH-H = 6.9 Hz, 3H, C3a-H); 1.65 (m, 
2H, Cd-H); 2.37 (s, 3H, C4'a-H); 2.40 (t, 
3
JH-H = 7.5 Hz, 2H, Cc-H); 2.56 (m, 4H, C3'-H, C5'-H); 
3.36 (m, 4H, C2'-H, C6'-H); 4.32 – 4.54 (m, 3H, C2-H, C3-H); 5.96 (AB system, 
2
JH-H = 5.4 Hz, 
2H, Ca-H); 7.44 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.20 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 
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(Cm); 18.3 (C3a); 22.7 (Cl); 24.6 (Ck); 29.1, 29.3, 29.3, 29.5, 29.6 (Ce-j); 31.9 (Cd); 34.0 (Cc); 46.4 
(C4'a); 50.6 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.4 (d, 
2
JC-F = 24.0 Hz, C8); 108.0 (C6); 123.0 (d, 
3
JC-F = 8.5 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 
131.9 (d, 
2
JC-F = 14.2 Hz, C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 
Hz, C9); 163.4 (C6a); 172.5 (d, 
4
JC-F = 2.6 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -120.9 (d, 
3
JF-H = 11.3 Hz). MS-ESI (positive mode, MeOH) m/z 574.7 [M+H]
+
. Elemental Anal. 
(C31H44FN3O6 · 0.4H2O); C, H, N: calcd, 64.10, 7.77, 7.23; found, 64.01, 7.52, 7.20. 
 
(3S)-6-[(Tetradecanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14f). The procedure 
described above ( ) applied to C13H27COOCH2Cl (137 mg, 0.5 mmol) gave after purification by  
chromatography (30g SiO2, 6-35μm; MeOH/NEt3/CH2Cl2 7.5/1/100) and subsequent acetone 
wash (10 mL) 234 mg (77%) of the title compound as a white solid. Rf 0.27 (CH2Cl2/MeOH, 
90/10). m.p. 184ºC. 1H NMR (300 MHz): 0.88 (t, 3JH-H = 6.8 Hz, 3H, Co-H); 1.20 – 1.37 (m, 
20H, Ce-n-H);1.53 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.65 (m, 2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 
(t, 
3
JH-H = 7.5 Hz, 2H, Cc-H); 2.57 (m, 4H, C3'-H, C5'-H); 3.36 (m, 4H, C2'-H, C6'-H); 4.33 – 4.55 
(m, 3H, C2-H, C3-H); 5.95 (AB system, 
2
JH-H = 5.7 Hz, 2H, Ca-H); 7.42 (d, 
3
JH-F = 12.6 Hz, 1H, 
C8-H); 8.20 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 (Co); 18.3 (C3a); 22.7 (Cn); 24.6 (Cm); 29.1, 
29.3, 29.3, 29.5, 29.6, 29.6, 29.7 (Ce-l); 31.9 (Cd); 34.0 (Cc); 46.4 (C4'a); 50.5 (d, 
4
JC-F = 4.1 Hz, 
C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.4 (d, 
2
JC-F = 24.0 Hz, C8); 108.0 (C6); 
123.0 (d, 
3
JC-F = 8.4 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.9 (d, 
2
JC-F = 14.3 Hz, C10); 
139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 163.4 (C6a); 172.5 (d, 
4
JC-F = 2.6 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -121.0 (d, 
3
JF-H = 11.3 Hz). MS-ESI 
(positive mode, MeOH) m/z 602.5 [M+H]
+
. Elemental Anal. (C33H48FN3O6); C, H, N: calcd, 
65.87, 8.04, 6.98; found, 65.65, 7.79, 6.94. 
 
(3S)-6-[(Hexadecanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14g). The procedure 
described above ( ) applied to C15H31COOCH2Cl (152 mg, 0.5 mmol) gave after purification by  
chromatography (30g SiO2, 6-35μm; MeOH/NEt3/CH2Cl2 7.5/1/100) and subsequent acetone 
wash (10 mL) 252 mg (79%) of the title compound as a white solid. Rf 0.28 (CH2Cl2/MeOH, 
90/10). m.p. 182ºC. 1H NMR (300 MHz): 0.88 (t, 3JH-H = 6.8 Hz, 3H, Cq-H); 1.21 – 1.36 (m, 
24H, Ce-p-H); 1.53 (d, 
3
JH-H = 6.9 Hz, 3H, C3a-H); 1.65 (m, 2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 
(t, 
3
JH-H = 7.2 Hz, 2H, Cc-H); 2.56 (m, 4H, C3'-H, C5'-H); 3.36 (m, 4H, C2'-H, C6'-H); 4.33 – 4.55 
(m, 3H, C2-H, C3-H); 5.96 (AB system, 
2
JH-H = 5.6 Hz, 2H, Ca-H); 7.42 (d, 
3
JH-F = 12.3 Hz, 1H, 
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C8-H); 8.20 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 (Cq); 18.3 (C3a); 22.7 (Cp); 24.6 (Co); 29.1, 
29.3, 29.4, 29.5, 29.6, 29.6, 29.7, 29.7 (Ce-n); 31.9 (Cd); 34.0 (Cc); 46.4 (C4'a); 50.5 (d, 
4
JC-F = 4.1 
Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.4 (d, 
2
JC-F = 24.0 Hz, C8); 108.0 
(C6); 123.0 (d, 
3
JC-F = 8.4 Hz, C7a); 123.5 (d, 
4
JC-F = 1.5 Hz, C10b); 131.9 (d, 
2
JC-F = 14.3 Hz, 
C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 163.4 (C6a); 
172.5 (d, 
4
JC-F = 2.6 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -120.9 (d, 
3
JF-H = 11.3 Hz). MS-
ESI (positive mode, MeOH) m/z 630.7 [M+H]
+
. Elemental Anal. (C35H52FN3O6 · 0.2H2O); C, H, 
N: calcd, 66.37, 8.34, 6.63; found, 66.29, 8.03, 6.60. 
 
(3S)-6-[(Octadecanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14h). The procedure 
described above ( ) applied to C17H35COOCH2Cl (166 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 6-35μm; MeOH/NEt3/CH2Cl2 5/1/100) and subsequent acetone wash 
(10 mL) 266 mg (81 %) of the title compound as a white solid. Rf 0.29 (CH2Cl2/MeOH, 90/10). 
m.p. 180ºC. 1H NMR (300 MHz): 0.88 (t, 3JH-H = 6.8 Hz, 3H, Cs-H); 1.20 – 1.36 (m, 28H, Ce-r-
H); 1.52 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.64 (m, 2H, Cd-H); 2.39 (s, 3H, C4'a-H); 2.40 (t, 
3
JH-H = 
7.5 Hz, 2H, Cc-H); 2.58 (m, 4H, C3'-H, C5'-H); 3.37 (m, 4H, C2'-H, C6'-H); 4.33 – 4.57 (m, 3H, 
C2-H, C3-H); 5.95 (AB system, 
2
JH-H = 5.7 Hz, 2H, Ca-H); 7.39 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 
8.18 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 (Cs); 18.3 (C3a); 22.7 (Cr); 24.6 (Cq); 29.1, 29.3, 
29.4, 29.5, 29.6, 29.6, 29.6, 29.7, 29.7 (Ce-p); 31.9 (Cd); 34.0 (Cc); 46.3 (C4'a); 50.4 (d, 
4
JC-F = 4.1 
Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.3 (d, 
2
JC-F = 24.0 Hz, C8); 107.9 
(C6); 123.0 (d, 
3
JC-F = 8.4 Hz, C7a); 123.5 (d, 
4
JC-F = 1.4 Hz, C10b); 131.8 (d, 
2
JC-F = 14.3 Hz, 
C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.8 Hz, C9); 163.4 (C6a); 
172.5 (d, 
4
JC-F = 2.7 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -121.0 (d, 
3
JF-H = 11.3 Hz). MS-
ESI (positive mode, MeOH) m/z 658.5 [M+H]
+
. Elemental Anal. (C37H56FN3O6 · 0.5H2O); C, H, 
N: calcd, 66.64, 8.62, 6.30; found, 66.53, 8.22, 6.22. 
 
(3S)-6-[(Eicosanoyloxy)methyl]-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate (14i). The procedure 
described above ( ) applied to C19H39COOCH2Cl (180 mg, 0.5 mmol) gave after purification by 
chromatography (30g SiO2, 6-35μm; MeOH/NEt3/CH2Cl2 7.5/1/100) and subsequent acetone 
wash (2 mL) 269 mg (79%) of the title compound as a white solid. Rf 0.32 (CH2Cl2/MeOH, 
90/10). m.p. 181ºC. 1H NMR (300 MHz): 0.88 (t, 3JH-H = 6.8 Hz, 3H, Cu-H); 1.19 – 1.36 (m, 
32H, Ce-t-H); 1.53 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.65 (m, 2H, Cd-H); 2.38 (s, 3H, C4'a-H); 2.40 
(t, 
3
JH-H = 7.5 Hz, 2H, Cc-H); 2.57 (m, 4H, C3'-H, C5'-H); 3.36 (m, 4H, C2'-H, C6'-H); 4.31 – 4.56 
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(m, 3H, C2-H, C3-H); 5.96 (AB system, 
2
JH-H = 5.7 Hz, 2H, Ca-H); 7.44 (d, 
3
JH-F = 12.3 Hz, 1H, 
C8-H); 8.20 (s, 1H, C5-H). 
13
C NMR (75 MHz): 14.1 (Cu); 18.3 (C3a); 22.7 (Ct); 24.6 (Cs); 29.1, 
29.3, 29.4, 29.5, 29.6, 29.7, 29.7, 29.7 (Ce-r); 31.9 (Cd); 34.0 (Cc); 46.4 (C4'a); 50.5 (d, 
4
JC-F = 4.1 
Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.1 (C2); 79.5 (Ca); 105.4 (d, 
2
JC-F = 24.1 Hz, C8); 108.0 
(C6); 123.0 (d, 
3
JC-F = 8.5 Hz, C7a); 123.5 (d, 
4
JC-F = 1.5 Hz, C10b); 131.9 (d, 
2
JC-F = 14.3 Hz, 
C10); 139.6 (d, 
3
JC-F = 6.8 Hz, C10a); 145.6 (C5); 155.7 (d, 
1
JC-F = 245.9 Hz, C9); 163.4 (C6a); 
172.5 (d, 
4
JC-F = 2.6 Hz, C7); 172.8 (Cb). 
19
F NMR (282 MHz): -120.9 (d, 
3
JF-H = 12.5 Hz). MS-
ESI (positive mode, MeOH) m/z 686.5 [M+H]
+
. Elemental Anal. (C39H60FN3O6 · 0.4H2O); C, H, 
N: calcd, 67.58, 8.84, 6.06; found, 67.47, 8.71, 6.02. 
 
Figure 59 Atom numbering for LEV ―mono-amides‖ 
 
General procedure for the synthesis of (3S)-N-Alkyl-9-fluoro-2,3-dihydro-3-methyl-
10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamides 
termed LEV “mono-amides” (17a–j). To a cooled (0 ºC) and stirred mixture of LEV (361 mg, 
1 mmol) and TCA (0.2 mL, 2 mmol) in 5 mL of dry CH2Cl2 was added dropwise, under argon, a 
solution of TPP (525 mg, 2 mmol) in 1 mL of dry CH2Cl2. The reaction mixture was stirred for 4 
h at r.t. to give a yellow residue which was centrifugated, washed with CH2Cl2 (5 mL) and used 
without further purification. A suspension of this acyl chloride in 1 mL of dry CH2Cl2 was then 
treated with alkylamine (1 mmol) followed by triethylamine (303 mg, 3 mmol). The reaction 
mixture was allowed to react for 18 h at r.t. it was diluted to 25 mL with CH2Cl2 and washed 
with brine (3 × 50 mL). The organic layer was dried over anhydrous MgSO4, concentrated under 
reduced pressure to provide after flash chromatography on silica gel (30g SiO2, 20-45μm; 
MeOH/CH2Cl2 7.5/100) the desired compound. 
 
(3S)-N-Butyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17a). With C4H9NH2 (59 mg, 1 mmol) the 
procedure described above provided after purification 143mg (34%) of the title compound as a 
yellowish solid. Rf 0.14 (CH2Cl2/MeOH, 90/10). m.p. 160ºC. 
1
H NMR (300 MHz): 0.95 (t, 
3
JH-H 
= 7.4 Hz, 3H, Ce-H); 1.37 – 1.51 (m, 2H, Cd-H); 1.57 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.58 (m, 
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2H, Cc-H); 2.36 (s, 3H, C4'a-H); 2.56 (m, 4H, C3'-H, C5'-H); 3.28 – 3.51 (m, 6H, C2'-H, C6'-H, Cb-
H); 4.26 – 4.74 (m, 3H, C2-H, C3-H); 7.69 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.63 (s, 1H, C5-H), 
9.97 (t, 
3
JH-H = 5.6 Hz, 1H, N-H). 
13
C NMR (75 MHz, CDCl3): 13.8 (Ce); 18.2 (C3a); 20.3 (Cd); 
31.7 (Cc); 38.9 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.8 (C3); 55.7 (C3',C5'); 68.2 
(C2); 105.1 (d, 
2
JC-F = 23.9 Hz, C8); 111.3 (C6); 122.4 (d, 
3
JC-F = 8.7 Hz, C7a); 124.3 (d, 
4
JC-F = 
1.3 Hz, C10b); 131.8 (d, 
2
JC-F = 14.6 Hz, C10); 139.4 (d, 
3
JC-F = 6.7 Hz, C10a); 143.8 (C5); 155.8 
(d, 
1
JC-F = 245.8 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 3.0 Hz, C7). 
19
F NMR (282 MHz): -121.2 
(d, 
3
JF-H = 12.4 Hz). MS-ESI (positive mode, MeOH) m/z 417.3 [M+H]
+
. Elemental Anal. 
(C22H29FN4O3 · 0.3H2O); C, H, N: calcd, 62.63, 7.07, 13.28; found, 62.59, 6.99, 13.09. 
 
(3S)-N-Hexyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17b). With C6H13NH2 (101 mg, 1 mmol) 
the procedure described above provided after purification 166 mg (37%) of the title compound as 
a yellowish solid. Rf 0.15 (CH2Cl2/MeOH, 90/10). m.p. 113ºC. 
1
H NMR (300 MHz): 0.88 (t, 
3
JH-
H = 6.9 Hz, 3H, Cg-H); 1.25 – 1.47 (m, 6H, Cd-f-H); 1.57 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.62 (m, 
2H, Cc-H); 2.36 (s, 3H, C4'a-H); 2.55 (m, 4H, C3'-H, C5'-H); 3.28 – 3.49 (m, 6H, C2'-H, C6'-H, Cb-
H); 4.27 – 4.48 (m, 3H, C2-H, C3-H); 7.68 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.64 (s, 1H, C5-H), 
9.96 (t, 
3
JH-H = 5.4 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Cg); 18.3 (C3a); 22.6, 26.8, 29.6, 
31.6 (Cc-f); 39.3 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F = 3.8 Hz, C2', C6'); 54.8 (C3); 55.7 (C3',C5'); 68.2 
(C2); 105.1 (d, 
2
JC-F = 23.3 Hz, C8); 111.3 (C6); 122.4 (d, 
3
JC-F = 8.3 Hz, C7a); 124.3 (d, 
4
JC-F = 
1.5 Hz, C10b); 131.8 (d, 
2
JC-F = 14.3 Hz, C10); 139.4 (d, 
3
JC-F = 6.8 Hz, C10a); 143.8 (C5); 155.8 
(d, 
1
JC-F = 246.0 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 3.0 Hz, C7). 
19
F NMR (282 MHz): -121.2 
(d, 
3
JF-H = 12.4 Hz). MS-ESI (positive mode, MeOH) m/z 445.5 [M+H]
+
. Elemental Anal. 
(C24H33FN4O3); C, H, N: calcd, 64.84, 7.48, 12.60; found, 64.83, 7.35, 12.57. 
 
(3S)-N-Heptyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17c). With C7H15NH2 (115 mg, 1 mmol) the 
procedure described above provided after purification 184 mg (36%) as yellowish solid. Rf 0.16 
(CH2Cl2/MeOH, 90/10). m.p. 115 °C. 
1
H NMR (300 MHz): 0.87 (t, 
3
JH-H = 6.8 Hz, 3H, Ch-H); 
1.20–1.45 (m, 8H, Cd-g-H); 1.57 (d, 
3
JH-H = 6.7 Hz, 3H, C3a–H); 1.63 (m, 2H, Cc-H); 2.36 (s, 3H, 
C4‘a-H); 2.54 (m, 4H, C3‘-H and C5‘-H); 3.28–3.50 (m, 6H, Cb-H, C2‘-H and C6‘-H); 4.27–4.48 
(m, 3H, C2-H and C3-H); 7.68 (d, 
3
JH-F = 12.5 Hz, 1H, C8-H); 8.64 (s, 1H, C5-H); 9.98 (t, 
3
JH-H = 
5.4 Hz, 1H, N–H). 13C NMR (75 MHz): 14.1 (Ch); 18.2 (C3a); 22.6, 27.1, 29.0, 29.6, 31.7, 39.3 
(Cc-g); 46.4 (C4‘a); 50.6 (d, 
4
JC-F = 3.8 Hz, C2‘ and C6‘); 54.8 (C3); 55.7 (C3‘ and C5‘); 68.2 (C2); 
105.1 (d, 
2
JC-F = 24.0 Hz, C8); 111.3 (C6); 122.4 (d, 
3
JC-F = 9.0 Hz, C7a); 124.3 (d, 
4
JC-F = 1.5 Hz, 
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C10b); 131.8 (d, 
2
JC-F = 14.3 Hz, C10); 139.4 (d, 
3
JC-F = 6.8 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 
246.0 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 3.0 Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JH-F = 
12.5 Hz). MS (ESI, positive mode): m/z 459.1 [M+H]+. Elemental Anal. (C25H35FN4O3); C, H, 
N: 65.48, 7.69, 12.22; found, 65.41, 7.47, 12.22. 
 
(3S)-N-Octyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17d). With C8H17NH2 (129 mg, 1 mmol) 
the procedure described above provided after purification 168 mg (36%) of the title compound as 
a yellowish solid. Rf 0.17 (CH2Cl2/MeOH, 90/10). m.p. 122ºC. 
1
H NMR (300 MHz): 0.88 (t, 
3
JH-
H = 6.8 Hz, 3H, Ci-H); 1.21 – 1.47 (m, 10H, Cd-h-H); 1.58 (d, 
3
JH-H = 6.9 Hz, 3H, C3a-H); 1.63 
(m, 2H, Cc-H); 2.37 (s, 3H, C4'a-H); 2.56 (m, 4H, C3'-H, C5'-H); 3.29 – 3.51 (m, 6H, C2'-H, C6'-H, 
Cb-H); 4.26 – 4.47 (m, 3H, C2-H, C3-H); 7.71 (d, 
3
JH-F = 12.3 Hz, 1H, C8-H); 8.64 (s, 1H, C5-H), 
9.98 (t, 
3
JH-H = 5.6 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Ci); 18.2 (C3a); 22.7, 27.2, 29.2, 
29.3, 29.7, 31.8 (Cc-h); 39.3 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.8 (C3); 55.7 
(C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.0 Hz, C8); 111.3 (C6); 122.5 (d, 
3
JC-F = 8.7 Hz, C7a); 
124.3 (d, 
4
JC-F = 1.3 Hz, C10b); 131.8 (d, 
2
JC-F = 14.6 Hz, C10); 139.4 (d, 
3
JC-F = 6.7 Hz, C10a); 
143.8 (C5); 155.8 (d, 
1
JC-F = 245.9 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR 
(282 MHz): -121.2 (d, 
3
JF-H = 11.3 Hz). MS-ESI (positive mode, MeOH) m/z 473.2 [M+H]
+
. 
Elemental Anal. (C26H37FN4O3 · 0.5H2O); C, H, N: calcd, 64.84, 7.95, 11.63; found, 64.87, 7.72, 
11.67. 
 
(3S)-N-Decyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-
pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17e). With C10H21NH2 (157 mg, 1 mmol) 
the procedure described above provided after purification 176 mg (35%) of the title compound as 
a yellowish solid. Rf 0.17 (CH2Cl2/MeOH, 90/10). m.p. 133ºC. 
1
H NMR (300 MHz): 0.88 (t, 
3
JH-
H = 6.6 Hz, 3H, Ck-H); 1.19 – 1.47 (m, 14H, Cd-j-H); 1.58 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-H); 1.64 
(m, 2H, Cc-H); 2.37 (s, 3H, C4'a-H); 2.56 (m, 4H, C3'-H, C5'-H); 3.29 – 3.50 (m, 6H, C2'-H, C6'-H, 
Cb-H); 4.27 – 4.46 (m, 3H, C2-H, C3-H); 7.71 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.64 (s, 1H, C5-H), 
9.98 (t, 
3
JH-H = 5.6 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Ck); 18.2 (C3a); 22.7, 27.2, 29.3, 
29.4, 29.5, 29.6, 29.6, 31.9 (Cc-j); 39.3 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.8 
(C3); 55.7 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.0 Hz, C8); 111.3 (C6); 122.5 (d, 
3
JC-F = 8.7 Hz, 
C7a); 124.3 (d, 
4
JC-F = 1.3 Hz, C10b); 131.8 (d, 
2
JC-F = 14.5 Hz, C10); 139.4 (d, 
3
JC-F = 6.7 Hz, 
C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 245.9 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F 
NMR (282 MHz): -121.2 (d, 
3
JF-H = 11.3 Hz). MS-ESI (positive mode, MeOH) m/z 501.5 
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[M+H]
+
. Elemental Anal. (C28H41FN4O3 · 0.3H2O); C, H, N: calcd, 66.46, 8.29, 11.07; found, 
66.35, 7.97, 11.07. 
 
(3S)-N-Dodecyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17f). With C12H25NH2 (185 mg, 1 
mmol) the procedure described above provided after purification 197 mg (37%) of the title 
compound as a yellowish solid. Rf 0.19 (CH2Cl2/MeOH, 90/10). m.p. 101ºC. 
1
H NMR (300 
MHz): 0.88 (t, 
3
JH-H = 6.8 Hz, 3H, Cm-H); 1.19 – 1.47 (m, 18H, Cd-l-H); 1.58 (d, 
3
JH-H = 6.6 Hz, 
3H, C3a-H); 1.63 (m, 2H, Cc-H); 2.37 (s, 3H, C4'a-H); 2.55 (m, 4H, C3'-H, C5'-H); 3.28 – 3.49 (m, 
6H, C2'-H, C6'-H, Cb-H); 4.26 – 4.46 (m, 3H, C2-H, C3-H); 7.71 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 
8.64 (s, 1H, C5-H), 9.98 (t, 
3
JH-H = 5.6 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Cm); 18.2 (C3a); 
22.7, 27.2, 29.3, 29.4, 29.5, 29.6, 29.6, 29.7, 31.9 (Cc-l); 39.3 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F = 4.1 
Hz, C2', C6'); 54.8 (C3); 55.7 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.0 Hz, C8); 111.3 (C6); 122.5 
(d, 
3
JC-F = 8.8 Hz, C7a); 124.3 (d, 
4
JC-F = 1.2 Hz, C10b); 131.8 (d, 
2
JC-F = 14.6 Hz, C10); 139.4 (d, 
3
JC-F = 6.7 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 245.9 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 
2.9 Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JF-H = 12.4 Hz). MS-ESI (positive mode, MeOH) 
m/z 529.6 [M+H]
+
. Elemental Anal. (C30H45FN4O3); C, H, N: calcd, 68.15, 8.58, 10.60; found, 
68.79, 8.06, 10.70. 
 
(3S)-N-Tetradecyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17h). With C14H29NH2 (213 mg, 1 
mmol) the procedure described above provided after purification 216 mg (39%) of the title 
compound as a yellowish solid. Rf 0.20 (CH2Cl2/MeOH, 90/10). m.p. 90ºC.
1
H NMR (300 MHz): 
0.89 (t, 
3
JH-H = 6.8 Hz, 3H, Co-H); 1.20 – 1.47 (m, 22H, Cd-n-H); 1.58 (d, 
3
JH-H = 6.6 Hz, 3H, C3a-
H); 1.64 (m, 2H, Cc-H); 2.38 (s, 3H, C4'a-H); 2.57 (m, 4H, C3'-H, C5'-H); 3.30 – 3.50 (m, 6H, C2'-
H, C6'-H, Cb-H); 4.27 – 4.47 (m, 3H, C2-H, C3-H); 7.72 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 8.64 (s, 
1H, C5-H), 9.98 (t, 
3
JH-H = 5.6 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Co); 18.2 (C3a); 22.7, 
27.2, 29.4, 29.4, 29.5, 29.6, 29.7, 29.7, 29.7, 29.7, 31.9 (Cc-n); 39.3 (Cb), 46.4 (C4'a); 50.6 (d, 
4
JC-F 
= 4.1 Hz, C2', C6'); 54.8 (C3); 55.7 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.0 Hz, C8); 111.3 (C6); 
122.5 (d, 
3
JC-F = 8.8 Hz, C7a); 124.3 (d, 
4
JC-F = 1.3 Hz, C10b); 131.8 (d, 
2
JC-F = 14.6 Hz, C10); 
139.4 (d, 
3
JC-F = 6.6 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 245.9 Hz, C9); 164.8 (C6a); 175.4 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JF-H = 14.1 Hz). MS-ESI (positive mode, 
MeOH) m/z 557.6 [M+H]
+
. Elemental Anal. (C32H49FN4O3); C, H, N: calcd, 69.03, 8.87, 10.06; 
found, 68.78, 8.67, 9.93. 
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(3S)-N-Pentadecyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-
oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide (17i). With C15H31NH2 (227 mg, 1 
mmol) the procedure described above provided after purification 231 mg (40%) of the title 
compound as a yellowish solid. Rf 0.20 (CH2Cl2/MeOH, 90/10). m.p. 87ºC. 
1
H NMR (300 
MHz): 0. 90 (t, 
3
JH-H = 6.6 Hz, 3H, Cp-H); 1.21 – 1.49 (m, 24H, Cd-o-H); 1.59 (d, 
3
JH-H = 6.6 Hz, 
3H, C3a-H); 1.65 (m, 2H, Cc-H); 2.38 (s, 3H, C4'a-H); 2.57 (m, 4H, C3'-H, C5'-H); 3.29 – 3.52 (m, 
6H, C2'-H, C6'-H, Cb-H); 4.28 – 4.49 (m, 3H, C2-H, C3-H); 7.72 (d, 
3
JH-F = 12.6 Hz, 1H, C8-H); 
8.65 (s, 1H, C5-H), 10.00 (t, 
3
JH-H = 5.7 Hz, 1H, N-H). 
13
C NMR (75 MHz): 14.1 (Cp); 18.3 
(C3a); 22.7, 27.2, 29.4, 29.4, 29.6, 29.7, 29.7, 29.7, 29.7, 29.7, 31.9 (Cc-o); 39.3 (Cb), 46.4 (C4'a); 
50.6 (d, 
4
JC-F = 4.1 Hz, C2', C6'); 54.9 (C3); 55.7 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.0 Hz, 
C8); 111.3 (C6); 122.5 (d, 
3
JC-F = 8.7 Hz, C7a); 124.3 (d, 
4
JC-F = 1.3 Hz, C10b); 131.9 (d, 
2
JC-F = 
14.6 Hz, C10); 139.4 (d, 
3
JC-F = 6.8 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 245.8 Hz, C9); 164.8 
(C6a); 175.4 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JF-H = 12.4 Hz). MS-ESI 
(positive mode, MeOH) m/z 571.6 [M+H]
+
. Elemental Anal. (C33H51FN4O3 · 0.6H2O);); C, H, N: 
calcd, 69.44, 9.01, 9.82; found, 69.10, 8.93, 9.75. 
 
Figure 60 Atom numbering for LEV ―di-amides‖ 
 
General procedure for the preparation of bis((3S)-N-alkyl-9-fluoro-2,3-dihydro-3-
methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-
carboxamide termed LEV “di-amides” (18a-h). TCA (0.2 mL, 2 mmol) was added dropwise, 
to a solution of LEV (295 mg, 0.83 mmol) in dry CH2Cl2 (5 mL). Then, a solution of 
triphenylphosphine (511 mg, 2 mmol) in CH2Cl2 (1 mL) was added dropwise, and the reaction 
mixture was left stirring from 0°C to r.t. for 4 hours. After filtration, the yellow residue (0.8 
mmol of acyl chloride) in 4 mL of dry CH2Cl2 was treated with diamine (0.4 mmol) followed by 
triethylamine (0.33 mL, 2.4 mmol). The reaction mixture was allowed to react for 18 h at r.t. The 
mixture was concentrated in vacuo, and the residue was washed with water. After filtration, the 
obtained residue was diluted with CH2Cl2, then diethyl ether was added to precipitate the desired 
compound which, after filtration, was purified by silica gel chromatography (CH2Cl2/MeOH 
10/0.3).  
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bis((3S)-N-butyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18a). The purification provided the 
desired compound (121 mg, 39%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.56 (d, 
3
JH-H = 
6.6 Hz, 3H, C3a-H); 1.74 (m, 4H, Cc-H); 2.36 (s, 6H, C4'a-H); 2.55 (m, 8H, C3'-H, C5'-H); 3.33 – 
3.51 (m, 12H, C2'-H, C6'-H, Cb-H); 4.26 – 4.31 (m, 2H, C3-H); 4.37 – 4.41 (m, 4H, C2-H); 7.67 
(d, 
3
JH-F = 12.6 Hz, 2H, C8-H); 8.61 (s, 2H, C5-H), 9.99 (t, 
3
JH-H = 5.7 Hz, 2H, N-H). 
13
C NMR 
(75 MHz): 18.2 (C3a); 27.2 (Cc); 38.8 (Cb), 46.3 (C4'a); 50.4 (d, 
4
JC-F = 4.0 Hz, C2', C6'); 54.7 (C3); 
55.6 (C3',C5'); 68.1 (C2); 104.9 (d, 
2
JC-F = 23.9 Hz, C8); 111.1 (C6); 122.3 (d, 
3
JC-F = 8.8 Hz, C7a); 
124.2 (d, 
4
JC-F = 0.9 Hz, C10b); 131.6 (d, 
2
JC-F = 14.5 Hz, C10); 139.3 (d, 
3
JC-F = 6.7 Hz, C10a); 
143.7 (C5); 155.6 (d, 
1
JC-F = 245.7 Hz, C9); 164.8 (C6a); 175.2 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR 
(282 MHz): -121.2 (d, 
3
JF-H = 12.4 Hz). MS CI (DCI/NH3): m/z 775.4 [M+H]
+
. Elemental Anal. 
(C40H48F2N8O6 · 1.5 H2O); C, H, N: calcd, 59.91, 6.41, 13.97; found, 60.05, 6.16, 13.82. 
 
bis((3S)-N-pentyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18b). The purification provided the 
desired compound (91 mg, 29%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.24 (m, 2H, Cd-
H); 1.56 (d, 
3
J  = 6.6 Hz, 6H, C3a-H); 1.68 (tt, 
3
J  = 7.2 Hz, 4H, Cc-H); 2.38 (s, 6H, C4‘a-H); 2.58 
(m, 8H, C3'-H, C5'-H); 3.33 –  3.47 (m, 12H, C2'-H, C6'-H, Cb-H); 4.26 – 4.31 (m, 2H, C3); 4.36 –  
4.42 (m, 4H, C2); 7.68 (d, 
3
JH-F = 12.6 Hz, 2H, C8); 8.62 (s, 2H, C5); 9.97 (t, 
3
J = 5.7 Hz, 2H, 
NH). 
13
C NMR (75 MHz): 18.2 (C3a); 24.6, 29.3, 39.1 (Cb-d); 46.3 (C4‘a); 50.5 (d, 
4
JC-F = 3.9 Hz, 
C2‘,C6‘); 54.7 (C3); 55.6 (C3‘,C5‘); 68.1 (C2); 105.0 (d, 
2
JC-F = 24 Hz, C8); 111.1 (C6); 122.3 (d, 
3
JC-F = 8.8 Hz, C7a);  124.2 (d, 
4
JC-F = 0.9 Hz, C10b); 131.6 (d, 
2
JC-F = 14.6 Hz, C10); 139.3 (d,
 3
JC-
F  = 6.7 Hz, C10a); 143.7 (C5); 155.7 (d, 
1
JC-F = 245.7 Hz, C9); 164.8 (C6a); 175.2 (d, 
4
JC-F = 2.9 
Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JH-F = 12.4 Hz). MS CI (DCI/NH3): m/z 789.3 
[M+H]
+
. Elemental Anal. (C41H50F2N8O6 · 2 H2O); C, H, N: calcd, 59.70, 6.60, 13.58; found, 
59.67, 6.53, 13.40. 
 
bis((3S)-N-hexyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18c). The purification provided the 
desired compound (132 mg, 41%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.43 (m, 4H, Cd-
H); 1.53 (d, 
3
JH-H = 6.9 Hz, 6H, C3a-H); 1.63 (tt, 
3
J  = 6.6 Hz, 4H, Cc-H); 2.33 (s, 6H, C4'a-H); 
2.52 (m, 8H, C3'-H, C5'-H); 3.30 – 3.44 (m, 12H, C2'-H, C6'-H, Cb-H); 4.25 – 4.29 (m, 2H, C3-H); 
4.36 – 4.42 (m, 4H, C2-H); 7.65 (d, 
3
JH-F = 12.6 Hz, 2H, C8-H); 8.60 (s, 2H, C5-H), 9.94 (t, 
3
JH-H 
= 5.7 Hz, 2H, N-H). 
13
C NMR (75 MHz): 18.2 (C3a); 26.8 (Cd); 29.5 (Cc); 39.1 (Cb); 46.3 (C4'a); 
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50.5 (d, 
4
JC-F = 4.0 Hz, C2', C6'); 54.7 (C3); 55.6 (C3',C5'); 68.1 (C2); 105.0 (d, 
2
JC-F = 24.0 Hz, 
C8); 111.2 (C6); 122.4 (d, 
3
JC-F = 8.7 Hz, C7a); 124.2 (d, 
4
JC-F = 1.0 Hz, C10b); 131.6 (d, 
2
JC-F = 
14.6 Hz, C10); 139.3 (d, 
3
JC-F = 6.6 Hz, C10a); 143.7 (C5); 155.7 (d, 
1
JC-F = 245.7 Hz, C9); 164.7 
(C6a); 175.2 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR (282 MHz): -121.3 (d, 
3
JF-H = 12.4 Hz). MS CI 
(DCI/NH3): m/z 803.3 [M+H]
+
. Elemental Anal (C42H52F2N8O6 · 1.5 H2O); C, H, N: calcd, 60.78, 
6.68, 13.50; found, 60.43, 6.29, 13.51. 
 
bis((3S)-N-heptyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18d). The purification provided the 
desired compound (120 mg, 37%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.40 (m, 6H, Cd,e-
H); 1.56 (d, 
3
J  = 6.9 Hz, 6H, C3a); 1.63 (tt, 
3
J  = 6.6 Hz, 4H, Cc-H); 2.37 (s, 6H, C4‘a); 2.56 (m, 
8H, C3'-H, C5'-H); 3.31 – 3.46 (m, 12H, C2'-H, C6'-H, Cb-H); 4.26 – 4.31 (m, 2H, C3-H); 4.37 – 
4.41 (m, 4H, C2-H); 7.69 (d, 
3
JH-F = 12.6 Hz, 2H, C8-H); 8.62 (s, 2H, C5-H); 9.94 (t, 
3
J = 5.7 Hz, 
2H, NH). 
13
C NMR (75 MHz): 18.2 (C3a); 26.9, 29, 29.5, 39.2 (Cb-e); 46.3 (C4‘a); 50.5 (d, 
4
JC-F = 
4 Hz, C2', C6'); 54.7 (C3); 55.6 (C3',C5'); 68.1 (C2); 105.0 (d, 
2
JC-F = 23.9 Hz, C8); 111.2 (C6); 
122.4 (d, 
3
JC-F = 8.8 Hz, C7a); 124.2 (d, 
4
JC-F = 1.0 Hz, C10b); 131.7 (d, 
2
JC-F = 14.6 Hz, C10); 
139.3 (d,
 3
JC-F  = 6.8 Hz, C10a); 143.7 (C5); 155.7 (d, 
1
JC-F = 245.7 Hz, C9); 164.7 (C6a);175.2 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR (282 MHz): -121.3 (d, 
3
JH-F = 12.4 Hz). MS CI (DCI/NH3):  m/z 
817.4 [M+H]
+
. Elemental Anal. (C43H54F2N8O6 · 1 H2O); C, H, N: calcd, 61.86, 6.76, 13.42; 
found, 61.52, 6.69, 13.21. 
 
bis((3S)-N-octyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18e). The purification provided the 
desired compound (67 mg, 23%) as a pale yellow solid.
 1
H NMR (300 MHz): 1.28 (m, 8H, Cd-H, 
Ce-H); 1.56 (d, 
3
JH-H = 6.6 Hz, 6H, C3a-H); 1.61 (tt, 
3
J  = 7.2 Hz, 4H, Cc-H); 2.39 (s, 6H, C4'a-H); 
2.59 (m, 8H, C3'-H, C5'-H); 3.33 – 3.45 (m, 12H, C2'-H, C6'-H, Cb-H); 4.26 – 4.30 (m, 2H, C3-H); 
4.37 – 4.41 (m, 4H, C2-H); 7.69 (d, 
3
JH-F = 12.3 Hz, 2H, C8-H); 8.62 (s, 2H, C5-H), 9.94 (t, 
3
JH-H 
= 5.7 Hz, 2H, N-H). 
13
C NMR (75 MHz): 18.2 (C3a); 27.1, 29.3 (Cd, Ce); 29.6 (Cc); 39.3 (Cb), 
46.2 (C4'a); 50.4 (d, 
4
JC-F = 3.8 Hz, C2', C6'); 54.8 (C3); 55.6 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 
24.1 Hz, C8); 111.4 (C6); 122.6 (d, 
3
JC-F = 9.0 Hz, C7a); 124.3 (d, 
4
JC-F = 1.0 Hz, C10b); 131.6 (d, 
2
JC-F = 14.7 Hz, C10); 139.4 (d, 
3
JC-F = 6.0 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 246.7 Hz, C9); 
164.8 (C6a); 175.3 (d, 
4
JC-F = 3.0 Hz, C7). 
19
F NMR (282 MHz): -121.3 (d, 
3
JF-H = 12.7 Hz). MS 
CI (DCI/NH3): m/z 831.4 [M+H]
+
. Elemental Anal. (C44H56F2N8O6 · 0.5 H2O); C, H, N: calcd, 
62.92, 6.84, 13.84; found, 62.74, 6.79, 13.51. 
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bis((3S)-N-nonyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18f). The purification provided the 
desired compound (63 mg, 20%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.28 (m, 10H, Cd-f-
H); 1.56 (d, 
3
JH-H = 6.6 Hz, 6H, C3a-H); 1.61 (tt, 
3
J  = 6.9 Hz, 4H, Cc-H); 2.38 (s, 6H, C4'a-H); 
2.58 (m, 8H, C3'-H, C5'-H); 3.33 – 3.45 (m, 12H, C2'-H, C6'-H, Cb-H); 4.25 – 4.30 (m, 2H, C3-H); 
4.35 –4.43 (m, 4H, C2-H); 7.69 (d, 
3
JH-F = 12.6 Hz, 2H, C8-H); 8.62 (s, 2H, C5-H), 9.94 (t, 
3
JH-H 
= 5.7 Hz, 2H, N-H). 
13
C NMR (75 MHz): 18.2 (C3a); 27.1, 29.4, 29.5, 29.6 (Cc-f); 39.3 (Cb); 46.2 
(C4'a); 50.4 (d, 
4
JC-F = 3.8 Hz, C2', C6'); 54.8 (C3); 55.6 (C3',C5'); 68.2 (C2); 105.1 (d, 
2
JC-F = 24.1 
Hz, C8); 111.4 (C6); 122.6 (d, 
3
JC-F = 9.0 Hz, C7a); 124.3 (d, 
4
JC-F = 1.0 Hz, C10b); 131.6 (d, 
2
JC-F 
= 15.1 Hz, C10); 139.5 (d, 
3
JC-F = 6.1 Hz, C10a); 143.8 (C5); 155.8 (d, 
1
JC-F = 246.7 Hz, C9); 164.8 
(C6a); 175.3 (d, 
4
JC-F = 3.0 Hz, C7). 
19
F NMR (282 MHz): -121.3 (d, 
3
JF-H = 12.1 Hz). MS CI 
(DCI/NH3):  m/z 845.4 [M+H]
+
. Elemental Anal. (C45H58F2N8O6 · 1.9 H2O); C, H, N: calcd, 
61.47, 7.08, 12.74; found, 61.34, 6.92, 12.79. 
 
bis((3S)-N-decyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-
7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18g). The purification provided the 
desired compound (94 mg, 20%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.28 (m, 12H, Cd-f-
H); 1.56 (d, 
3
J  = 6.6 Hz, 6H, C3a-H) ; 1.62 (tt, 
3
J  = 7.1 Hz, 4H, Cc-H); 2.44 (s, 6H, C4'a-H); 2.67 
(m, 8H, C3'-H, C5'-H); 3.33 – 3.50 (m, 12H, C2'-H, C6'-H, Cb-H); 4.27 – 4.30 (m, 2H, C3-H); 4.38 
– 4.42 (m, 4H, C2-H); 7.70 (d, 
3
JH-F = 12.3 Hz, 2H, C8-H); 8.63 (s, 2H, C5-H); 9.93 (t, 
3
J = 5.7 
Hz, 2H, N-H). 
13
C NMR (75 MHz): 18.2 (C3a); 27.1, 29.3, 29.5, 29.6, 39.3 (Cb-f); 46.1 (C4‘a); 
50.2 (d, 
4
JC-F = 3.8 Hz, C2', C6'); 54.8 (C3); 55.6 (C3',C5'); 68.2(C2); 105.1 (d, 
2
JC-F = 24.1 Hz, C8); 
111.4 (C6); 122.7 (d, 
3
JC-F = 9 Hz, C7a); 124.3 (d, 
4
JC-F = 1.0 Hz, C10b); 131.5 (d, 
2
JC-F = 14.3 Hz, 
C10); 139.5 (d,
 3
JC-F  = 6.8 Hz, C10a); 143.8 (C5);  155.7 (d, 
1
JC-F = 245.7 Hz, C9); 164.8 
(C6a);175.3 (d, 
4
JC-F = 3 Hz, C7). 
19
F NMR (282 MHz): -121.4 (d, 
3
JH-F = 11.8 Hz). MS 
(DCI/NH3): m/z 859.4 [M+H]
+
. Elemental Anal. (C46H60F2N8O6 · 1.5 H2O); C, H, N: calcd, 
62.36, 7.17, 12.65; found, 62.31, 7.02, 12.52. 
 
bis((3S)-N-dodecyl-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-
oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxamide) (18h). The purification provided 
the desired compound (75 mg, 27%) as a pale yellow solid. 
1
H NMR (300 MHz): 1.25 (m, 16H, 
Cd-g-H); 1.56 (d, 
3
J = 6.6 Hz, 6H, C3a-H); 1.62 (tt, 
3
J = 6.9 Hz, 4H, Cc-H); 2.44 (s, 6H, C4'a-H); 
2.66 (m, 8H, C3'-H, C5'-H); 3.39 – 3.46 (m, 12H, C2'-H, C6'-H, Cb-H), 4.26 – 4.31 (m, 2H, C3-H); 
4.38 – 4.42 (m, 4H, C2-H); 7.70 (d, 
3
JH-F = 12.3 Hz, 2H, C8-H); 8.63 (s, 2H, C5-H); 9.93 (t, 
3
J = 
6.0 Hz, 2H, N-H).
 13
C NMR (75 MHz): 18.2 (C3a); 27.1, 29.3, 29.4, 29.6, 29.6, 39.2 (Cb-g); 46.3 
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(C4‘a); 50.5 (d, 
4
JC-F = 4 Hz, C2', C6'); 54.7 (C3); 55.6 (C3',C5'); 68.1 (C2); 105 (d, 
2
JC-F = 23.9 Hz, 
C8); 111.2 (C6); 122.4 (d, 
3
JC-F = 8.7 Hz, C7a); 124.2 (d, 
4
JC-F = 1.0 Hz, C10b); 131.7 (d, 
2
JC-F = 
14.6 Hz, C10); 139.3 (d,
 3
JC-F  = 6.7 Hz, C10a); 143.7 (C5); 155.7 (d, 
1
JC-F = 245.7 Hz, C9); 164.7 
(C6a); 175.2 (d, 
4
JC-F = 2.9 Hz, C7). 
19
F NMR (282 MHz): -121.2 (d, 
3
JH-F = 12.4 Hz). MS 
(DCI/NH3): m/z 887.4 [M+H]
+
.  Elemental Anal. (C48H64F2N8O6 · 1.5 H2O); C, H, N: calcd, 
63.07, 7.39, 12.26; found, 63.05, 7.30, 12.07. 
 
2. Synthesis of octadecanoyloxymethyl ester of LEV 14h 
2.1 Reaction monitoring during the synthesis of octadecanoyloxymethyl ester of LEV 14h 
HPLC analysis was performed on a Waters system (Waters Associates Inc., Milford, MA, 
USA) consisting of a 600 controller pump, a PDA996 diode array detector, a Waters 2420 
Evaporative Light Scattering (ELS) detector, a 717 Plus autosampler and a Lisa 30 Ecrosas (ICS) 
oven at 30 ºC. The instrument was controlled by the Empower software. The experiments were 
carried out on a C18 Luna (Phenomenex®) reverse-phase column (length 100 × 3 mm i.d., 3 m 
particle size) eluted with a mobile phase consisting of various linear gradients of Solvent A 
(MeOH + 0.1% TFA)/Solvent B (water + 0.1% TFA) at a flow rate of 0.6 mL/min. The eluting 
solvents were prepared daily and degassed with helium during analyses. The detection was set at 
325 nm. In a typical experiment 100 l of reaction mixture was diluted with CHCl3 (HPLC 
grade) to a final volume of 5 mL and analyzed by HPLC (5 l injection volume). 
2.1.1 HPLC Conditions 
The mobile phase consisted of linear gradient presented in Table 83. Waters 2420 
Evaporative Light Scattering (ELS) detector was used for the quantification. 
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Table 83 Mobile phase composition for reaction monitoring 
Time, min A
a
, % B
b
, % 
0 20 80 
1 20 80 
5 0 100 
20 0 100 
21 20 80 
25 20 80 
a
0.1% trifluoroacetic acid in water 
b
0.1% trifluoroacetic acid in methanol 
2.1.2 Calibration 
Compound 14h and LEV were dissolved in the appropriate volume CHCl3 according to 
Table 84 to produce the final solutions. 
 
Table 84 Calibration solution preparation for reaction monitoring 
Ref Mw mass, mg CHCl3 volume, mL Final concentration, mg/mL 
LEV 361.4 19.30 50 0.3860 
14h 657.9 40.11 50 0.8022 
 
Each compound in CHCl3 solution (final solution from Table 84) was mixed with 
appropriate volume of CHCl3, according to Table 85, to yield 4 separate standard solutions (four 
different concentrations per compound) which were further used to build the calibration curves. 
Two injections were made for each concentration. 
 
Table 85 Standard solutions for reaction monitoring 
№ Compound solution volume CHCl3 volume Degree of dilution 
1 1 mL – 1.000 
2 2 mL 1 mL 0.6666 
3 1 mL 2 mL 0.3333 
4 1 mL 9 mL 0.1000 
 
Separate standard solutions were injected using appropriate gradient (Table 83). 
Analytical data were processed by the Empower® software, leading to the corresponding 
equation: 
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Peak area (LS Units · sec) = A + B × concentration (mg/mL) + C × concentration2 (Table 86) 
 
Table 86 Calibration parameters for reaction monitoring 
Reference Retention time, min A · 10-3 B · 10-6 C · 10-6 R2 
LEV 0.971 5.91 1.39 14.0 0.9987 
14h 5.816 -270 5.12 9.05 0.9997 
 
2.1.3 Reaction monitoring procedure 
47.25 mg (0.096 mmol) of cesium salt of levofloxacin and 46.46 mg (0.139 mmol) of 
chloromethyloctadecanoate 10h were dissolved in 4.85 mL of dry DMF (H2O < 6ppm) and the 
resulted solution was stirred at 90ºC. During the first hour four consequent probes of the reaction 
mixture were taken and analyzed (0 min, 20 min, 40 min and 60 min probe). Each probe 
consisted of 100 L aliquot which was further diluted by CHCl3 to the final volume of 5 mL 
(analyzed and quantified by HPLC, Table 87) and 50 L aliquot which was further diluted by 
CDCl3 to the final volume of 0.6 mL (analyzed by NMR). Then another two probes (50 L 
aliquot) were taken at 2h and 3h time points and analyzed by NMR. After 3h of stirring the 
solvent was removed under reduced pressure. The solid residue was dissolved in 25mL of CHCl3 
(Solution 1) and 1mL of it was diluted by CHCl3 to the final volume of 10mL (Solution 2). 
Solution 2 was analyzed by HPLC in order to prove the reliability of HPLC data in the 
estimation of the yield. The solvent was removed from the rest 24mL of Solution 1 under 
reduced pressure and the solid residue was purified by column chromatography on the silica gel 
(20g SiO2, 6-35 m; CH2Cl2/MeOH, 10/1) to yield 31 mg (misol) of octadecanoyloxymethyl ester 
of LEV 14h. 
 
Table 87 HPLC analysis of aliquots during the reaction monitoring 
Probe 
Concentration, mg/mL 
14h LEV 
20 min 0.169 0.067 
40 min 0.173 0.066 
60 min 0.173 0.065 
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2.1.4 Calculation of isolated and determined by HPLC yields 
The theoretical amount of octadecanoyloxymethyl ester of LEV 14h if no aliquots were 
taken: mtheor 100% = 63mg. 
To calculate the theoretical amount of octadecanoyloxymethyl ester of LEV 14h which is 
left after all aliquots, we have to take into account the total volume of aliquots taken (100 L × 4 
+ 50 L × 6 = 0.7mL) and the 1mL of Solution 1 taken away for HPLC analysis: mtheor = mtheor 
100% × (4.85mL – 0.7mL)/4.85mL × (24/25) = 51.8mg. 
So the isolated yield misol/mtheor × 100% = 60%. 
After the HPLC analysis of Solution 2 we have obtained the following concentration of 
octadecanoyloxymethyl ester of LEV 14h: 0.139 mg/mL. So the theoretical amount of 
octadecanoyloxymethyl ester of LEV 14h, in the initial reaction mixture after 3h, without taking 
into account the aliquots taken and according to the HPLC data was the following: mHPLC = 
0.139 mg/mL × 250 mL × 4.85mL/(4.85mL – 0.7mL) = 40.6mg. 
So the yield determined by HPLC mHPLC / mtheor 100% × 100% = 64%. 
 
2.2 Reaction optimization experiments for the synthesis of octadecanoyloxymethyl ester of 
LEV 14h 
HPLC analysis was performed on the previously mentioned Waters system, column and 
solvent composition. The detection was set at 325 nm for LEV derivatives. In a typical 
experiment the solvent was removed from reaction mixture and a solid residue was dissolved in 
50 ml of CHCl3 (HPLC Grade). The resulting solution was further analyzed by HPLC (5 L 
injection volume). 
2.2.1 HPLC Conditions 
The mobile phase consisted of linear gradient presented in Table 88. PDA996 diode 
array detector was used for the quantification. 
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Table 88 Mobile phase composition for reaction optimization 
Time, min A
a
, % B
b
, % 
0 20 80 
8 20 80 
12 0 100 
18 0 100 
19 20 80 
23 20 80 
a
0.1% trifluoroacetic acid in water 
b
0.1% trifluoroacetic acid in methanol 
2.2.2 Calibration 
The standard solutions described in the previous section (Table 84, Table 85) were 
reinjected using appropriate gradient Table 88. Analytical data were processed by the 
Empower® software, leading to the corresponding equation: 
 
Peak area ( V · sec) = A + B × concentration ( mol) (Table 89) 
 
Table 89 Calibration parameters for reaction optimization 
Reference Retention time, min λ, nm A · 10-5 B · 10-7 R2 
LEV 0.816 325 2.413 1.555 0.9994 
14h 8.206 325 -3.167 1.017 0.9993 
 
2.2.3 Reaction optimization procedure 
During the series of small-scale experiments the correspondent amount of cesium salt of 
LEV and chloromethyl octadecanoate 10h were dissolved in 2ml of appropriate solvent and were 
stirred for the fixed number of hours at 90ºC (Table 90). 
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Table 90 Conditions for reaction optimization experiments 
Entry 
Cesium salt of 
LEV, mg 
10h 
Solvent Time 
Mass, mg Equivalent 
1 27.16 27.16 1.48 CH3CN 3h 
2 21.11 21.83 1.5 DMF 1h 
3 24.24 16.83 1.02 DMF 1h 
 
In each experiment, the solvent was removed under reduced pressure after the reaction 
and the solid residue was dissolved in 50mL of CHCl3. The resulted solution was injected using 
appropriate gradient (Table 88) and quantified using previously obtained regression model. The 
mass of octadecanoyloxymethyl ester of LEV 14h was calculated by the following equation: 
concentration obtained by HPLC × 50mL; 
 
3. Stability tests 
HPLC analysis was performed on the previously mentioned Waters system, column and 
solvent composition. The detection was set at 292 or 325 nm for LEV derivatives, 280 or 345 nm 
for CIP derivatives. All injections (10 L) were made in duplicate. In a typical experiment, 1 mL 
of a 1 mM solution of tested compound in DMSO was diluted with acetonitrile/phosphate buffer 
(pH 7.4) (50:50) to a final volume of 10 mL. An aliquot was discarded and kept at 4 ºC (0 day 
probe). The remaining solution placed in a sealed tube was heated in a water bath at 37 ºC for 7 
days (7 day probe). 
 
3.1 Detailed procedure for stability investigation of CIP “di-amides” 
3.1.1 HPLC Conditions 
The mobile phase consisted of linear gradient presented in Table 91. 
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Table 91 Mobile phase composition for CIP ―di-amides‖ 7 
Time, min 
Gradient for 7 series 
A
a
, % B
b
, % 
0 70 30 
2 70 30 
7 0 100 
18 0 100 
20 70 30 
a
0.1% trifluoroacetic acid in water 
b
0.1% trifluoroacetic acid in methanol 
3.1.2 Calibration 
PBS preparation: 8.0 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 were dissolved 
in 800 mL of water/acetonitrile mixture (50/50). Then pH was adjusted to 7.4 by 0.1M HCl and 
the resulted solution was diluted by water/acetonitrile to 1 L. The use of acetonitrile was 
necessary to obtain homogenous solutions due to the low solubility of tested compounds in PBS. 
Compounds 7 were dissolved in the appropriate volume of DMSO according to Table 92. 
Resulted DMSO solutions were diluted with water/acetonitrile phosphate-buffered saline (PBS 
pH = 7.4) to produce the final concentrations. 
 
Table 92 DMSO solutions for CIP ―di-amides‖ 
Ref. Mw mass, mg 
DMSO 
voulme, mL 
Conc. in 
DMSO, M 
Final conc. in 
buffer, M 
7b 857.0 9.43 20.0 550
a
 55 
7c 885.0 8.96 10.1 1000 100 
7e 913.1 10.12 11.1 1000 100 
a
Not soluble in DMSO at 1000 M concentration. 
 
Each compound in DMSO solution (Table 92) was mixed with appropriate volume of 
PBS, according to Table 93, to yield 4 separate standard solutions (four different concentrations 
per compound) which were further used to build the calibration curves. Two injections were 
made for each concentration. 
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Table 93 Calibration solutions for CIP ―di-amides‖ 
№ Compound solution volume PBS volume Degree of dilution 
1 1 mL – 1.000 
2 2 mL 1 mL 0.6666 
3 1 mL 2 mL 0.3333 
4 1 mL 9 mL 0.1000 
 
Separate standard solutions were injected using appropriate gradient (Table 91). 
Analytical data were processed by the Empower® software, leading to the corresponding 
equation: 
 
Peak area ( V · sec) = A + B × concentration ( mol) (Table 94) 
 
Table 94 Calibration parameters for CIP ―di-amides‖ 
Reference Retention time, min λ, nm A · 10-4 B · 10-4 R2 
7b 14.50 280 -5.472 7.092 0.9989 
7c 15.08 345
a
 -1.168 1.211 0.9999 
7e 15.45 280 1.405 6.793 0.9980 
a
7c peak was slightly overlapped with impurity peak. Detection wavelength was shifted 
to eliminate its contribution to the peak area. 
3.1.3 Stability investigation procedure 
Fifteen milliliters of each compound solution (final solutions from Table 92) were added 
to 20 mL glass vials which were sealed with glass stoppers, covered with teflon film, and placed 
on a 37º C shaker water bath and shaken gently for 7 days. Intermediate samples were taken at 3 
and 5 days. All collected samples were analyzed by HPLC and quantified using previously 
obtained regression models. 
To evaluate the rate of degradation of the tested compounds, CIP (degradation product 
expected for 7 was injected. This retention time was 2.6 min. For compounds whose stability 
was less than 100%, the ratio [compound peak area / (compound peak + degradation product 
peak) area] was calculated. 
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3.2 Detailed procedure for stability investigation of LEV “mono-amides” 17 and “mono-
acyloxymethyl esters” 14 
3.2.1 HPLC Conditions 
The mobile phase consisted of linear gradient presented in Table 95. 
 
Table 95 Mobile phase composition for LEV derivatives 
Time, min 
Gradient for 17 series 
A
a
, % B
b
, % 
0 65 35 
2 65 35 
7 0 100 
15 0 100 
17 65 35 
 
Time, min 
Gradient for 14 series 
A
a
, % B
b
, % 
0 65 35 
2 65 35 
7 0 100 
18 0 100 
20 65 35 
a
0.1% trifluoroacetic acid in water 
b
0.1% trifluoroacetic acid in methanol 
3.2.2 Calibration 
Compounds were dissolved in DMSO according to Table 96. Resulted solutions were 
diluted by water/acetonitrile phosphate buffer (pH = 7.4) to produce final concentration. 
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Table 96 DMSO solutions for LEV ―mono-amides‖ 17 and ―mono-
acyloxymethyl esters‖ 14 
Ref. Mw mass, mg V(DMSO), mL 
Conc. in 
DMSO, M 
Final conc. in 
buffer, M 
LEV 361.4 3.82 105.8 100 10 
17a (n=3) 416.5 5.43 13.5 1000 100 
17b (n=6) 444.6 5.26 11.8 1000 100 
17d (n=8) 472.6 6.28 13.3 1000 100 
17h(n=14) 556.8 5.62 10.1 1000 100 
14a (n=2) 461.5 5.45 11.8 1000 100 
14c (n=6) 517.6 5.76 11.1 1000 100 
14e (n=10) 573.7 5.70 9.95 1000 50
a
 
14g (n=14) 629.8 6.64 10,5 1000 10
a
 
a
Corresponding volume of DMSO was added to the final solution to maintain constant 
DMSO concentration (10% v/v) 
 
Each DMSO solution was mixed with appropriate amount of PBS, according to Table 
97, to yield separate standard solutions (four different concentrations per compound) which were 
further used to build the calibration curves. Two injections were made for each concentration. 
 
Table 97 Calibration solutions for LEV ―mono-amides‖ 17 and ―mono-
acyloxymethyl esters‖ 14 
№ Compound solution volume PBS volume Degree of dilution 
1 1 mL – 1.000 
2 2 mL 1 mL 0.6666 
3 1 mL 2 mL 0.3333 
4 1 9 mL 0.1000 
 
Separate standard solutions were injected using appropriate gradient. Analytical data 
were processed by the Empower® software leading to the corresponding equation: 
 
Peak area ( V · sec) = A + B × concentration ( mol) (Table 98) 
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Table 98 Calibration parameters for LEV ―mono-amides‖ 17 and ―mono-
acyloxymethyl esters‖ 14 
Reference Retention time, min λ, nm A · 10-4 B · 10-4 R2 
LEV 2.35 292 -0.1716 3.125 0.9999 
17a 11.73 292 -2.289 3.554 0.9998 
17b 12.89 292 2.445 3.212 0.9998 
17d 13.67 292 3.038 3.388 0.9999 
17h 15.40 292 2.759 3.114 0.9998 
14a 7.14 292 -3.128 3.298 0.9999 
14c 12.73 292 -1.439 3.361 0.9998 
14e 13.95 292 0.8696 3.247 0.9997 
14g 14.95 325 -0.2231 1.387 0.9996 
3.2.3 Stability investigation procedure 
Fifteen milliliters of each compound solution (final solution from Table 96) were added 
to 20 mL glass vials which were sealed with rubber septum stoppers and placed on a 37º C 
shaker water bath and shaken gently for 7 days. Intermediate samples were taken at 3 and 5 days. 
All collected samples were analyzed by HPLC and quantified using previously obtained 
regression models. 
To evaluate the rate of degradation of the tested compounds, LEV (degradation product 
expected for acyloxymethyl esters 14a–i and amides 17a–j) was injected. Under these 
conditions, all derivatives were totally separated with respective retention times at 2.4 min 
(LEV), 7.1–15.0 min (esters 14a,c,e,g) and 11.7–15.4 min (amides 17a,b,d,h). For compounds 
whose stability was less than 100%, the following ratio was calculated: stability(%) = [mean 
measured concentration (n = 2) at 7days /mean measured concentration (n = 2) at t0] x100. 
 
4. Biological evaluation of synthesized derivatives 
4.1 Microbiology 
4.1.1 Evaluation of In Vitro Antimicrobial activities 
MICs were determined by broth dilution micromethod. Briefly, 100  of Trypcase soy 
broth (Biomérieux, France) was placed in each well of a 96-well microtiter plate. Hundred 
microlitres of the solutions to be tested (prepared in 10% DMSO) was added to the first column. 
Then 2-fold dilutions were carried out from one column to the next up to column 10. Columns 
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11 and 12 were used as a sterility control (without product and without bacteria) and a growth 
control (without product, with inoculum) of the medium. Fresh bacterial suspensions were 
prepared at 10
8
cells/mL using standard strains (S. aureus CIP 4.83, E. hirae CIP 5855, P. 
aeruginosa CIP 82.118 and E. CIP 53126) obtained from the Institut Pasteur Collection (France). 
The microplates were inoculated using a multipoint inoculator (Denley) to obtain a final 
concentration of 10
6cells/mL. Plates were then incubated at 37 °C for 18–24 h under aerobic 
conditions. MIC was determined as the lowest concentration with no visible growth. Assays 
were performed in duplicate. 
4.1.2 In vitro inhibition of Mycobacterium Tuberculosis 
Susceptibility of M. tuberculosis (strain H37Rv) to the synthetic compounds was tested 
by determining the MIC. A colorimetric microassay based on the reduction of MTT to formazan 
by metabolically active cells was used. Briefly, serial twofold dilutions of each compound were 
prepared in 7H9 broth (Middlebrook 7H9 broth base, Difco) using 96-well microtiter plates and 
100 L of M. tuberculosis suspension in 7H9 broth were added to each well. After 6 days 
incubation, MTT was added (50 L, 1 mg/mL). After one day incubation, solubilization buffer 
was added to each well. The optical densities were measured at 570 nm. The MIC was 
determined as the lowest concentration of compound that inhibited bacterial growth (absorbance 
from untreated bacilli was taken as a control for growth). 
4.2 Evaluation of in vitro cell proliferation by means of the MTT colorimetric assay 
The assessment of cell population growth is based on the capability of living cells to 
reduce the yellow product MTT (Sigma, Bornem, Belgium) to a blue product, formazan, by a 
reduction reaction occurring in the mitochondria
190
. The five cell lines were incubated for 24 h in 
96-microwell plates (at a concentration of 10
4
 to 3 x 10
4
 cells/mL culture medium depending on 
the cell type) to ensure adequate plating prior to cell growth determination. The number of living 
cells after 120 h of culture in the presence or absence (control) of the various drugs is directly 
proportional to the intensity of the blue color, measured by spectrophotometry using a 680XR 
microplate reader (Bio-Rad Laboratories Inc, Hercules, CA) at a wavelength of 570 nm (with a 
reference at 630 nm). Each experiment was carried out in hexaplicate. Nine concentrations 
ranging from 10
-3
 to 10
-7
 Mw (with semi-log decrease in concentration) were tested for each of 
the compounds under study. 
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4.3 In vivo testing maximum tolerated dose procedure 
The acute MTD was determined following single i.p. administration of increasing drug 
doses to groups of three healthy B6D2F1 female mice (Charles River, Brussels, Belgium). Five 
dose levels (5, 10, 20, 40 and 80 mg/kg) of drug were evaluated. The MTD was defined as the 
dose just below the lowest dose level that killed at least one mouse in a treatment group after a 
maximum of 28 days. 
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Dérivés lipophiles de la ciprofloxacine et de la lévofloxacine : synthèse et évaluation de leurs 
activités antibactérienne, antimycobactérienne et antiproliférative 
 
La ciprofloxacine (CIP) et la lévofloxacine (LEV) appartiennent à la large famille des 
antibiotiques de type fluoroquinolone (FQ). Ce sont des agents antibactériens qui ont également été 
recommandés pour le traitement de la tuberculose. Malgré tous leurs avantages, l‘apparition des 
phénomènes de résistance dans les souches pathogènes bactériennes et M. tuberculosis devient un 
problème majeur. C‘est pourquoi, le besoin de développer de nouveaux agents existe toujours.  
Des études ont montré que CIP et LEV ont des activités antiproliférative et apoptotique contre 
plusieurs lignées de cellules cancéreuses. Le mécanisme exact de cette activité des FQs est inconnu, mais 
il a été prouvé qu‘ils peuvent inhiber la topoisomérase II mammifère, les G-quadruplex, et la 
polymérisation de tubuline. De plus, nous avons mis en évidence que certains dérivés lipophiles de la CIP 
possèdent une activité antiproliférative. Le greffage de longues chaînes alkyles pourrait donc conduire à 
des agents anticancéreux. 
Au cours de cette thèse, nous avons développé et synthétisé cinq séries des dérivés lipophiles de 
la CIP et de la LEV. Afin de contourner les difficultés synthétiques rencontrées (en particulier la faible 
réactivité de l‘acide carboxylique en C-3 du motif quinolone) nous avons réalisé différents essais 
d‘optimisation des conditions réactionnelles. L‘influence de différents paramètres a été étudiée (des 
réactions ont été conduites sous microondes, en présence ou absence de catalyseur) ce qui nous a permis 
d‘améliorer les rendements et de réduire le temps de réaction. 
Les activités biologiques des cinq séries de dérivés ont été évaluées in vitro et pour les analogues 
les plus actifs les DMT ont été déterminées in vivo. L‘analyse détaillée des activités antibactérienne, 
antimycobactérienne et antiproliférative nous a permis de mettre en évidence quelques règles générales de 
relation structure-activité concernant l‘influence du type de substitution du noyau quinolone, de la 
longueur de la chaîne alkyle et de la structure type dimère ou monomère sur les différentes cibles 
biologiques. 
 
 
Lipophilic ciprofloxacin and levofloxacin derivatives: synthesis and evaluation as antibiotic, 
antimycobacterial and antiproliferative agents 
 
Ciprofloxacin (CIP) and levofloxacin (LEV) are members of the large family of fluoroquinolone 
(FQ) antibiotics. Though they have proved to be reliable and effective antibacterial broad-spectrum 
agents, with several members also approved as second-line drugs for tuberculosis treatment. Nevertheless, 
the emerging resistance among key bacterial pathogens and M. tuberculosis hinders their future 
effectiveness. So there is a constant need for new compounds which could help to overcome these 
obstacles.  
In addition, studies have shown that LEV and CIP have antiproliferative and apoptotic activities 
against several cancer cell lines. The exact mechanism by which FQs exert their tumour growth inhibitory 
activity and lead to cell death is not fully understood but these molecules could inhibit mammalian 
topoisomerase II, G-quadruplexes and tubulin polymerization. Moreover, we reported that some 7-(4-
substituted)piperazin-1-yl) derivatives of CIP with increased lipophilicity displayed increased 
antiproliferative
 
activity in vitro, suggesting that grafting long alkyl chain could give rise to antitumor 
agents.  
During the course of the thesis, we have designed and synthesized five series of CIP and LEV 
derivatives. A number of optimization runs were conducted in order to overcome the low reactivity of C-3 
carboxylic acid on quinolone core. The influence of various parameters was examined (microwave-
assisted synthesis versus thermal conditions, presence or absence of catalyst), which permitted us to 
increase the yields and decrease the reaction time.  
Biological evaluation of these five series of FQ analogs was conducted in vitro together with in 
vivo MTD determination for the most potent ones. The detailed analysis of antimicrobial, 
antimycobacterial and antiproliferative activities permitted us to deduce general structure-activity 
relationships concerning the influence of substitution type on quinolone core, the length of the grafted 
alkyl chain and the ―dimeric‖ or ―monomeric‖ structure on the selectivity and potency against these 
various biological targets. 
 
